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GENERAL ABSTRACT 
Zinc is a critical metal ion that has wide-ranging effects on cellular function. It is required for 
growth and development, immunity, and metabolism, and is therefore, vital for life. 
Disturbances in zinc homeostasis lead to various disease states including cancer, neurological 
disorders and diabetes. Recent studies have highlighted the dynamic role of zinc as an insulin 
mimetic and a cellular second messenger that controls many processes associated with insulin 
signalling and other downstream pathways that are amendable to glycaemic control. Therefore, 
mechanisms that contribute to the decompartmentalization of zinc and dysfunctional zinc 
transporter mechanisms, including zinc signalling are associated with metabolic disease.  
As zinc cannot pass through biological membranes unassisted, cellular zinc storage, release 
and distribution are controlled by a family of proteins: zinc transporters and metallothioneins. 
Increasing evidence suggests that dysregulation of these proteins might act as key causative or 
promoting factors in several chronic pathologies such as insulin resistance and type 2 diabetes. 
Of these, emerging research has highlighted a role for several zinc transporters in the initiation 
of zinc signalling events in cells that lead to metabolic processes associated with maintaining 
insulin sensitivity and thus glycaemic homeostasis. One principle zinc transporter, Zip7 is 
emerging as a ‘gate-keeper’ of zinc flux from intracellular organelles including the Golgi 
apparatus and endoplasmic reticulum. Recent studies have identified that this transporter 
facilitates the mobilisation of intracellular zinc flux into the cytosol and the subsequent zinc-
mediated activation of cell signalling molecules involved in glucose homeostasis. However, 
the mechanisms whereby zinc and Zip7 achieve glucose control is not known.     
The present study evaluated the insulin-like effects of zinc on cell signalling pathways 
associated with controlling glucose homeostasis. Initially, key molecules involved in 
controlling glucose metabolism including tyrosine, PRSA40, Akt, ERK1/2, SHP-2, GSK-3β 
and p38, and the physiological response of glucose oxidation were analysed in the presence of 
zinc treatment in mouse and human skeletal muscle cells. Insulin and zinc treatment 
independently led to the phosphorylation of these proteins over a 60-minute time course in both 
mouse and human skeletal muscle cells and was concomitant with an increase in glucose 
oxidation. Similarly, utilising a commercially available protein array that contains several key 
proteins implicated in insulin signalling pathways we identified that zinc could active the 
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phosphorylation of p38, ERK1/2 and GSK-3β in human and ERK1/2 and GSK-3β in mouse 
skeletal muscle cells.  
 
Glucose oxidation assays were performed on skeletal muscle cells treated with insulin, zinc, or 
a combination of both and resulted in a significant induction of glucose consumption in mouse 
and human skeletal muscle cells when treated with zinc alone. Insulin, as expected, increased 
glucose oxidation in mouse and human skeletal muscle cells, however the combination of zinc 
and insulin did not augment glucose consumption in these cells. Given that we did not observe 
an additive effect of insulin and zinc treatment together on glucose oxidation, we sought to 
determine whether a functional insulin receptor is required to facilitate zinc activation of pAkt. 
We utilised mouse C2C12 skeletal muscle cells treated with an insulin receptor tyrosine kinase 
inhibitor (HNMPA-(AM)3) in the presence of insulin or zinc. We observed that HNMPA-
(AM)3 was sufficient to inhibit insulin-induced pAkt. Similarly, we identified that HNMPA-
(AM)3 inhibited zinc-induced pAkt and suggests that zinc potentially acts through the insulin 
signalling pathway. 
 
Previous studies have identified that Zip7 controls cell signalling pathways associated with 
glycaemic control in skeletal muscle cells. It was suggested that dysfunctional cell signalling 
processes in disease states such as insulin resistance and type 2 diabetes might be due to 
aberrant Zip7 expression and/or function. Accordingly, we initially set out to determine the 
role of Zip7 in an insulin-resistant cell culture model. Initially we tested the ability of glucose 
to regulate Zip7 protein levels. We found that 25 mM of glucose treatment of C2C12 mouse 
skeletal muscle cells significantly increased Zip7 protein levels. We also determined that Zip7 
(and Glut4) were significantly reduced in insulin resistant skeletal muscle cells through 
inhibition of insulin receptor signalling and palmitate-induced insulin resistance. These studies 
suggest that Zip7 plays an important role in maintaining cell signalling processes associated 
with glucose control. We next focused our studies to determine if the expression of Zip7 
changed in a mouse model of obesity. We found that Zip7 and the glucose transporter, Glut4 
was reduced in obese mice fed a high fat diet. 
 
From the above studies we established a Zip7 overexpression cell culture model to test the 
ability of this transporter to regulate genes implicated in glucose homeostasis. These studies 
were based on previous work which identified that a reduction in Zip7 in skeletal muscle cells 
led to several changes in genes associated with insulin signalling and glycaemic control. 
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Accordingly, utilising an insulin signalling pathway array that contained 84 genes involved in 
insulin signalling, we identified that overexpression of Zip7 in mouse C2C12 skeletal muscle 
cells led to significant changes in Akt3, Dok2, Fos, Hras, Kras, Nos2, Pck2, and Pparg. 
 
In these studies, we demonstrated that zinc acts as an insulin mimetic, activating key molecules 
implicated in cell signalling to maintain glucose homeostasis in mouse and human skeletal 
muscle cells. Similarly, these studies demonstrated that Zip7 is involved in processes 
associated with insulin signalling and glucose control in skeletal muscle. This study also raises 
the possibility that zinc transporters could provide novel utility to be targeted experimentally 
and in a clinical setting to treat patients with insulin resistance and thus introduce a new class 
of drug target with utility for diabetes pharmacotherapy. 
 
 
 
 
 
  
 
 
 
 
 
CHAPTER 1 
GENERAL INTRODUCTION 
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1.1. Background. 
Type 2 diabetes mellitus (T2DM) is a chronic, progressive, and inadequately understood 
metabolic disease that is linked to several serious health problems, including cardiovascular 
disease, blindness, kidney failure, cognitive decline, and premature death (1). The number of 
people with diabetes (those having a fasting plasma glucose value of greater than or equal to 
7.0 mmol/L or on medication for diabetes/raised blood glucose) has steadily risen over the past 
few decades, due to population growth, an increase in the average age of the population, and 
the rise in prevalence of diabetes with increasing age (2). Worldwide, the number of people 
with diabetes has substantially increased between 1980 and 2014, rising from 108 million to 
current number that are around four times higher. World health organization (WHO) estimates 
that, globally, 422 million adults aged over 18 years were living with diabetes in 2014 (3). The 
largest numbers of people with diabetes were estimated for the WHO South-East Asia and 
Western Pacific Regions (which includes Australia), accounting for approximately half the 
diabetes cases in the world. Also, the increase in the percentage of total deaths attributable to 
high blood glucose for adults aged 20-69 years, for years 2000 and 2012 was highest in the 
Western Pacific Region, where the total number of deaths attributable to high blood glucose 
during this period increased from 490,000 to 944,000 (2, 4). 
 
A key characteristic of T2DM is insulin resistance (IR), a pathophysiological condition 
associated with disrupted biological responses to endogenous insulin which contributes to 
compromised glucose homeostasis specifically in liver, adipose tissue and skeletal muscle (5). 
Several years before being diagnosed with T2DM, a patient typically presents with IR. A 
leading concern for individuals with IR is compromised insulin secretion and function due to 
the chronic and progressive failure of pancreatic β-cell function (6). Therefore, there exists a 
“window of opportunity” to understand prevention strategies to halt or lessen the disease 
progression. This would have an enormous health impact for our society and for individuals 
with this disorder. Although T2DM is largely predictable through anthropometric, lifestyle and 
clinical factors, the molecular mechanisms and metabolic pathways that underpin the 
progression from normal glycaemia to IR and subsequent T2DM are inconclusive. Moreover, 
due to the lack of knowledge about the pleiotropic effects that medications have on specific 
molecular targets, treatments for IR have not progressed significantly during the last few 
decades (7). Therefore, finding strategies to discover new molecular targets that increase the 
efficacy and safety of therapeutic options for IR and T2DM are critical. 
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In this context, research on the molecular mechanisms and metabolic processes associated with 
IR and T2DM has revealed a biochemical and physiological role of zinc in the pathophysiology 
of these disorders (8). The suggestion that zinc deficiency and T2DM might be linked and that 
nutritional zinc supplementation could be efficacious to prevent this condition is appealing. It 
appears in some patients that zinc supplementation can improve the efficacy of oral 
hypoglycaemic agents by decreasing blood glucose, triglycerides and inflammation (9). 
However, in most cases of zinc-related cellular dysfunction, the defect appears to be associated 
with dysregulation of the proteins involved in controlling cellular zinc concentrations and the 
subsequent decompartmentalisation of zinc in subcellular organelles rather than one of 
generalised zinc deficiency (8). Accordingly, the research focus is shifting to the importance 
of zinc and the zinc transporter proteins that transport the metal ion as possible therapeutic 
targets for disease states associated with dysfunctional metabolism, including IR and T2DM. 
Several studies have determined a significant role for zinc as an insulin ‘mimetic’ in 
modulating cell signalling pathways involved in glucose homeostasis, and therefore may have 
therapeutic implications for IR and T2DM (10-12). Zinc is at the ‘nexus’ of controlling cell 
signalling molecules amendable to glucose homeostasis. However, the link between IR and the 
zinc modulation of proteins implicated in glucose homeostasis is unsubstantiated. As such, it 
is important to delineate the molecular mechanisms on how zinc activates cellular enzymes 
responsible for controlling the insulin-zinc signalling ‘axis’. Importantly, the assessment of this 
‘axis’ could lead to novel therapeutic strategies and interventions that are amendable to 
preclinical trials in controlling glucose homeostasis in IR and T2DM.  
 
1.2. Insulin signalling and insulin resistance. 
Insulin is a potent anabolic hormone which regulates a wide variety of biological processes in 
skeletal muscle including glucose uptake, glycogen synthesis, glucose transport, protein 
synthesis, and gene expression (13). The insulin receptor is a heterotetrameric protein 
consisting of two alpha-subunits localised to the extracellular space, and two transmembrane-
bound beta-subunits connected by disulfide bonds (14). Insulin signalling involves a cascade 
of events initiated by insulin binding to the alpha-subunits of its receptor (15). This causes 
autophosphorylation of specific tyrosine residues in the insulin receptor tyrosine kinase domain 
of the intracellular part of the beta-subunit, and subsequent recruitment, binding and tyrosine 
phosphorylation of the insulin receptor substrate1 (IRS1), which mediates an association with 
phosphoinositide 3-kinase (PI3K) (14).  
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The next critical step in insulin signalling is the activation of Akt (protein kinase B), which is 
a serine/threonine kinase located downstream of PI3K  (14). Akt serves as a highly regulated 
point for downstream signalling to 1) transport glucose through the glucose transporter GLUT4 
(in skeletal muscle), 2) to synthesize glycogen through glycogen synthase kinase 3 (GSK3) and 
glycogen synthase (GS) (16), also 3) to synthesize protein through the mammalian target of 
rapamycin (mTOR) pathway (17).  Akt mediates GLUT4 translocation in response to insulin 
and promotes glucose transportation into the cells. In the basal state, the majority of GLUT4 
protein is localised intracellularly. Insulin stimulates glucose transport by promoting GLUT4 
exocytosis and promoting the tethering, docking, and thus fusion of GLUT4 vesicles to the 
outer plasma membrane and subsequent uptake and import of extracellular glucose into the cell 
(18).  
 
Extracellular signal-regulated protein kinase1/2 (ERK1/2), SHP-2 and Protein-Rich Akt 
Substrate of 40 kDa (PRAS40) are known as Akt mediators in insulin signalling pathway. SHP-
2 is a protein tyrosine phosphatase involved in insulin signalling, and can bind to IRS1 in 
response to insulin to mediate  receptor tyrosine kinase- signalling (19). PRAS40 is also among 
the most prominent Akt substrate that is phosphorylated in response to insulin in eukaryotes 
(20). PRAS40 also decreases mTOR expression which is a negative regulator of IRS1 in 
skeletal muscle, and mediates an increase in insulin-stimulated Akt phosphorylation and 
glucose uptake (20). Figure 1.1 below shows an overview of the insulin signalling pathway. 
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Figure 1.1. Schematic diagram of the insulin signalling pathway. Insulin mediates its action 
through binding to the insulin receptor, activation of insulin receptor substrates (IRSs) and 
PI3K, and induction of Akt phosphorylation. This mediates the mobilisation and translocation 
of intracellular Glut4 molecules to the outer plasma membrane surface and initiation of glucose 
uptake into fat and muscle cells. Other components include the activation of the SOS/RAS 
pathway leading to increased ERK phosphorylation and transcriptional activation of growth 
promoting factors. (GLUT4: Glucose transporter 4, PI3K: Phosphoinositide 3 kinase, PDK1: 
Pyruvate Dehydrogenase Kinase 1, PKB: Protein kinase B, GRB2: Growth factor receptor-
bound protein 2, SHP2: (SH2)-containing protein tyrosine phosphatase 2, mTOR: Mammalian 
target of rapamycin, PRAS40: Proline-rich AKT substrate of 40 kDa, SOS: Salt Overly 
Sensitive, Mek: Mitogen-activated protein kinase kinase, ERK: Extracellular signal-regulated 
protein kinase, GSK-3: Glycogen synthesis kinase-3, GS: Glycogen synthase). Figure was 
produced using Smart Servier Medical Art, http://smart.servier.com.  
 
Promotion of glucose transport and glycogen synthesis are key biological actions of insulin in 
skeletal muscle. Defects in these actions appear to be major determinants of skeletal muscle 
IR. IR can be defined as an impaired biological response to either endogenous or exogenous 
insulin. This is an extremely common pathophysiological condition in which patients present 
with diminished insulin sensitivity and thus reduced insulin-stimulate glucose uptake and 
glycogen synthesis, particularly in skeletal muscle and liver (21). This has major implications 
for the individual as they are unable to obtain the required energy from glucose to sustain 
cellular metabolic processes. IR is of major global concern as it is associated with the 
development of several disorders and disease states including T2DM, hyperglycaemia, obesity, 
polycystic ovary syndrome (PCOS), liver cirrhosis (13) atherosclerosis, hypertension and 
stroke (22). 
 
Although several somatic cell lines express insulin receptors, the role of insulin in glucose 
homeostasis is characterized by its direct effects on skeletal muscle, liver, and white adipocyte 
tissues which they perform different roles in metabolic homeostasis, necessitating tissue-
specific insulin signal transduction pathways (23). For instance, insulin promote glucose 
consumption and storage in skeletal muscle cells by improving glucose transport and glycogen 
synthesis (24). In liver, insulin plays an important role to increase glycogen synthesis and 
lipogenic gene expression, and to decrease the expression of gluconeogenic gene (25). In white 
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adipocytes, insulin decreases lipolysis and increases glucose transport and lipogenesis. Despite 
these diverse roles, the proximal components involved in insulin signal transduction are very 
similar in different types of insulin responsive cell lines (26). 
The major function of insulin in skeletal muscle is to increase cellular glucose uptake through 
the translocation of Glut4. Insulin-stimulated skeletal muscle glucose uptake is extremely 
susceptible to IR and is indeed a key component of T2DM (26). Because skeletal muscle tissue 
is the predominant site of insulin-mediated glucose disposal, muscle IR has a huge effect on 
the whole body glucose turnover (26, 27). Insulin stimulation of glycogen synthesis and 
glycolysis both require intact insulin-stimulated glucose uptake to replenish substrate 
availability, so these effects also become resistant to insulin action (21). In patients with T2DM, 
the translocation of glucose into the cell is the major rate-controlling step responsible for the 
reduction in insulin-stimulated muscle glycogen synthesis, which is defective in IR condition 
(26). 
Skeletal muscle IR is observable to defects at the most proximal levels of insulin signalling 
pathway including insulin receptor, IRS1, PI3K, and AKT activity. Defects in insulin receptor 
kinase activity is also suggested by reduced IRS1 tyrosine phosphorylation observed in insulin-
resistant skeletal muscle cells (28). Blunted insulin stimulation of IRS1-associated PI3K 
activity is also reproducibly observed in skeletal muscle IR. Interestingly, skeletal muscle of 
patients with T2DM does not develop IR to mitogenic signalling through Mitogen-activated 
protein kinase (MAPK) (28). Although impaired insulin activation of other distal effectors, 
including AKT, is often seen in skeletal muscle IR, the simultaneous presence of proximal 
insulin signalling defects makes it difficult to realise whether these distal defects have an 
independent origin or are secondary to proximal defects (26, 29). 
Treatments for IR and T2DM have not advanced significantly in the last few decades due to 
the insufficient knowledge about the pleiotropic effects that many diabetic drugs have on 
molecular targets. Accordingly, this leads into a suggested role for zinc in the treatment of IR 
and T2DM through understanding the mechanisms of action of zinc protein transporters (10).  
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1.3. Zinc, zinc transporter proteins and insulin signalling. 
It has long been a consensus that a well-balanced diet, exercise and diabetic agents are 
cornerstones for the prevention and treatment of IR and T2DM. However, reducing the decline 
and eventual failure of functioning pancreatic beta-cells is of paramount importance in 
preventing T2DM and halting disease progression in affected patients (30). The increased 
global prevalence of T2DM and the progressive decline in metabolic control in patients are 
clear demonstrations that present therapeutic strategies are somewhat inadequate. Therefore, 
there are pressing requirements for anti-diabetic agents that target metabolic processes before 
the development of beta-cell destruction and T2DM progression.  
Recently, research on type 2 diabetes has revealed an exciting role for zinc as a dietary 
supplementation in diseases associated with abnormal cellular signalling and metabolism such 
as IR (31). Zinc is an interesting candidate metal ion since it is a component of insulin crystals. 
Before insulin crystallisation in pancreatic β-cells, and subsequently delivery into the blood 
circulation, this hormone is packaged as Zn2+ coordinated hexamers to increase the 
stabilisation of insulin monomers (31, 32). This suggests that disruptions in zinc homeostasis 
would have severe consequences on the packaging, storage and secretion of insulin and 
therefore contribute to glucose intolerance and subsequent failure of beta-cell function.   
In the human body there is approximately two to four grams of total zinc making it the most 
abundant trace element in tissue next to iron (approximately four grams which is localised 
primarily in blood) (12). At the cellular level, 30-40% of total cellular zinc is found in the 
nucleus, 50% in the cytosol and organelles (such as the endoplasmic reticulum), and the 
remainder is found in plasma membranes. Zinc is essentially bound to macromolecules within 
these compartments including zinc proteins/enzymes, lipids, and DNA/RNA. In fact, research 
of the human genome has established that approximately 10% of the proteome consists of 
potential zinc binding proteins, now identified as the “zincome” (12). Accordingly, the 
compartmentalisation, availability, transport and re-distribution of zinc must be tightly 
controlled to maintain a balance between health and disease states (11). Moreover, since zinc 
cannot pass through biological membranes unassisted, several proteins including 
metallothioneins and zinc transporters are involved in the intrinsic control of 
intracellular/extracellular zinc concentrations in mammals (8, 33, 34). 
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Metallothionein (MT) are small cysteine-rich proteins which are dedicated to controlling zinc 
homeostasis in humans and other mammals (35). MTs are redox-active zinc proteins that buffer 
and translocate zinc within the cytosol depending on the availability of cellular zinc. MTs 
participate in cellular metal muffling; a process that contributes to the cellular distribution and 
compartmentalisation of zinc to maintain zinc homeostasis (36). 
 
The second group of factors involved in controlling zinc movement, and thus zinc 
concentrations in cells, are zinc transporter proteins. Two families exist; the ZIP proteins 
(Zrt/Irt-like, solute-linked carrier 39, SLC39) and the ZnT proteins (solute-linked carrier 30, 
SLC30).  ZIP and ZnT family members facilitate zinc transport into the cytosol and out of the 
cytosol, respectively (37, 38). The balance between ZIP and ZnT transporters regulates 
cytosolic and intra-organelle zinc levels (39). A similar protein structure is observed between 
the same family members of these transporters (37) and suggests that they might have 
overlapping fiction or some protein redundancy, although this still needs to be established.  
 
Given the role of zinc as an insulin “memetic” and a modulator of several cell signalling events 
leading to glucose utilisation, and the specificity of zinc transporter proteins in maintaining 
cellular zinc homeostasis, it is likely that aberrant expression of these transporters and/or zinc 
departmentalisation will have deleterious effects on cellular viability.  
 
1.4. Thesis Overview  
The following Chapters outlined below provide a “snap shot” of the subsequent larger Chapters 
to better understand the role of zinc in cellular processes associated with glycaemic control in 
skeletal muscle and to highlight its potential mechanisms of action. It should also be 
highlighted that this thesis is a combination of traditional thesis text (Chapters 1, 4, and 6) and 
peer-reviewed published articles (Chapters 2, 3 and 5).  
 
1.4.1. Chapter 2: Norouzi, Shaghayegh, Adulcikas, John, Sohal, Sukhwinder Singh and 
Myers, Stephen (2017), Zinc transporters and insulin resistance: therapeutic implications for 
type 2 diabetes and metabolic disease. Published in the Journal of Biomedical Science, 2017, 
24:87; DOI: 10.1186/s12929-017-0394-0.  
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This Chapter examined in detail the role of zinc transporter proteins and the mechanisms 
involved in the decompartmentalisation of zinc and dysfunctional zinc signalling associated 
with metabolic disease including T2DM. The Chapter introduces the reader to the development 
and pathophysiology of T2DM. It outlines the importance of current drug therapy for the 
treatment of T2DM and the need to develop novel therapeutic targets that have greater efficacy 
and safety. The Chapter then discusses zinc and its role as an essential trace metal ion and the 
compartmentalisation of zinc in various cellular organelles. This is highly significant because 
zinc is tightly controlled and decompartmentalisation of zinc is associated with various disease 
states including T2DM (10). The Chapter then discusses the zinc transporter family in detail 
with a specific focus on their roles in cellular signalling and insulin resistance. Of the zinc 
transporters some detail on the role of these proteins in T2DM is given where possible. 
However, extrapolation of zinc transporters involved in other metabolic diseases and their role 
in cell signalling processes associated with cellular homeostasis provides greater clarity to their 
potential function. Finally, a role for the zinc transporter protein ZnT8 is discussed as a 
significant representative of this family of proteins in maintaining insulin storage, secretion, 
and action and how understanding the mechanisms of this transporter (and others) could help 
elucidate novel therapeutic options for the treatment of early diabetic symptoms and T2DM 
(10).  
Research has revealed an important role for zinc and zinc transporters in diseases associated 
with abnormal cellular signalling and metabolism (11). The zinc transporter proteins are unique 
as they can release zinc into the cytosol from intracellular organelles to affect/direct cell 
signalling events (39). Accordingly, zinc transporters have emerged as potential therapeutic 
targets associated with dysfunctional disease states of metabolism. Emerging research has also 
shown that zinc can initiate zinc-mediated signalling events in cells that lead to metabolic 
processes associated with insulin secretion and glucose homeostasis (39). For example, ZnT8, 
a member of the ZnT zinc transporter family, is critical for the compartmentalisation, structure 
and secretion of insulin in beta-cells of the pancreas (10). It has been shown that ZnT8 plays 
an important role in the development of T2DM in humans. In pancreatic β-cells, ZnT8 is highly 
expressed in the insulin secretory vesicles close to the cell membrane (37). Cytoplasmic zinc 
is translocated into the insulin-containing vesicles via ZnT8 to be utilised for insulin 
crystallisation. Mice with pancreatic ZnT8 knockout have defects in the processing, 
crystallisation and secretion of insulin from pancreatic beta-cells (37). These data clearly show 
that ZnT8 is essential for proper beta-cell function and insulin homeostasis. Moreover, a single-
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nucleotide polymorphism (SNP) at amino acid position 325 of the ZnT8 transporter 
(rs13266634) causes susceptibility to diabetes in humans (37). 
ZnT7, another member of the ZnT transporter family, plays an important role in the 
translocation of cytosolic zinc into the Golgi apparatus and ZnT7-containing granules. In 
insulin secreting β-cells, ZnT7 overexpression causes an increase in insulin synthesis and 
secretion (40). It has also been shown that total body zinc concentration is decreased in Znt7 
knock-out mice compared to the wild-type controls (37). In addition, Znt7 knock-out mice also 
have higher blood glucose levels two hours after an oral glucose administration, indicating that 
the Znt7-null mutation may affect glucose homeostasis (37). In fact, ZnT7 affects glucose 
homeostasis and pathogenesis of diabetes through regulating the insulin signalling pathway in 
insulin sensitive peripheral tissues such as skeletal muscle (37). 
ZIP6 and ZIP7, members of the ZIP transporter family, may also play a role in pancreatic 
insulin homeostasis via changes in the pool of available zinc in the cytosol and/or subcellular 
organelles. Knock-down studies in mouse islet cells that reduced the levels of ZIP6 and ZIP7 
resulted in severe oxidative stress and a significant reduction in glucose-stimulated zinc uptake 
(39). These authors speculate that the compromised expression of ZIP6 and ZIP7 potentially 
disrupts zinc homeostasis and produces defects in beta cell function and insulin secretion that 
may initiate the development of diabetes.  
Research has also identified ZIP7 is expressed exclusively in the endoplasmic reticulum and 
the Golgi apparatus to act as the “gate-keeper” of zinc release from these subcellular organelles 
where it is involved in regulating cell signalling and metabolism (41). A reduction in the 
expression of ZIP7 via small interfering RNA (siRNA) in skeletal muscle cells resulted in a 
significant reduction in genes and proteins involved in glucose metabolism, including the 
insulin receptor, IRS1 and IRS2, Akt phosphorylation, glucose transporter Glut4, and glycogen 
branching enzyme (42). These data suggest that ZIP7 is involved in the cellular release of zinc 
that acts on metabolic pathways that lead to glycaemic control in skeletal muscle (42). 
However, the potential mechanism by which zinc and Zip7 can improve glycaemic control is 
not understood. In Chapter 3, 4 and 5, this is evaluated to determine the potential roles of zinc 
and Zip7 on insulin signalling and glucose metabolism in skeletal muscle. 
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1.4.2. Chapter 3: Norouzi, Shaghayegh, Adulcikas, John, Sohal, Sukhwinder Singh and 
Myers, Stephen (2018). Zinc stimulates glucose oxidation and glycemic control by modulating 
the insulin signalling pathway in human and mouse skeletal muscle cells. Published in PLOS 
ONE, 10.1371/journal.pone.0191727.  
This Chapter discusses the important role of zinc in activating the insulin-zinc axis in human 
and mouse skeletal muscle cells. The Chapter demonstrates the role of zinc as an insulin 
mimetic in activating key molecules involved in insulin signalling and glucose homeostasis 
including phospho-tyrosine, PRSA40, Akt, ERK1/2, SHP-2, GSK-3β and p38 and the 
concomitant increase in glucose oxidation in human and mouse skeletal muscle cells (43). It 
also identified that the phosphorylation of Akt, ERK1/2, SHP, and tyrosine could be induced 
by 20 µM of zinc in mouse C2C12 and human skeletal muscle cells. These studies were 
confirmed by treatment of the skeletal muscle cells with 10 nM of insulin which also led to the 
phosphorylation of these molecules. Insulin served as a control as its signalling action on these 
molecules is well-established (43). Similarly, this paper showed that insulin and zinc could 
activate PRAS40, GSK-3β and p38 in a mouse and human protein array that contained several 
proteins implicated in the insulin signalling pathway (43). These studies are the first to 
comprehensively confirm the activation of several insulin signalling molecules by zinc in 
skeletal muscle and further highlights zinc’s insulin mimetic role in the zinc-insulin axis.      
Chapter 3 also describes the effect of glucose consumption through zinc-mediated mechanisms 
in human and mouse skeletal muscle cells. It was identified that in the presence of zinc, glucose 
oxidation was enhanced significantly. These studies were supported by a similar effect with 
insulin treatment where it is well established that insulin increases glucose oxidation in skeletal 
muscle cells (43). 
While it is unclear of the mechanisms whereby zinc activates glucose oxidation, some 
preliminary data in this Chapter suggests that Akt is involved. To address this, we sought to 
determine if a functional insulin receptor was required for the zinc-mediated action on Akt. 
Inhibition of the insulin receptor with a specific antagonist HNMPA-(AM)3 completely 
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abolished insulin-mediated phosphorylation of Akt as expected (43). Similarly, inhibition of 
the insulin receptor eliminated zinc-mediated activation of Akt. These studies therefore suggest 
that zinc-mediated activation of Akt requires a functional insulin receptor (43). Thus, zinc 
independently activates proteins involved in the insulin signalling pathway and both zinc and 
insulin play critical roles in maintaining glucose homeostasis in mouse and human skeletal 
muscle cells. 
As mentioned above, we have shown that zinc could enhance glucose oxidation in skeletal 
muscle cells (43). We hypothesised that the increased glucose oxidation by zinc is due to the 
increased glucose transporter protein (Glut4) translocation to the cell membrane and 
consequent increased glucose uptake by Glut4 transporters. This was investigated in Chapter 4 
outlined below.  
1.4.3. Chapter 4 investigated the effects of zinc on Glut4 mobilisation and glucose 
homeostasis. It is well stablished that insulin induces translocation of the glucose transporter 
Glut4 from intracellular storage compartment to the plasma membrane in skeletal muscle (44). 
Glut4 in muscle and adipose tissue is indispensable for glucose homeostasis. Animal studies 
that show a tissue-specific (adipose and skeletal muscle) deletion of Glut4 compromises 
glucose homeostasis and initiates insulin resistance (45). This is in contrast to the deletion of 
insulin-signalling components from these tissues having minimal effect on compromising 
glucose homeostasis (45). These studies highlight the extreme importance of a functional Glut4 
despite a compromised insulin signalling axis. Moreover, muscle-specific Glut4–knockout 
mice develop severe hyperglycaemia, glucose intolerance, and insulin resistance by eight 
weeks of age (46). It remains unclear whether zinc has a regulatory role in mobilising Glut4 in 
skeletal muscle. Accordingly, these studies presented in Chapter 4 were designed to address 
the zinc-mediated activity of Glut4 in C2C12 skeletal muscle cells. Initially we measured the 
protein levels of Glut4 in the presence of zinc for a period of 16 hours and observed that zinc 
increased Glut4 protein expression after two hours of treatment in mouse C2C12 skeletal 
muscle cells. Then, total membrane and cytoplasm fractions were prepared to measure Glut4 
levels in cells treated with zinc and insulin (as a control). Glut4 transporters were highly 
abundant in the membrane of the skeletal myocytes treated with insulin for 15 minutes. We did 
not detect any changes in the Glut4 membrane abundancy in the skeletal myocytes treated with 
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zinc for 15 minutes compared to the control (untreated cells). In fact, it appeared that the 
experimental procedures might have contributed to this unexpected result. This is outlined in 
detail in Chapter 4.   
We also investigated mobilisation and translocation of Glut4 from intracellular vesicles to the 
outer plasma membrane in C2C12 cells treated with zinc or insulin by confocal microscopy. 
We utilised two strategies to test this, 1) measurement of endogenous Glut4, and 2) 
measurement of exogenous Glut4 bound to Green Fluorescent Protein (Glut4-GFP).  
According to the results, insulin or zinc treatment did not significantly affect mobilisation and 
translocation of Glut4 to the skeletal muscle outer plasma membrane surface from intracellular 
stores in the presence of insulin or zinc. Several reasons why these experiments did not result 
in translocation of Glut4 for are given in Chapter 4. Of these, several research articles suggest 
that C2C12 cells have diminished responses to insulin and reduced Glut4 machinery to enable 
efficient translocation (43). However, this is not congruent with the data from our recent 
publications and others that show insulin can activate pAkt and lead to glucose uptake in these 
cell lines (43, 47). In addition, it is not clear why zinc treatment did not initiate the translocation 
of Glut4. Evidence to possibly support this result are given in Chapter 4.   
1.4.4. Chapter 5. Norouzi, S. Adulcikas, J. Henstridge, D. C. Sonda, S. Sohal, S. S. and Myers, 
S. (2019). The Zinc Transporter Zip7 Is Downregulated in Skeletal Muscle of Insulin-Resistant
Cells and in Mice Fed a High-Fat Diet, Published in Cells, 8: DOI: 10.3390/cells8070663.
Given we have identified several lines of evidence showing zinc can activate several cell 
signalling molecules involved in glucose uptake, we turned our attention to the “gate-keeper” 
of zinc flux, Zip7. It has previously been shown that Zip7 ablation resulted in reduced Glut4 
levels as well as reduced insulin-stimulated glycogen synthesis in mouse skeletal muscle cells 
(42). These data suggest that Zip7 is involved in the cellular release of zinc that acts on 
metabolic pathways that lead to glycaemic control in skeletal muscle.  
To further investigate the role of Zip7 on insulin signalling and glucose metabolism, in Chapter 
5 we examined the effect of hyperglycaemia in mouse skeletal muscle cells treated with glucose 
and measured Zip7 expression. It was identified that treatment of mouse skeletal muscle cells 
with 25 mM glucose robustly upregulated Zip7 protein. Given that Zip7 protein expression 
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could be regulated by glucose, several studies were performed to recapitulate a compromised 
glucose state in mouse skeletal muscle cells. Accordingly, two experimental procedures were 
utilised to create an insulin resistant state in skeletal muscle cells: 1) an inhibitor of the insulin 
receptor HNMPA-(AM)3, and 2) fatty acid (palmitate) treatment. It was identified that Zip7 
(and Glut4) were significantly reduced in insulin resistant mouse skeletal muscle cells using 
the pharmacological inhibitor of the insulin receptor HNMPA-(AM)3 and palmitate. A 
significant decrease in the Akt phosphorylation and tyrosine expression was also observed. 
These studies were intriguing. Given Zip7 is down regulated in a classic insulin signalling 
pathway suggests that this transporter has the potential to modulate the cell signalling pathways 
induced by insulin. To this end, an overexpression Zip7 plasmid was transfected into mouse 
skeletal muscle cells and tested for its ability to regulate genes involved in the insulin signalling 
and glucose homeostasis. A significant overexpression of Zip7 mRNA and protein was 
observed in the skeletal muscle cells. Utilising a commercially available insulin signalling 
pathway array, we detected significant changes (overexpressions and downregulations) in 
several genes including Akt3, Dok2, Fos, Hras, Kras, Nos2, Pck2 and Pparg. These studies 
suggested that Zip7 plays a critical role in maintaining cell signalling processes associated with 
glucose control in mouse skeletal muscle. 
Similarly, Zip7 is reduced in an insulin-resistant state when treated pharmacologically with 
fatty acids. This suggests that Zip7 could be regulated by changes in fatty acids, palmitate or a 
high fat diet (HFD). These results prompted additional studies in an in vivo obese mouse model. 
Accordingly, C57 black 6 mice were fed a diet of normal chow (NC) or HFD for 10 weeks. As 
expected on the HFD, body fat, body mass, and fat percentages were increased in the HFD 
versus the NC. Similarly, an oral glucose tolerance test revealed that the HFD had reduced 
glucose clearance compared to the NC controls. To determine the protein expression of Zip7 
in NC versus HFD, western blots were performed. It was identified that the protein expression 
of both Zip7 and Glut4 were reduced in HFD compare to the NC controls. These data suggest 
that Zip7 plays a role in regulating insulin signalling pathways in skeletal muscle cells and 
these pathways are compromised when Zip7 is downregulated in an insulin resistant state.   
1.5. Summary 
To summarise, IR is a medical disorder that is associated with the development of T2DM. Zinc 
is a crucial component of insulin signalling and glucose metabolism and it may delay the onset 
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of T2DM among patients with IR. Zinc is able to activate insulin signalling molecules and 
increase glucose oxidation possibly independent of insulin in skeletal muscle cells. 
However, this still needs be confirmed. Atypical levels of zinc or aberrant 
compartmentalisation, transport and storage of this ion will have biological effects that could 
be amendable to clinical intervention. Zip7, as the gate keeper of zinc release from 
subcellular organelles, acts on metabolic pathways involved in glucose haemostasis by 
modulating insulin signalling molecules and is reduced in an insulin-resistant state and in 
mice fed a HFD. Further studies are required to clear the molecular mechanism by which 
zinc and Zip7 contribute in insulin signalling and glycaemic control. 
1.6. Hypothesis and aims 
While studies elucidating the role of zinc and zinc transporters in various disease states are 
emerging, their role in activating cell signalling molecules associated with insulin sensitivity 
and glucose metabolism is not well-established. Accordingly, the overall hypothesis of this 
thesis is:  
Zinc and the zinc transporter Zip7 regulate insulin sensitivity in skeletal muscle cells 
Skeletal muscle cells respond to insulin and previous studies have shown that insulin is required 
to activate cell signalling molecules such as the phosphorylation of Akt that are essential for 
driving insulin-specific glycaemic control (42). To determine if zinc is involved in signalling 
events independent, or dependent on insulin activity, the following Aims were performed.  
Aim 1: To determine the action of insulin and zinc on insulin-mediated signalling in skeletal 
muscle cells.  
IR is a precursor to T2DM and studies addressing the molecular mechanisms of IR are critical 
to develop novel therapies to better manage this disorder before the development of T2DM. To 
determine if IR affects zinc-dependent cell signalling events, the following Aim 2 was 
proposed.  
Aim 2: To create insulin-resistant skeletal muscle cells and determine the effect of zinc on 
insulin signalling.  
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 The zinc transporter ZIP7 is implicated in the “gated” release of zinc into the cytosol where it 
can act on cell signalling events that lead to metabolic processes associated with cell viability 
(41). The following Aim 3 was proposed to address the role of Zip7-mediated activation of 
insulin-dependent cell signalling pathways. 
 
Aim 3: To determine the role of Zip7-mediated cell signalling events controlling glucose 
metabolism in insulin resistant skeletal muscle cells and obese mice.  
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Zinc transporters and insulin resistance:
therapeutic implications for type 2 diabetes
and metabolic disease
Shaghayegh Norouzi, John Adulcikas, Sukhwinder Singh Sohal and Stephen Myers*
Abstract
Background: Zinc is a metal ion that is essential for growth and development, immunity, and metabolism, and
therefore vital for life. Recent studies have highlighted zinc’s dynamic role as an insulin mimetic and a cellular second
messenger that controls many processes associated with insulin signaling and other downstream pathways that are
amendable to glycemic control.
Main body: Mechanisms that contribute to the decompartmentalization of zinc and dysfunctional zinc transporter
mechanisms, including zinc signaling are associated with metabolic disease, including type 2 diabetes. The
actions of the proteins involved in the uptake, storage, compartmentalization and distribution of zinc in cells is under
intense investigation. Of these, emerging research has highlighted a role for several zinc transporters in the initiation of
zinc signaling events in cells that lead to metabolic processes associated with maintaining insulin sensitivity and thus
glycemic homeostasis.
Conclusion: This raises the possibility that zinc transporters could provide novel utility to be targeted experimentally
and in a clinical setting to treat patients with insulin resistance and thus introduce a new class of drug target with utility
for diabetes pharmacotherapy.
Keywords: Zinc ions, Skeletal muscle, Cell signaling, Glycemic control
Background
Insulin resistance (IR) is a common pathophysiological
condition in which patients present with reduced insulin
sensitivity and thus glucose intolerance, particularly in
liver, adipose tissue and skeletal muscle [1]. This has
significant implications for the patient, as they are unable
to obtain to process the required energy from glucose to
maintain cellular metabolic processes. IR is of major global
concern as it is well-established as underpinning many
chronic health conditions including type 2 diabetes mellitus
(T2DM), obesity, cardiovascular disease polycystic ovary
syndrome (PCOS), liver cirrhosis [2] atherosclerosis,
hypertension, and stroke [3]. Moreover, given that IR
usually precedes the development of T2DM and contrib-
utes to the progressive nature of this challenging and devas-
tating disease, understanding the molecular mechanisms
that lead to IR will help facilitate the development of
novel therapeutic strategies to prevent or lessen disease
progression. However, despite extensive ongoing research
into IR, its molecular mechanism(s) of action remains
largely elusive.
Recently, research on metabolic processes associated
with IR and T2DM has revealed an exciting role for the
biochemical and physiological role of zinc and the proteins
that transport zinc in cells in diseases associated with
abnormal cellular signaling [4]. Accordingly, zinc and the
proteins that transport this metal ion have emerged as
potential therapeutic targets for disease states associated
with dysfunctional metabolism. For example, zinc in the
diet and zinc transporter proteins that influence/regulate
zinc metabolism are implicated in metabolic homeostasis in
peripheral tissues (e.g. skeletal muscle and liver) that re-
spond to insulin [4].
Zinc is ubiquitous in physiological systems, albeit, within
tightly controlled parameters, and therefore suggests that
atypical levels are likely to have significant biological and
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clinical effects on disease processes. Knowing how zinc
transporter proteins and the storage of zinc in cells are in-
volved in metabolic processes implicated in IR for example,
may present opportunities to develop novel drugs targeting
these transporters to prevent or treat IR and T2DM disease
progression.
Type 2 diabetes mellitus
Type 2 diabetes mellitus (T2DM) is devastating disorder
characterised by hyperinsulinemia, hyperglycaemia, com-
promised energy metabolism and expenditure, and the
progression of chronic illness and disease. T2DM is high
complex involving both genetic predisposition and envir-
onmental factors. A major factor involved in a person’s
susceptibility to T2DM can be linked through family
history of diabetes. For example, Pacific Islander peoples
are a unique population with especially high rates of T2DM
[5]. The environment also plays a major role in the devel-
opment of IR and T2DM with inactivity and poor nutri-
tional status being two key factors [6].
Development of T2DM
The development of T2DM is preceded by IR, a disorder
associated with hyperinsulinemia, glucose intolerance
and dysfunctional energy metabolism [7]. A leading con-
cern for people with IR is the progressive failure of pan-
creatic β-cell function (a major determinant of T2DM
progression) and thus, compromised insulin secretion
[8]. T2DM occurs primarily due to pancreatic β-cell fail-
ure, including disruption of β-cell function and mass [8].
Elevated blood glucose causes the pancreatic β-cells to
produce more insulin resulting in hyperinsulinemia. Thus,
pancreatic β-cells amplify insulin synthesis as well as insulin
secretion pathways to overcome IR through an adaptive
response called β-cell compensation [9]. Consequently, the
failure of β-cells occurs in response to elevated insulin
levels and thus elevated blood glucose which results in in-
sulin insufficiency and overt diabetes. Accordingly, T2DM
patients with loss of β-cell function will cease to live a
normal life and will endure life-long pharmacological inter-
vention, often with episodes of illness from unfavourable
side-effects associated with the anti-diabetic treatments.
Therefore, prevention strategies that take advantage of this
“window of opportunity” (before β-cell failure) to prevent
or lessen disease progression would have an enormous im-
pact on the health and wellbeing of our communities.
Current drug treatments for T2DM
There are a range of medicines available to manage and
treat IR and T2DM, however, side effects of these drugs
have always been a foremost challenge in relation to the
goal of pharmacotherapy [10] (Table 1). Yet, treatments
for IR have not advanced significantly in the last few
decades because of the inadequate knowledge about the
pleiotropic effects that these drugs have on specific
molecular targets [11]. Therefore, finding strategies to
increase the efficacy and safety of therapeutic treatment for
IR and T2DM is highly critical. In this context, research
over the last decade has suggested a role for zinc in the
treatment of T2DM [12]. For example, lowered zinc
concentrations have been identified in some patients
with T2DM [13] and zinc supplementation appears to
improve the effectiveness of oral hypoglycaemic agents,
decreasing blood glucose, triglycerides and inflammation
in some patients [14]. However, many of these kinds of
studies are not consistent in their findings and adds fur-
ther complications in determining a role for zinc in these
processes. Thus, it will be important to look at the role of
zinc transporters and how they transport zinc within a
cellular context during disease progression.
Zinc
Zinc is an essential trace element that is found in all
parts of the body including the fluids and secretions,
tissues and organs. Zinc is one of the most abundant
trace metals (next to iron) in the human body, con-
taining approximately 2–4 g [15]. The concentration
of zinc in tissues is highest in the prostate (approxi-
mately 200 μg/ml), followed by the pancreas (approxi-
mately 40 μg/ml) and then muscle (approximately
50 μg/ml). In human plasma, there is approximately
14–16 μM of total zinc that is distributed to cells and
subcellular organelles [15]. In multicellular organisms,
almost all zinc is intracellular with the nucleus har-
bouring approximately 30–40%, the cytoplasm, organ-
elles and specialised vesicles approximately 50%, and
the cell membrane has about 10% [12]. Under normal
cellular conditions there is no free zinc and therefore,
the compartmentalization and distribution of cellular
zinc is highly important and tightly controlled so that
zinc homeostasis is maintained with an appropriate
cellular concentration and physiological range. This is
achieved by a family of zinc transporter proteins and
metallothioneins [16, 17].
Table 1 Some common anti-diabetic therapies and their side
effects
Current Therapies Side Effects
Metformin (dimethylbiguanide) Gastrointestinal intolerance and
side effects [76, 77].
Sulphonylureas Hypoglycaemia risk, weight gain
[78], cardiovascular disease [79].
Incretin-based therapies Arrhythmia [80], pancreatitis [81].
Thiazolidinediones Risk of heart failure [82].
Dipeptidylpeptidase-4 inhibitors Heart failure [83].
Sodium-coupled glucose co-
transporter (SGLT-2) inhibitors
Dehydration and urinary infections
in elderly patients [84].
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Metallothioneins and zinc transporters
Two families of zinc transporter proteins and zinc buffering
proteins play a critical role in the influx, efflux, buffering
and compartmentalization of zinc. These are the zinc trans-
porters (ZnT proteins and Zrt/Irt-like ZIP proteins),
and the intracellular zinc-binding metallothionein (MT)
proteins [18]. MT proteins are a group of soluble low
molecular weight metal binding proteins that buffer
and translocate zinc within the cytosol [19]. The ZIP
and ZnT1 zinc transporters belong to a family of trans-
membrane proteins that control zinc movement and
thus zinc concentrations in cells. The ZnT family mem-
bers (ZnT1–10) are involved in depleting cytosolic zinc by
moving this metal ion into intracellular organelles or from
the extracellular space while the ZIP family members in-
crease cytosolic zinc by transporting this metal ion from
outside the cell or from intracellular organelles (Fig. 1).
ZIP transporter family
The original member of the ZIP family of zinc transporters
was identified in Saccharomyces cerevisiae (designated
ZRT1) based on an amino acid sequence similarity to
that of Irt1p, an Fe(II) regulated transporter from
Arabidopsis thaliana [20, 21]. Consistent with the pro-
posed role of ZRT1 in zinc uptake, zinc uptake was
increased when this transporter was overexpressed in
yeast cells. Similarly, a mutation that disrupted the func-
tion of ZRT1 led to reduced levels of zinc uptake and poor
cellular growth in the mutant yeast strain [21].
The ZIP family of zinc transporters have a predicted
eight transmembrane domain (TMD) structure and this
is orientated with the N- and C-terminal facing the extra-
cytosolic region. Many of these members have a predicted
long histidine-rich loop region (HXn, n = 3–5) situated
between TMD 3 and TMD 4 that is suggested to serve as
a zinc-binding site (Fig. 2) [22, 23]. In mammals, there are
at least fourteen ZIP transporters that have critical roles in
the transport of zinc into cytoplasm from extracellular
sources and intracellular storage compartments such as
the Golgi apparatus and endoplasmic reticulum, when the
cytosolic zinc is depleted. The ZIP transporters are regu-
lated by intracellular and extracellular zinc concentrations,
and hormones and cytokines. They are also expressed in
several tissues and cell types and their proteins are local-
ized to specific subcellular compartments and have been
extensively reviewed elsewhere [24].
ZnT transporter family
The ZnT zinc transporters are a large family that include
members with similar structural homology to bacteria,
fungi, nematodes, insects, plants and mammals [25]. This
family is predicted to have six transmembrane domains
(TMDs) with a histidine-rich loop region between TMD 4
and TMD 5 (Fig. 2). The original mammalian ZnT was
identified from a rodent cDNA library and was shown ex-
perimentally to confer resistance to zinc toxicity in baby
hamster kidney cell lines [26]. Since the discovery of
ZnT1, nine other members have been identified (desig-
nated SLC30A1–10). ZnTs are implicated in the transport
of zinc into subcellular organelles and from the cytosol
through the plasma membrane into the extracellular space
[25]. Like the ZIPs, the ZnTs are regulated by intracellular
and extracellular zinc, hormones, and cytokines and are
extensively reviewed elsewhere [24].
Zinc, zinc transporters and cellular signaling: A prelude to
cell signaling and insulin resistance
Changes in zinc compartmentalization and availability in
cells is typically detected and regulated by the intrinsic
control of zinc transporter proteins. The cellular homeosta-
sis of zinc is highly complex and there are several highly
significant reviews on these processes [12, 15, 16, 27–30].
Accordingly, this section of the review aims to delineate the
mechanisms by which zinc, and zinc transporters contrib-
ute to cell signaling and how these processes might provide
insights into the molecular mechanisms implicated in
disease processes such as insulin resistance and type
2 diabetes.
Zinc mimics the action of several molecules implicated
in cellular metabolism including hormones, growth factors,
and cytokines, and given the large number of mammalian
zinc transporters that regulate zinc homeostasis, it is not
surprising that this metal ion has been highlighted as a
leading signaling molecule like calcium. Two modes of
zinc signaling have been described. These are 1) early
Fig. 1 Cellular and subcellular localization of zinc transporters ZIP
and ZnT. The primary localization of ZIP transporters (red arrow
heads) and ZnT transporter (purple arrows) is shown representing
the direction of zinc transport. Figure was produced using
Smart Servier Medical Art, http://smart.servier.com/ and adapted
from Kimura and Kambe (2016) [22]
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zinc signaling (EZS) and, 2) late zinc signaling (LZS).
EZS, is a process that is independent of gene transcrip-
tion and results in rapid changes in intracellular levels
of zinc that occurs in minutes (the ‘zinc wave’ response)
through the triggered release of zinc from subcellular
organelles into the cytosol [31]. This phenomenon was
first shown in studies in mast cells where an extracellular
stimulation of these cells with the high affinity IgE re-
sulted in a rapid increase in intracellular zinc from the
endoplasmic reticulum within minutes [32]. LZS can
also be triggered by extracellular stimuli but involves
transcriptional-dependent changes in genes and thus
proteins that are involved in zinc homeostasis such as
storage proteins or transporters [33]. The importance
of these two mechanisms of EZS and LZS highlight the
diverse roles that this metal ion plays in processes that re-
quire rapid signals (such as metabolism) and more long-
term functions such as cell differentiation and cell growth.
The defining role of zinc as a signaling molecule was
shown in early studies in rat adipocytes where zinc could
stimulate lipogenesis, independent, and additive to that
of insulin [34]. Similarly, in rat adipocytes, zinc activated
cAMP phosphodiesterase and the mobilization of glucose
transporters to the plasma membrane, independent of
insulin receptor kinase activity [35]. Since these studies
implicating zinc as a signaling molecule, there is increas-
ing evidence suggesting zinc acts in extracellular signal
recognition [32], second messenger activity [36], protein
kinase activity [37], protein phosphorylation [38], and
transcription factor regulation [39]. These studies clearly
highlight the role of zinc in signaling processes that are
also associated with insulin-mediated metabolism.
The mechanisms of the insulin-mimetic action of zinc
have been delineated in several studies however it is still
unclear how these processes occur. One well-established
mechanism of zinc action on cellular signaling events
occurs through the inhibition of protein tyrosine phosphat-
ase 1B (PTP1B). PTP1B functions as a negative regulator of
insulin and leptin signaling transduction pathways [40].
Thus, the inhibition of PTP1B by zinc ions can prolong the
insulin signal through the insulin receptor. Similarly, the
ability of zinc to modulate glucose transport, glycogen syn-
thesis, lipogenesis, to inhibit gluconeogenesis and lipolysis,
and to regulate key elements of the insulin signaling
pathway [41] suggests that this metal ion could provide
therapeutic insight or utility in the management and/or
treatment of insulin resistance. This is an interesting
notion in a clinical context since patients that are insulin
resistance have a “blunted” response to insulin and subse-
quent downstream cellular signaling responses. Therefore,
the activation of cellular insulin signaling cascade that is
critical to achieve glycemic control might involve zinc.
However, the question remains as to whether zinc inde-
pendently activates critical molecules involved in cellular
signaling in the absence of insulin or whether zinc requires
insulin for these processes.
Zinc transporters, cellular signaling and insulin resistance
Given the well-established role of zinc transporters in
mediating the critical control of zinc homeostasis in
cells, it will be important to further delineate their func-
tion in cell signaling events in the context of metabolic
control. Currently, information is limited to what role the
zinc transporters might play in cell signaling events in the
context of insulin resistance. Therefore, extrapolation of
studies from other cellular systems or disease states that
have identified zinc transporters and thus zinc flux in
facilitating cell signaling events might prove useful.
Studies accessing the role of zinc transporters in cellular
signaling found that the zinc transporters ZnT5 and ZnT7
are responsible for loading zinc to alkaline phosphatases
(ALPs) in the biosynthetic-secretory pathway in chicken B
Fig. 2 Predicted structure of the zinc transporters ZIP and ZnT. ZIP transporters are predicted to have eight transmembrane domains (TMDs) with
a long histidine loop between TMDs 3 and 4. The ZnT transporters are predicted to have six TMDs with a histidine loop between TMDs 4 and 5.
Figure was produced using Servier Medical Art, http://www.servier.com
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lymphocyte-derived cells [42]. These authors noted that
mutant cells lacking both ZnTs resulted in a marked loss
in ALP activity and this activity could be restored by over-
expressing both ZnT5 and ZnT7. Similarly, the coopera-
tive activity of ZnT1, ZnT4 and metallothioneins are
required for the full activation of alkaline ALP in the
early-secretory pathway [43]. Accordingly, the above stud-
ies demonstrate that ALP can be activated by the ZnT
family of zinc transporters and therefore aid in the control
of numerous cellular events.
In other studies, ZnT1 can regulate Raf-1 enzymatic
activity in Xenopus oocytes and cultured mammalian cells
[44]. Raf-1 plays a critical role in signal transduction in
eukaryote cells where it phosphorylates and activates
MEK1, a protein threonine and tyrosine kinase that acti-
vates the MAPK family members ERK1 and ERK2 [45].
ZnT1 was shown to bind to the amino end of the Raf-1
protein and promote kinase activation. Moreover, increas-
ing the concentration of intracellular zinc inhibited
Ras-mediated signaling through zinc blocking the abil-
ity of ZnT1 to bind Raf-1 [44] suggesting that Raf-1
activity requires functional ZnT1.
Of the ZIP transporters, ZIP14 is important in G-protein
coupled receptor (GPCR)-mediated signaling through the
maintenance of intracellular cAMP levels via suppression
of phosphodiesterase activity [46]. In these studies, fasting
gluconeogenesis is impaired in the livers of ZIP14 knockout
mice which was attributable to changes in GPCR signaling
processes. Similarly, in ZIP14 knock-out mouse chondro-
cytes, parathyroid hormone-related peptide (PTHrP)-
mediated c-fos activity was significantly reduced. PTHrP
stimulates the phosphorylation of cAMP response element-
binding protein (CREB) which in turn induces the tran-
scription of c-fos [47].
Studies in MCF breast cancer cell lines have identified
that ZIP7 is essential in the redistribution of zinc from
intracellular stores to the cytoplasm and subsequent zinc-
induced inhibition of phosphatases [36]. Moreover, ZIP7
knock-down in these cells prevented the zinc-induced acti-
vation of epidermal growth factor receptor (EGFR), insulin-
like growth factor-1 receptor (IGF-1R), and protein kinase
B (AKT); key molecules implicated in cellular metabolism.
In fact, ZIP7 has been coined the “gatekeeper” of cytosolic
release from the endoplasmic reticulum (ER) and Golgi
apparatus [48]. ZIP7 is phosphorylated by CK2 in MCF-7
cells and this activation leads to the “gated” release of zinc
from the ER and the subsequent activation of multiple
downstream signaling pathways including AKT and extra-
cellular signal-regulated kinases 1and 2 (ERK1/2) [48].
ZIP7 is essential for the proliferation of intestinal epithe-
lial cells and mice lacking this transporter in intestinal epi-
thelium have massive apoptosis of transit-amplifying cells
due to increased endoplasmic reticulum stress (ER) [49].
Similarly, studies identified that the phosphorylation of
ZIP7 was increased in cardiomyocytes under hypergly-
cemia conditions and was implicated in driving ER
stress [50]. Given that ZIP7 facilitates the release of
zinc from the ER [48] and ablation of ZIP7 in mesen-
chymal stem cells led to the accumulation of zinc in
the ER and subsequent ER dysfunction [51], it is plaus-
ible that ZIP7 could also be implicated in ER stress in
type 2 diabetes. Undeniably, ER stress and the dysregu-
lation of ER function in pancreatic beta cells are central
in the pathogenesis of diabetes [52].
Previously we have identified a role for ZIP7 in glycemic
control in skeletal muscle [53]. Skeletal muscle acts as a
major reservoir for zinc containing approximately 60% of
total whole-body zinc [54]. Knock-down of ZIP7 in C2C12
mouse skeletal muscle cells led to a significant reduction in
several genes and proteins involved in glucose metabolism
including the insulin receptor (Ir), insulin receptor sub-
strates 1 and 2 (Irs1 and Irs2), the phosphorylation of Akt,
glucose transporter Glut4, and glycogen branching enzyme
(Gbe) [53]. These data suggest that ZIP7 controls glucose
metabolism via the phosphorylation of Akt and Glut4
mobilization (Fig. 3). It is not clear if reduced ZIP7 and thus
reduced zinc levels leads to changes associated with the
phosphorylation status of the insulin receptor substrates
directly, or if reduced ZIP7 leads to inhibition of insulin
receptor signaling via binding of PTP-1B. Studies have
identified that the ZIPs play a major role in regulating cyto-
solic zinc homeostasis and insulin secretion [55]. In these
studies, it was suggested that the zinc transporters ZIP6
and ZIP7 may have a role in insulin secretion in pancreatic
beta cells via alterations in cytosolic and/or subcellular
organelle-specific zinc pools. The down regulation of these
transporters via knock-down studies led to a significant
reduction in glucose-stimulated zinc uptake and oxidative
stress in mouse islet cells [55]. These authors speculate that
reduced expression of ZIP6 and ZIP7 may disrupt zinc
homeostasis and thus produce defects in insulin secretion
and beta cell viability that could potentially lead to the
development of diabetes.
Recent studies have shown a relationship with ZIP13 and
beige adipocyte biogenesis and thermogenesis [56]. In
primary white preadipocytes isolated from white fat from
ZIP13 null mice, there was a slight increase in common
white fat genes but a significant increase in the gene expres-
sion of brown-fat specific genes and suggests that this trans-
porter is implicated the inhibition of beige fat differentiation
[56]. Moreover, these authors demonstrated that ubiqui-
nated C/EBP-β was decreased in ZIP13 null mice. C/EBP is
a major regulator of adipogenesis through the activation of
genes essential for mitotic clonal expansion and thus, ter-
minal adipocyte differentiation [57]. Accordingly, these stud-
ies suggest that ZIP13 deletion promotes beige adipocyte
production and is associated with increased exergy expend-
iture, reduced diet-induced obesity and insulin resistance.
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ZIP14 has been identified as a critical route for non-
transferrin bound iron (NTBI) uptake into liver and pan-
creatic acinar cells and is essential for the development of
liver iron overload in hemochromatosis [58]. Diabetes is
frequently associated with hemochromatosis and patients
with type 2 diabetes present with high ferritin levels which
correlate with diabetic retinopathy [59]. Similarly, ZIP14
knock-out mice have enlarged pancreatic islets, low
grade inflammation, and subsequent hyperinsulinemia
and increased body fat which are characteristic of type
2 diabetes [60].
Do the zinc transporters and zinc signaling play a role
in insulin resistance and the progression of type 2
diabetes?
Zinc plays a major role in many aspects of cell signal-
ing events in several physiological and pathophysio-
logical processes. While it is well established that at
least one zinc transporter (ZnT8) is critical for the
compartmentalization, structure and secretion of insu-
lin in beta cells of the pancreas [30], there is little
information about the other family members in this
context. Nonetheless, given the important role that
zinc transporters play in delivering bioactive zinc to
extracellular, cytosolic and subcellular milieu, and the
action of this metal ion on cell signaling events, it is
highly tempting to speculate that aberrant storage and
release of zinc will result in unfavorable processes
associated with insulin signaling and glycemic control.
ZnT8 and type 2 diabetes
Zinc is critical for the physiological role of insulin in the
form of storage in the secretory granules of the pancreas
as an inactive zinc-insulin hexamer [61, 62]. When the
zinc-insulin hexamer is released into the blood circulation,
a change in pH drives the dissociation of the complex into
a bioactive monomer of insulin [63]. The zinc transporter
that initializes zinc movement into insulin granules of the
pancreatic β-cells is ZnT8. In fact, this transporter is al-
most exclusively localized in pancreatic β-cells and it is
critical for the synthesis, storage and action of insulin [64].
Genome-wide association studies (GWAS) have discov-
ered that a nonsynonymous single nucleotide polymorph-
ism (SNP) in ZnT8 (rs13266634) encodes a C→T base
substitution resulting in a change in the coded protein
(p.Arg325Trp) and the production of two protein variants
R and W of which the C allele (R variant) is associated with
susceptibility to type 2 diabetes [65]. The frequency of the
diabetes risk R allele is 91.5%, 71.7% and 56.7% in Africans,
Europeans, and Asians, respectively [66]. Moreover, the
corresponding at-risk R325 variant had reduced zinc trans-
porter activity compared to the W325 ZnT8 in pancreatic
beta-cell lines. Therefore, carriers of the R325 variant may
have compromised packaging of insulin in pancreatic beta-
cell granules [67]. In studies of 846 European individuals,
each of whom had a parent with type 2 diabetes, it was
demonstrated that homozygous carriers of the major C
risk-allele variant had compromised pancreatic β-cell insu-
lin secretion following an intravenous glucose load [68]. It
was suggested by these authors that the function and/or
Fig. 3 Potential role of ZIP7-mediated glucose metabolism in skeletal muscle. The ZIP7-gated release of zinc from the Golgi apparatus
and/or the endoplasmic reticulum activates the phosphorylation of AKT and the subsequent mobilization of the glucose transporter
GLUT4 which in turn brings glucose into the cytosol. Zinc also inactivates the negative regulation of insulin signalling, PTP-1B which
allows the insulin signalling cascade process. The role of zinc activation of insulin receptor substrates (IRS) is not known (dashed lines)
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production of ZnT8 in carriers of the C risk allele is re-
duced and therefore likely to contribute to compromised
pancreatic beta-cell function.
Although GWAS studies have been successful in identi-
fying variant ZnT8 alleles, it does not necessarily imply
that the risk allele has a direct pathophysiological effect
on beta-cell insulin secretion. A Meta-Analysis of Glucose
and Insulin-related traits Consortium (MAGIC) was
recently formed to conduct large-scale meta-analyses of
genome-wide data for continuous diabetes-related traits
in non-diabetics [69]. Meta-analyses were performed on
approximately 2.5 M directly genotyped or imputed
SNPs from twenty-one GWAS that were informative
for fasting glucose (FG), fasting insulin (FI) and, pan-
creatic beta-cell function (HOMA-B) and insulin resist-
ance (HOMA-IR) in non-diabetic participants [69]. It
was identified that the risk allele for ZnT8 was associ-
ated with higher FG levels and an increase in two-hour
glucose response in non-diabetics. Although these studies
identified several genetic glycemic risk loci for type 2 dia-
betes, including ZnT8, not all loci are associated with
pathological levels of glucose and type 2 diabetes risk.
More recent studies that sequenced approximately
150,000 individuals across five ancestry groups reported
twelve rare protein-truncating mutations in ZnT8 which
together explain a 65% reduced risk of developing type 2
diabetes [70]. It was found that a nonsense variant en-
coding (c.412C→T, p.Arg138*) heterozygosity yielded a
53% reduction in type 2 diabetes risk. Similarly, hetero-
zygosity for the variant encoding p.Lys34Serfs*50 which
is predicted to cause a frameshift and loss of all six
ZnT8 transmembrane domains was associated with an
80% reduction in type 2 diabetes risk.
Recently, studies aimed to delineate the effect of dietary
factor interactions with ZnT8 polymorphism (rs13266634)
and the risk of developing metabolic syndrome found a sig-
nificant interaction among omega-3 fatty acid consumption
and ZnT8 in the context of metabolic syndrome, dyslipid-
emia, and abdominal obesity [71]. Participants with the CC
genotype benefited more from the consumption of omega-
3 fatty acids than carriers of the CT +TT genotypes. Car-
riers of the CC genotype had reduced risk of developing
these disease states with increased consumption of omega-
3 fatty acids. Moreover, the risk of abdominal obesity in the
CT +TT genotype groups increased significantly with salty
snack consumption but not in the CC homozygote carriers.
Studies to investigate the role of ZnT8 and glucose
homeostasis has been established with ZnT8 null mouse
models with global deletion of ZnT8 or pancreatic beta-
cell specific ZnT8 deletion [72]. Most models resulted in
impaired or unaltered glucose tolerance, however in
ZnT8-depleted beta cells insulin granule abnormalities
were observed, and this was concomitant with a loss of
zinc release from secretory granules [73]. Similarly, ZnT8-
specific deletion in beta cells resulted in reduced periph-
eral insulin concentrations despite an unexpected increase
in insulin secretion from isolated ZnT8-depleted islets
[74]. These authors suggest that secreted insulin from the
pancreas in the ZnT8 knock-out mouse suppresses hep-
atic insulin clearance and dysregulation of this process
could play a role in the pathogenesis of type 2 diabetes. A
recent study [75] revealed ZnT8 deletion in mouse beta-
cells resulted in a significant impairment in zinc release,
normal or increased insulin secretion and subsequent im-
pairment in glucose tolerance. Moreover, transgenic mice
that overexpressed ZnT8 in beta cells showed a significant
improvement in zinc release, lower levels of insulin secre-
tion and improved glucose tolerance [75].
Given the pancreatic tissue-specificity of ZnT8 there is
potential for this transporter to be amendable to therapy
in the treatment of diabetes. However, targeting ZnT8 in
the treatment of diabetes could prove to be highly com-
plex. Although results from ZnT8 null mice suggest that
increasing ZnT8 could improve insulin secretion and
glycemic control, loss of function mutations in ZnT8
suggest a protective role for this transporter in type 2
diabetes. While ZnT8 plays a critical role in insulin
physiology, and over the last decade or so this trans-
porter has been given much attention for its role in dia-
betes, other zinc transporters have not had the same
focused attention until recently. Apart from the many
studies on zinc signaling in cells and the insulin-mimetic
action of zinc, it is unclear which zinc transporters are
involved in initiating these signaling processes. Clues
from studies on the role of ZIP7 as the “gate-keeper” of
zinc release from the Golgi apparatus [48] and subse-
quent ZIP7-mediated cell signaling events in skeletal
muscle [49] no doubt place this transporter in an im-
portant position for further studies. Identifying how the
zinc transporters are implicated in zinc signaling events
that are amendable to insulin signaling processes in in-
sulin resistance may help elucidate novel therapeutic op-
tions for the treatment of early diabetic symptoms and
thus the long-term management of this disorder and as-
sociated type 2 diabetes.
Conclusion
Zinc is an essential metal ion that is ubiquitous in many
metabolic and physiological processes. The emerging
role of zinc as an insulin mimetic in maintaining cellu-
lar function suggests that atypical levels, and aberrant
compartmentalization, transport and storage of zinc
will have biological effects that could be amendable to
clinical intervention. Although current understandings
on the role of zinc transporters in insulin resistance is
not available, and this knowledge is only just emerging
in type 2 diabetes, it is clear from studies on ZnT8 that
this family of transporters has utility for the development
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of novel diabetic therapies. While ZnT8 plays a significant
role in insulin biology and therefore represents an attract-
ive target for diabetes therapy, the other members of the
zinc transporter family in diabetes are less defined. How-
ever, we can speculate from the information presented in
this review that the other transporters are involved in pro-
cesses that facilitate insulin signaling and glycemic control
and therefore could offer exciting new targets that are
amendable to therapeutic intervention in the treatment of
diseases associated with insulin resistance and type 2
diabetes.
Endnotes
1For brevity, the terms ZIP and ZnT will be used
throughout.
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Zinc stimulates glucose oxidation and
glycemic control by modulating the insulin
signaling pathway in human and mouse
skeletal muscle cell lines
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Launceston, Tasmania, Australia
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Abstract
Zinc is a metal ion that is an essential cell signaling molecule. Highlighting this, zinc is an
insulin mimetic, activating cellular pathways that regulate cellular homeostasis and physio-
logical responses. Previous studies have linked dysfunctional zinc signaling with several dis-
ease states including cancer, obesity, cardiovascular disease and type 2 diabetes. The
present study evaluated the insulin-like effects of zinc on cell signaling molecules including
tyrosine, PRSA40, Akt, ERK1/2, SHP-2, GSK-3β and p38, and glucose oxidation in human
and mouse skeletal muscle cells. Insulin and zinc independently led to the phosphorylation
of these proteins over a 60-minute time course in both mouse and human skeletal muscle
cells. Similarly, utilizing a protein array we identified that zinc could active the phosphoryla-
tion of p38, ERK1/2 and GSK-3B in human and ERK1/2 and GSK-3B in mouse skeletal
muscle cells. Glucose oxidation assays were performed on skeletal muscle cells treated
with insulin, zinc, or a combination of both and resulted in a significant induction of glucose
consumption in mouse (p<0.01) and human (p<0.05) skeletal muscle cells when treated
with zinc alone. Insulin, as expected, increased glucose oxidation in mouse (p<0.001) and
human (0.001) skeletal muscle cells, however the combination of zinc and insulin did not
augment glucose consumption in these cells. Zinc acts as an insulin mimetic, activating key
molecules implicated in cell signaling to maintain glucose homeostasis in mouse and
human skeletal muscle cells. Zinc is an important metal ion implicated in several biological
processes. The role of zinc as an insulin memetic in activating key signaling molecules
involved in glucose homeostasis could provide opportunities to utilize this ion therapeutically
in treating disorders associated with dysfunctional zinc signaling.
Introduction
Insulin resistance is a common pathophysiological condition in which patients present with per-
turbed biological responses to endogenous insulin leading to compromised glucose homeostasis
specifically in liver and skeletal muscle [1]. The contribution of insulin resistance in various dis-
eases such as type 2 diabetes (T2D), obesity, liver cirrhosis, atherosclerosis and cardiovascular
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disease [1, 2] is highly significant. A foremost concern for people with insulin resistance is the pro-
gressive failure of pancreatic β-cell function (a major determinant of type 2 diabetes progression)
and compromised insulin secretion. Therefore, prevention strategies that take advantage of this
“window of opportunity” (before β-cell failure) to prevent or lessen disease progression would
have an enormous impact on the health and wellbeing of our communities. Currently, zinc is
being investigated for its role in cell signaling pathways that are amendable to glucose homeostasis
and thus have implications for insulin resistance and type 2 diabetes [3].
Zinc is present in all parts of the body including organs, tissues, fluids and secretions [4]
and plays a critical role in a wide variety of biological processes [5, 6]. For example, zinc has a
unique and extensive role in nucleic acid and lipid metabolism, cell signaling, growth and dif-
ferentiation, apoptosis, enzyme activity, and brain and immune function [7]. Normal zinc
homeostasis has a critical role in the release and action of insulin to maintain glucose homeo-
stasis [8] since zinc has insulin mimetic activity and controls cellular processes including insu-
lin receptor signal transduction, and insulin storage and secretion [9].
Zinc is essential for the processing, crystallization, and storage of insulin in pancreatic β-
cells through the function of the pancreatic zinc transporter ZnT8 that moves zinc into insulin
secretory cells [10, 11]. Beta-cell specific ZnT8 knock out mice display glucose intolerance,
abnormal β-cell morphology, reduced islet insulin processing, a reduction in the total number
of granules, and an increase in empty atypical granules suggesting that insulin crystallization
and packaging is compromised [10]. In fact, there is a strong association between a mutation
in ZnT8 (an arginine is replaced with a tryptophan at position 325 [R325W] in the cytoplasmic
domain) which increases the risk of type 2 diabetes [12,13].
Early studies on zinc’s insulin mimetic activity revealed that this metal ion increased
glucose metabolism in isolated rat adipocytes [14]. Similarly, in 3T3-L1 adipocyte cells, zinc
treatment increased tyrosine phosphorylation of the insulin receptor β subunit and phosphor-
ylation of Akt, and this was concomitant with enhanced glucose transport, independent of
insulin [15]. These studies were further supported in C2C12 skeletal muscle cells where zinc
could phosphorylate tyrosine, and the insulin receptor substrate 1 (ISR1) in the absence of
insulin [16]. Moreover, zinc stimulated glucose consumption in normal and insulin-resistant
L6 myotubes and was concomitant with the upregulation of Akt, the translocation of Glut4
and the phosphorylation of Gsk3β [17]. In delineating the mechanism whereby zinc exerts its
effect on tyrosine phosphorylation, it was shown that zinc can increase tyrosine phosphoryla-
tion by inhibiting tyrosine phosphatases in C6 glioma cells [18,19]. These data are supported
by recent studies that showed zinc ions inhibited PTP1B activity through direct binding to the
enzyme [20]. These above studies on zinc as an insulin mimetic relay important information
into the complexities of the role of this metal ion in signaling pathways and provide justifica-
tion to further explore these pathways in more detail in metabolic processes associated with
glycemic control.
Given the role of zinc as an insulin mimetic in controlling cellular metabolism, we sought
to delineate the role of this metal ion in cellular processes amendable to controlling glucose
homeostasis in skeletal muscle cells. We identified that in mouse and human skeletal muscle
cells, zinc could affect several insulin-dependent cell signaling pathways that was concomitant
with increased glucose oxidation.
Materials and methods
Antibodies
Akt (#9272), phospho-Akt (Ser473; #4058), phosphor-p44/42 MAPK (Erk1/2, Thr201/Tyr204;
#8544), phospho-p44/42 MAPK (Eek1/2; #9102), SHP-2 (#3752), phospho-SHP-2 (Tyr580;
Zinc modulates glycemic control in skeletal muscle
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#3703), phospho-Tyrosine (P-Tyr-100; #5465), GAPDH (#2118), and HRP-linked secondary
antibodies (Anti-rabbit #7074; Anti-mouse #7067) were obtained from Cell Signaling Technol-
ogy, USA. Intracellular signaling array kit (PathScan #7323) was also purchased from Cell Sig-
naling Technology.
Cell culture
Mouse C2C12 cells (a generous gift from Professor Steve Rattigan, Menzies Institute for Medi-
cal Research, Hobart, Australia) and human skeletal muscle cells (Thermo Fisher, Australia;
catalog number A12555) were cultured in DMEM (Thermo Fisher) medium containing 10%
fetal calf serum (FCS) and 100 U/mL penicillin/streptomycin (Thermo Fisher) and were main-
tained at 37˚C and 5% CO2 in a humidified atmosphere. Cells were treated with insulin (10
nM), zinc (20 μM) and/or zinc pyrithione (10 μM) (Sigma Aldrich, Australia) for 60 minutes.
The dose of zinc used is consistent with previous studies [21–23, 3] and represents the physio-
logical level of plasma zinc which can range from 10.7 μM following a morning fast to 21.1 μM
in healthy individuals [24].
Seventy-two hours before treatment, skeletal muscle cells were differentiated into myotubes
by the addition of media containing 2% horse serum (Thermo Fisher). Three hours before
treatments, the cells were exposed to serum-free conditions.
Immunoblot analysis
Whole cell lysates were prepared in RIPA Lysis buffer in the presence of protease and protein
phosphatase inhibitors (Thermo Fisher). Lysates were vortexed every 10 minutes for 1 hour at
4˚C, and centrifuging at 15000 rpm for 5 minutes. Protein concentrations of the supernatants
were determined using the BCA assay kit as per manufacturer’s instructions (Thermo Fisher).
For western blotting analysis, equal amounts of proteins were heated to 95˚C, separated on
4–15% SDS-polyacrylamide gels (Bio-Rad, Australia) and wet transferred to PVDF at 200 mV
for 1 hour at 4˚C (Polyvinylidene Difluoride) membranes (Thermo Fisher). The membrane
was then blocked 2 hours in TBST (50 mmol/L Tris-Cl, pH 7.6, 150 mmol/L NaCl and 0.1%
Tween 20) containing 5% (w/v) casein, and then incubated with the appropriate primary anti-
body as indicated overnight at 4˚C. The membrane was washed four times with TBST, then
incubated with HRP-conjugated secondary antibody for 1 hour. The membrane was again
washed four times with TBST, and the blots were developed using SuperSignal West Femto kit
[25] (Thermo Fisher). All phosho-immunoreactive species, Akt, ERK, SHP were normalized
against total Akt, ERK or SHP. Immunoreactive phospho-tyrosine was normalized to
GAPDH.
Intracellular signaling array
The intracellular signaling protein array kit (chemiluminescent Readout) is a slide-based anti-
body array founded upon the sandwich immunoassay principle. The array kit allows for the
simultaneous detection of 18 important signaling molecules when phosphorylated or cleaved.
Skeletal muscle cells were treated with 10 nM insulin, 20 μM ZnSO4 in the presence of 10 μM
sodium pyrithione (NaPy), 20 μM ZnSO4 alone, or no treatment (as a control) over 30 minutes
and cells were lysed in RIPA lysis buffer supplemented with protease and protein phosphatase
inhibitors. The assay procedure was performed according to the manufacturer’s protocol.
Briefly, cell lysates were incubated on the array slide followed by a biotinylated detection anti-
body cocktail. Streptavidin-conjugated HRP and LumiGLO reagent were then used to visualize
the bound detection antibody by chemiluminescence. An image of the slide was captured with
a digital imaging system. Spot intensities for each phosho-immunoreactive protein in the
Zinc modulates glycemic control in skeletal muscle
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insulin and zinc treated extracts were normalized to their untreated control. The image was
analyzed, and the spot intensities quantified using densitometry array analysis software, Image
J (https://imagej.nih.gov/ij/).
Glucose oxidation assay
To determine the amount of glucose consumption by cells, glucose oxidase (GOx) activity
assay kit was used as per manufacturer’s instructions (Sigma). To establish the glucose oxida-
tion assay, cells were cultured in 96 well plate to reach 100% confluence. As the assay medium
should be without any exogenous fuel substrate supplementation, cells were cultured in the
serum-free media for another 24 hours. After 24 hours serum-free condition, cells were treated
with 10 nM insulin, 20 μM of ZnSO4 in the presence of 10 μM NaPy, a combination of 10 nM
insulin and 20 μM ZnSO4 in the presence of 10 μM pyrithione, and DMEM alone as a control.
The concentration of glucose added to initiate glucose oxidation was 10 mM, which was deter-
mined in preliminary experiments to be above saturation. After incubation for 3 hours, cell
lysate was collected and reaction mixture (GOx assay buffer, GOx developer, fluorescent per-
oxidase substrate and GOx substrate) was added and the absorbance was measured at 570 nm
using a TECAN infinite M200 PRO flow cytometer. The background was corrected subtract-
ing the blank measurement value from the sample measurement value.
Insulin receptor inhibition
C2C12 skeletal muscle cells were treated with an insulin receptor tyrosine kinase inhibitor
HNMPA-(AM)3 (abcam, Australia) at 0, 25, 50 and 100 μM for 1 hour followed by treatment
of cells with either insulin (100 nM) for 30 mins, or zinc (20 μM) plus NaPy (10 μM) for 30
minutes. Following treatment, whole cell lysates were prepared and immunoblot analysis was
performed on pAkt and total Akt as previously described in the methods above.
Statistical analysis
Data, represented as the means ± SEM, were analyzed by the one-way ANOVA for multiple
comparisons using the Graph Pad Prism 5 software to determine any significant differences.
P< 0.05 was considered significant.
Results
Effect of zinc on insulin-dependent cell signaling molecules Akt, Tyrosine,
SHP, ERK1/2, and PRAS40
We measured the phosphorylation status of several proteins implicated in the insulin-signaling
cascade in the presence of insulin or zinc. To assess that skeletal muscle cells responded to
insulin we measured the phosphorylation status of protein kinase B (Akt), a well-established
protein that is phosphorylated in the presence of insulin [26]. Skeletal muscle cells were treated
with 10 nM insulin over 60 minutes and subsequent western blots were performed for the
immunoreactivity of p-Akt. We observed that 10 nM of insulin-activated p-Akt in both C2C12
mouse and human skeletal muscle cells and thus confirmed our cells responded to insulin
treatment (Fig 1). To test whether zinc has insulin mimetic activity to induce the phosphoryla-
tion of Akt, skeletal muscle cells were also treated with 20 μM ZnSO4 in the presence of 10 μM
pyrithione. Similarly, zinc induced the phosphorylation of Akt within 15 minutes of treatment
in both mouse and human cell lines (Fig 1).
The components of the mitogen-activated protein kinase/extracellular signal-regulated pro-
tein kinase (MAPK/ERK) pathway are modifiers of cellular insulin responsiveness [27], and
Zinc modulates glycemic control in skeletal muscle
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therefore sensitive to insulin. Accordingly, we compared the phosphorylation status of ERK1/2
in cells treated with insulin and ZnSO4. Insulin induced the phosphorylation of ERK1/2 within
15 minutes of treatment in mouse and human skeletal muscle cells (Fig 2). Similarly, ZnSO4 in
the presence of pyrithione induced ERK phosphorylation within 15 minutes of treatment in
these cell lines (Fig 2).
We also identified that treatment of mouse and human skeletal muscle cells with insulin
and zinc led to the phosphorylation of SHP-2, a protein tyrosine phosphatase involved in insu-
lin signaling pathway [28] (Fig 3). Insulin and ZnSO4 induced pSHP-2 within 30 minutes of
treatment in mouse and human skeletal muscle cells. pSHP-2 increased at 60 minutes of treat-
ment in the human skeletal muscle cells, but not in mouse skeletal muscle (Fig 3).
Fig 1. Analysis of p-Akt in mouse and human skeletal muscle cells treated with insulin, zinc, and NaPy over 60
min. Top and bottom panel represents mouse and human skeletal muscle cells, respectively. Time is shown in minutes
from 0, 15, 30 and 60 and total Akt was used as an internal loading control in both panels and levels of pAKT were
normalized to total Akt.
https://doi.org/10.1371/journal.pone.0191727.g001
Fig 2. Analysis of p-ERK in mouse and human skeletal muscle cells treated with insulin, zinc, and NaPy over 60
min. Top and bottom panel represents mouse and human skeletal muscle cells, respectively. Time is shown in minutes
from 0, 15, 30 and 60 and total ERK was used as an internal loading control in both panels and levels of p-ERK were
normalized to total ERK.
https://doi.org/10.1371/journal.pone.0191727.g002
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The activation and/or transduction of many signaling pathways including insulin signaling
depends on the phosphorylation of tyrosine [29]. To test whether zinc plays a role in the phos-
phorylation of tyrosine residues in skeletal muscle, we treated mouse and human cells with
insulin or ZnSO4 over 60 minutes. Insulin and ZnSO4 induced the phosphorylation of tyrosine
residues over the time course in both mouse and human skeletal muscle cell lines (Fig 4).
We also detected significant changes in the phosphorylation of Akt, ERK1/2, glycogen syn-
thesis kinase-3 (GSK-3β), Protein-Rich Akt Substrate of 40 kDa (PRAS40), and p38 using an
Intracellular signaling protein array (Table 1 and Fig 5A and 5B). Positive signals for PRSA40,
ERK1/2, Akt and GSK-3β were detected in skeletal muscle cells in the mouse protein array
when compared to the control panel. Insulin activated PRAS40 and Akt, while ZnSO4 acti-
vated PRAS40, ERK1/2, Akt and GSK-3β in this system (Fig 5A). In the human protein array,
we observed that insulin activated ERK1/2, Akt and PRAS40 when compared to the control.
ZnSO4 activated ERK1/2, Akt, GSK-3β and p38 but not PRAS40 in this instance (Fig 5B).
Fig 3. Analysis of p-SHP in mouse and human skeletal muscle cells treated with insulin, zinc, and NaPy over 60
min. Top and bottom panel represents mouse and human skeletal muscle cells, respectively. Time is shown in minutes
from 0, 15, 30 and 60 and total SHP was used as an internal loading control in both panels and levels of p-SHP were
normalized to total SHP.
https://doi.org/10.1371/journal.pone.0191727.g003
Fig 4. Analysis of p-tyrosine in mouse and human skeletal muscle cells treated with insulin, ZnSO4, and NaPy
over 60 min. Top and bottom panel represents mouse and human skeletal muscle cells, respectively. Time is shown in
minutes from 0, 15, 30 and 60 and GAPDH was used as an internal loading control in both panels and levels of p-
tyrosine were normalized to GAPDH.
https://doi.org/10.1371/journal.pone.0191727.g004
Zinc modulates glycemic control in skeletal muscle
PLOS ONE | https://doi.org/10.1371/journal.pone.0191727 January 26, 2018 6 / 15
Shaghayegh Norouzi 
The Role of Zinc and the Zip7 Transporter in Disease Processes Associated with IR in Skeletal Muscle Page 37
Densitometry was performed on the protein arrays to determine the level of protein expres-
sion between the insulin and ZnSO4 treatment and the control. In mouse skeletal muscle cell
lines, Akt and ERK1/2 protein expression was significantly higher (p< 0.01 and p<0.001
respectively) in the ZnSO4 treated cells when compared to the control (Fig 6A and 6B, respec-
tively). GSK-3β expression and activation play a critical role in mammalian cells and impacts
various cellular processes including glycogen synthesis and glucose transport [30]. The GSK-
3β protein levels were significantly higher (p<0.001) in cells treated with ZnSO4 compared to
control (Fig 6C). PRAS40, another important cell signaling molecule, is among the most
prominent Akt and mTOR complex 1 (mTORC1) substrates being phosphorylated in response
to growth factor stimulation such as insulin in eukaryotes [31]. The PRAS40 protein expres-
sion was also significantly higher (p<0.001) in mouse cells treated with ZnSO4 when com-
pared to control (Fig 6D).
In the human cell lines, pAkt expression was significantly different (p<0.001) over the con-
trol during ZnSO4 and insulin treatment (Fig 7A). Similarly, pERK1/2 protein expression was
significantly different for ZnSO4 treatment (p<0.01) and insulin treatment (p< 0.001) over
Table 1. Protein target map of intracellular signaling array (cell signaling).
Positive control ERK1/2 ERK1/2 Stat1 Stat1 Positive control
Stat3 Stat3 Akt (Thr308) Akt (Thr308) Akt (Ser473) Akt (Ser473)
AMPKα AMPKα S6 Ribosomal Protein S6 Ribosomal Protein mTOR mTOR
HSP27 HSP27 Bad Bad p70 S6 Kinase p70 S6 Kinase
PRAS40 PRAS40 p53 p53 p38 p38
SAPK/JNK SAPK/JNK PARP PARP Caspase-3 Caspase-3
Positive control GSK-3β GSK-3β Negative control Negative control Negative control
https://doi.org/10.1371/journal.pone.0191727.t001
Fig 5. Effect of insulin and zinc on intracellular proteins via analysis of an intracellular protein array (see
Table 1). a. Mouse skeletal muscle cells. Top panel, control (untreated cells), middle panel, insulin treated cells; bottom
panel, ZnSO4 treated cells. Positive and negative controls are shown labelled on the control panel. Significant responses
to insulin and ZnSO4 (PRAS40, Akt, ERK1/2 and GSK-3β) are shown. b. Human skeletal muscle cells. Top panel,
control (untreated cells), middle panel, insulin treated cells; bottom panel, ZnSO4 treated cells. Positive and negative
controls are shown labelled on the control panel. Significant responses to insulin (PRSA40, Akt and ERK1/2) and
ZnSO4 (Akt, ERK1/2, GSK-3β and p38) are shown. All positive signaling molecules in the insulin and zinc treated
arrays were normalized to their corresponding signaling molecule on the control array (no treatment).
https://doi.org/10.1371/journal.pone.0191727.g005
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that of the control (Fig 7B). The GSK-3β protein level was also significantly higher when
treated with zinc (p< 0.001) than insulin treatment (p<0.05) and when compared to the con-
trol group (Fig 7C). There was no significant difference in the levels of PRAS40 when treated
with ZnSO4 and compared to the control (Fig 7D). However, insulin treatment resulted in a
significant increase (p< 0.001) in PRAS40 compared to the control group. Lastly, ZnSO4 treat-
ment resulted in a significant increase in p38 (p< 0.001) over the control group but there was
no significance identified during the insulin treatment (Fig 7E). p38, is another signaling factor
that plays a significant role in the regulation of glucose transport [32].
Fig 6. Densitometry results from Fig 5 protein array in mouse skeletal muscle cells. a. pAkt, b. pERK1/2, c. GSK-3β,
and d. PRAS40. Control (untreated cells), ZnSO4 and insulin treatments are shown. Differences between the
expressions of proteins in cells were determined by one-way ANOVA. The results of 3 independent experiments are
presented as a mean ± standard error. p< 0.05,  p< 0.01 and  p<0.001 considered significant when compared
to the control.
https://doi.org/10.1371/journal.pone.0191727.g006
Fig 7. Densitometry results from Fig 5 protein array in human skeletal muscle cells. a. pAkt, b. pERK1/2, c. pGSK-
3β, d. PRAS40, and e. p38. Control (untreated cells), ZnSO4 and insulin treatments are shown. Differences between the
expressions of proteins in cells were determined by one-way ANOVA. The results of 3 independent experiments are
presented as a mean ± standard error.  p< 0.05,  p< 0.01 and  p<0.001 considered significant when compared
to the control.
https://doi.org/10.1371/journal.pone.0191727.g007
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Zinc effect of glucose consumption in mouse C2C12 and human skeletal
muscle cells
It is clear that zinc affects several cell signaling molecules, analogous to insulin signaling, that
are implicated in glucose homeostasis in skeletal muscle. Accordingly, we tested whether zinc
could activate glucose oxidation in both mouse and human skeletal muscle cells. Initially we
tested glucose oxidation in the presence of insulin treatment, and as expected, insulin signifi-
cantly induced glucose oxidation in mouse (p< 0.001) and human (p< 0.001) skeletal muscle
cells compared to the untreated cells (Fig 8A and 8B). Similarly, ZnSO4 significantly induced
glucose oxidation in both mouse (p< 0.01) and human (p< 0.05) skeletal muscle cells com-
pared to the untreated control (Fig 8A and 8B). We did not observe a significant additive effect
of insulin and ZnSO4 treatment together when compared to ZnSO4 or insulin treatment alone.
Zinc activation of pAKT potentially acts through a functional insulin
receptor
Given that we did not observe an additive effect of insulin and ZnSO4 treatment together on
glucose oxidation, we sought to determine whether a functional insulin receptor is required to
facilitate zinc activation of pAkt. To address this, we utilized C2C12 skeletal muscle cells
treated with an insulin receptor tyrosine kinase inhibitor in the presence of insulin or zinc. We
observed that 50 μM of the insulin receptor tyrosine kinase inhibitor HNMPA-(AM)3 was suf-
ficient to inhibit insulin-induced pAkt (Fig 9). Similarly, we identified that 25 μM of HNMPA-
(AM)3 inhibited zinc-induced pAkt and this was completely abolished at 50 and 100 μM of
HNMPA-(AM)3 (Fig 9).
Discussion
In this study, we analyzed the effects of zinc on insulin signaling in mouse and human skeletal
muscle cell lines. Insulin signaling is an important and highly conserved regulatory network
coordinating metabolism and growth in multicellular organisms [33]. Dysregulation of insulin
signaling is common in metabolic disorders. For example, insulin resistance which is a hall-
mark of type 2 diabetes mellitus [33], is characterized by a reduced insulin-mediated activation
of the PI3K/Akt pathway regulating glucose uptake [34]. Several studies have suggested that
zinc, as an essential trace element, has a potent ability on glucose handling by promoting beta
cell function and insulin sensitivity [35]. Zinc in skeletal muscle accounts for most of the
Fig 8. Glucose oxidation assay in the presence of insulin and ZnSO4. a. Mouse skeletal muscle cells, and b. Human
skeletal muscle cells. The results of 3 independent experiments are presented as a mean ± standard error.  p< 0.05, 
p< 0.01 and  p<0.001 considered significant compared with the control (untreated cells).
https://doi.org/10.1371/journal.pone.0191727.g008
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whole-body zinc (approximately 60%) [36], and as skeletal muscle is the major site of periph-
eral insulin resistance [37], we investigated the effects of zinc signaling in skeletal muscle cells.
Regarding the participation of zinc in insulin signaling, it is emphasized that this metal ion
promotes activation of phosphatidylinositol protein 3-kinase and protein kinase B (Akt),
increasing transport of glucose uptake to cells [38]. Our data shows that there is an increase in
the phosphorylation of Akt in mouse C2C12 and human skeletal muscle cells treated with
zinc, indicating the role of zinc in the induction of Akt phosphorylation. During insulin signal-
ing, the activated insulin receptor kinase, phosphorylates tyrosine residues on insulin receptor
substrate 1 (IRS1) and insulin receptor substrate 2 (IRS2) and this subsequently generates a
tyrosine phosphorylation cascade to transmit the insulin signal [39]. Our data show that there
is an increase in phospho-tyrosine in both mouse and human skeletal muscle cell treated with
zinc and suggests that zinc also plays a role in transmitting the insulin signal.
Previous studies have shown that SHP-2 can bind to IRS-1 in response to insulin and mod-
ulate receptor tyrosine kinase-mediated signaling [40]. Our data indicates that zinc can also
activate SHP-2 in mouse and human skeletal muscle cells. Similarly, studies have shown that
the ERK/MAP kinase signaling pathway is an important mediator in insulin responsiveness
[41]. According to our results, zinc increases the expression of ERK in both cell lines which
might help to improve insulin signaling in skeletal muscle.
Our results have also shown that zinc exhibited insulin-like glucose transporting effects by
phosphorylation of key proteins involved in the insulin signaling cascade including GSK-3β.
GSK-3β plays several important roles in mammalian cells, and impacts such diverse cellular
processes including glycogen synthesis and glucose transport. Overactivity of GSK-3β in skele-
tal muscle of obese type 2 diabetic humans is associated with an impaired ability of insulin to
activate glucose disposal and glycogen synthase [42]. Studies have also demonstrated that inhi-
bition of non-phosphorylated form of GSK-3 can improve insulin-stimulated glucose trans-
port activity through enhanced post-insulin receptor insulin signaling and GLUT-4 glucose
Fig 9. Effect of insulin receptor tyrosine kinase inhibitor HNMPA-(AM)3 on insulin and zinc-induced pAkt. Mouse C2C12 skeletal
muscle cells were treated with increasing concentrations (0, 25, 50, and 100 μM) of HNMPA-(AM)3 followed by either treatment with insulin
(10 nM) or zinc (20 μM) for 1 hour. Concentrations of HNMPA-(AM)3 are given at 0, 25, 50 and 100 μM. Top panel: insulin-treated
measurement of pAkt, Lower panel: zinc-treated measurement of pAkt. Total Akt was used as an internal loading control in both panels and
levels of pAKT were normalized to total Akt.
https://doi.org/10.1371/journal.pone.0191727.g009
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transporter translocation [43]. Accordingly, GSK-3β serine phosphorylation, which is the inac-
tive form of GSK-3β, increased after treating cells with zinc.
Our data indicate that zinc increases PRAS40 in mouse skeletal muscle cells. PRAS40 is a
regulator of insulin sensitivity which has an inhibitory effect on mTOR and consequently
decreases mTOR expression which is a negative regulator of IRS1 in mouse skeletal muscle cell
line. It causes an abundance in IRS1 and enhances insulin-mediated Akt phosphorylation and
increases glucose uptake [44].
Activation of p38 is not only dependent on stimulus, but on cell type as well. For example,
insulin can stimulate p38 in 3T3-L1 adipocytes, but down-regulates p38 activity in chick fore-
brain neuron cells [45]. We have reported that the expression of p38 increases in human skele-
tal muscle cells treated with zinc. Although p38 phosphorylation has been reported to be
increased in response to insulin in skeletal muscle from non-diabetic subjects [46], we did not
observe this in our experiments. It is not clear why p38 did not respond to insulin in this
study. Possibly, the thirty-minute, insulin treatment time-point used on the protein arrays
missed the maximum response for p38. For example, treatment of mouse L6 myotubes with
100 nM insulin resulted in a maximum p38 response at ten minutes which declined at fifteen
minutes of treatment [47]. Similarly, in rat vascular smooth muscle cells (VSMC), p38 was rap-
idly activated in the presence of insulin at five minutes and quickly declined to basal levels at
fifteen minutes [48]. We also identified that zinc can oxidize glucose in both mouse and
human skeletal muscle cells. A previous study in rat adipocytes showed that zinc could
enhance the metabolism of glucose which was indicative of enhancement of facilitated glucose
transport [49]. While both insulin or zinc could independently activate glucose oxidation, an
additive effect of insulin and zinc was not observed. Additionally, we found that inhibition of
insulin receptor tyrosine kinase activity abolished the ability of insulin and zinc to activate
pAkt and therefore suggests that zinc potentially acts through the insulin signaling pathway.
These data are supported by previous studies where co-incubation with zinc and insulin did
not enhance glucose consumption in normal L6 cells and suggests that zinc and insulin may
act through the same downstream pathways [17]. However, in insulin-resistant L6 myotubes,
zinc and insulin together could enhance glucose consumption when compared to insulin treat-
ment alone [17]. These data suggest that disrupted insulin signaling in the insulin resistant L6
cells respond differently to zinc than in normal L6 cells and therefore might provide clues on
alternative signaling pathways under zinc stimulation.
Skeletal muscle is of major importance in insulin resistance and T2DM as it accounts for
85% of whole body insulin-dependent glucose uptake and therefore plays a critical role in
maintaining systemic glucose metabolism [37]. Defects in glucose metabolism in insulin resis-
tant skeletal muscle include reduced insulin receptor tyrosine phosphorylation [50] decreased
Akt phosphorylation [51–52], and impaired GLUT4 translocation [52,53]. These insulin pro-
tein targets are also activated by zinc treatment in skeletal muscle [3,17,54].
The ability of zinc to regulate insulin signaling processes suggests that this metal ion might
have utility to be targeted experimentally to improve the management and/or treatment of insu-
lin resistance. One well-studied target of the insulin-mimetic effects of zinc is protein tyrosine
phosphatase 1B (PTP1B). This phosphatase has a key role in the regulation of insulin action by
dephosphorylating the insulin receptor and insulin receptor substrates 1 and 2, thereby inhibit-
ing the insulin signaling cascade [55]. It is well-established that zinc can inhibit PTP1B which
affects insulin signaling [18]. Moreover, PTP1B knockout mice are highly sensitive to insulin,
have low adiposity, and are protected from diet-induced obesity [56]. These studies highlight
the dynamic role of zinc in insulin signaling processes and therefore offers opportunities to be
further investigated. Type 2 diabetes mellitus is increasing globally and is approaching pan-
demic levels. Current strategies for prevention are limited in scope and effectiveness, and the
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persistently high prevalence of T2DM confirm the shortfalls of available therapeutic options.
The ‘window of opportunity’ that presents before the loss of β-cell function and the develop-
ment and progression of T2DM suggests that a strategy aimed at reversing insulin resistance
would have major clinical outcomes and benefits for health and wellbeing. From a therapeutic
perspective, it is important that the molecular mechanisms of dysfunctional zinc transport and
defective zinc compartmentalization are identified in human skeletal muscle cells. Similarly,
characterizing how zinc leads to increased glucose homeostasis is paramount to understanding
potential intervention strategies where zinc transport could be manipulated experimentally to
improve glucose metabolism in patients with insulin resistance or T2DM.
Conclusions
Zinc is an essential metal ion implicated in several biological processes. Dysfunctional zinc sig-
naling is associated with various disease states. We have shown that zinc independently acti-
vates insulin signaling pathway proteins in mouse and human skeletal muscle cell lines. The
subsequent phosphorylation events associated with insulin signaling and increased glucose
oxidation was also mirrored with zinc treatment leading to the supposition that both insulin
and zinc are critically important in maintaining glucose homeostasis in skeletal muscle.
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CHAPTER 4 
INVESTIGATING THE EFFECTS OF 
ZINC ON GLUT4 AND GLUCOSE 
HOMEOSTASIS 
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4.1. Background. 
Glut4 belongs to a 12-member family of glucose transporters  and is largely expressed in 
insulin-sensitive tissues that require glucose  such as adipose, skeletal muscle, and cardiac 
muscle tissue (1). Glut4 contains unique amino acid sequence motifs in the N- and C-terminal 
cytoplasmic regions that direct  characteristic membrane translocation  capability (1). Glut4 is 
stored in the basal state in intracellular compartments including the trans-Golgi network (TGN) 
and small tubular vesicles, which contrasts with other glucose transporters that are 
constitutively found in the plasma membrane.  In response to insulin and other stimuli, Glut4 
is mobilised from its intracellular location and translocated to the outer plasma membrane to 
facilitate glucose entry into the cell (2). 
Insulin-dependent Glut4 mobilisation and membrane translocation is a multistep process. 
Following insulin targeting the insulin receptor in adipose and skeletal muscle, Glut4 vesicles 
are mobilised from their intracellular storage compartment and sequestered to the plasma 
membrane. Here Glut4 is docked on the plasma membrane through an interaction with a 
membrane targeting-SNARE complex (SNAREs are the fundamental cellular machinery that 
mediates membrane fusion (3). Once docked, Glut4 vesicles contact and fuse with the plasma 
membrane to enable glucose influx. Therefore, one of the major roles of insulin is uptake of 
glucose in muscle and adipose tissue through the translocation of Glut4 to the plasma 
membrane (4). 
The transport of glucose in tissues that are sensitive to insulin has received considerable 
attention based on the critical importance of whole body glycaemic control and maintenance 
in the adult (5, 6). The transport of glucose uptake in insulin-sensitive tissues such as adipose 
and skeletal muscle is a rate-limiting step  under most conditions (1).  
We have previously shown that zinc could enhance glucose oxidation in both mouse and human 
skeletal muscle cells (7). We hypothesised that the increased glucose oxidation in skeletal 
muscle cells treated with zinc is, at least partially, due to the increased Glut4 translocation to 
the cell membrane and increased glucose uptake by Glut4 transporters. This hypothesis is based 
on the following experimental evidence: 1)  zinc stimulates the phosphorylation of the β subunit 
of the insulin receptor and promotes activation of phosphatidylinositol protein 3-kinase and 
protein kinase B (known as Akt), increasing transport of glucose inside cells (8); 2) zinc induces 
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the translocation of Glut4 in a dose-dependent manner in L6 skeletal muscle myotubes and this 
was augmented in the presence of insulin (9); and 3) zinc significantly increased glucose 
transport via PI3K and Akt in 3T3-L1 fibroblasts and adipocytes (10). 
 
Accordingly, this study aimed to test the ability of zinc to translocate Glu4 to the cell surface 
of skeletal muscle cells utilising western blotting and confocal microscopy. We identified that 
zinc treatment significantly increased the levels of the Glut4 protein in C2C12 skeletal muscle 
cells. Treatment of C2C12 cells with insulin or zinc and the subsequent subcellular 
fractionation of cytosolic versus membrane components, resulted in the majority of Glu4 
expression confined to the membrane component. However, control C2C12 cells not treated 
with insulin or zinc also showed membrane localised Glu4 expression. Similarly, confocal 
microscopy of Glut4 following stimulation of C2C12 cells with insulin or zinc resulted in 
cytosolic localisation of Glut4. This was also not different from the control cells not treated 
with insulin or zinc. These results suggest there was potentially some experimental design and 
process issues, or C2C12 cells are somewhat insensitive to insulin and/or lack functional Glut4 
machinery that is required to translocate to the outer plasma membrane.    
 
4.2. Methodology. 
4.2.1. Cell culture. 
C2C12 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) containing 4.5 g/L 
D-glucose, L-glutamine and 110 mg/L sodium pyruvate with 10% fetal calf serum and 5% 
penicillin-streptomycin-glutamine. The cells were incubated at 37°C and 5% CO2 in a 
humidified atmosphere. 
 
Passaging and Culturing Adherent Cells: Proliferating C2C12 cells were washed using a 37°C 
balanced salt solution without calcium and magnesium (approximately 2 mL per 10 cm2 culture 
surface area). Pre-warmed trypsin (Thermo fisher, Australia) (37°C), was added to the side of 
the flask (Thermo fisher, Australia) (approximately 0.5 mL per 10 cm2 to cover the cell layer) 
and the culture vessel was incubated at room temperature for approximately two minutes. 
When approximately 90% of the cells were detached, the equivalent of two volumes (twice the 
volume used for the dissociation reagent) of pre-warmed complete DMEM growth medium 
was added. The medium was dispersed by pipetting over the cell layer surface several times. 
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The cells were transferred to a 15-mL conical tube (Thermo fisher, Australia) and centrifuged 
at 200 × g for 5 minutes at room temperature. The cell pellet was resuspended in a pre-warmed 
complete DMEM growth medium and the cells were seeded into the culture vesicle at a 
density of only 5.0 x103 viable cells/cm2 and incubated at 37°C. 
4.2.2. Protein Extraction and Western Blot. 
Total cellular protein was extracted by scraping cells with RIPA buffer (Thermo Fisher, 
Victoria, Australia) containing a protease and phosphatase inhibitor cocktail (Sigma, New 
South Wales, Australia) and samples were placed on ice for 1 hour with constant vortexing 
every 10 minutes. The samples were centrifuged at 13,000 rpm for 5 minutes and the 
supernatant was collected. Total protein concentration was determined using a BCA kit as per 
manufacturer’s instructions (Thermo Fisher). Thirty micrograms of total soluble protein were 
loaded in protein loading dye (5X solution of 250 mM Tris-HCl, pH 6.8, 10% SDS, 30% (v/v) 
Glycerol, 10 mM DTT, 0.05% (w/v) Bromophenol Blue). Proteins were resolved on a 4–15% 
SDS-PAGE gradient gel (BioRad, New South Wales, Australia) and transferred to a 
nitrocellulose membrane (Thermo Fisher). The membrane was blocked for 1 hour in TBS-
Tween 20 buffer (50 mmol/L Tris-Cl, pH 7.6, 150 mmol/L NaCl and 0.1 % Tween 20) 
containing 5 % (w/v) casein. The membrane was then incubated overnight with the primary 
antibody in 0.5% casein in TBS-Tween buffer. Following primary antibody incubation, the 
membrane was washed four times for 10 minutes in TBS-Tween buffer. Then, the membrane 
was incubated with the secondary antibody for 1 hour at room temperature in 0.5% casein in 
TBS-Tween buffer. Following this, the membrane was washed four times for 10 minutes in 
TBS-Tween buffer. Immunoreactive signals were detected using SuperSignal West Femto kit 
(Thermo Fisher) and visualized by a UVITEC Alliance digital imaging system (Thermo 
Fisher).  To assess protein loading consistency, the membranes were stripped with Restore Plus 
Western Blot Stripping Buffer (Thermo Fisher) by incubating the membrane in the buffer for 
15 minutes at room temperature on an end-over-end shaker. The membranes were subsequently 
washed in TBS-Tween buffer and blocked with 5% skim milk before adding the appropriate 
primary antibody (11). The subsequent blots were then processed as outlined above.  
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4.2.3. Subcellular fractionation of cultured cell samples. 
To establish the subcellular fractionation assay, C2C12 skeletal muscle cells were cultured in 
six well plates to reach 100% confluence. After three hours of serum-free condition, the cells 
were treated with 10 nM insulin, 20 μM of ZnSO4 in the presence of 10 μM sodium pyrithione 
(NaPy) (Sigma), and DMEM alone (control) for 15 minutes. The cytosolic, membrane and 
nuclear subcellular fractionation of skeletal muscle cells was performed using Qproteome Cell 
Compartment Kit (QIAGEN, Victoria, Australia). By sequential addition of several different 
extraction buffers to the C2C12 cell pellet, proteins in the membrane and cytoplasm of skeletal 
muscle cells were selectively isolated (Table 4.1). 
Table 4.1. Subcellular protein fractionation from cellular components. 
Buffer Isolated proteins 
Extraction buffer CE1 Cytosol 
Extraction buffer CE2 Membranes 
Extraction Buffer CE1 was added to cells to disrupt the plasma membrane without solubilising 
it, resulting in the isolation of cytosolic proteins. Plasma membranes and compartmentalised 
organelle membranes were then pelleted by centrifugation. The pellet was then resuspended in 
Extraction Buffer CE2 to solubilise the plasma membrane and all organelle membranes except 
the nuclear membrane. After solubilisation, the sample was centrifuged. The subsequent 
supernatant contained all membrane proteins and proteins from the lumen of organelles. 
The procedure is as follows; 
A cell suspension containing 5 x 106 cells was transferred into a 15 mL conical tube and 
centrifuged at 500 x g for 10 minutes at 4°C. The supernatant was removed and discarded. The 
cell pellet was resuspended in 2 mL ice-cold PBS by pipetting up and down with a 1 mL pipette 
tip and the cell suspension was transferred into a microcentrifuge tube. Cells were then pelleted 
by centrifuging at 500 x g for 10 minutes at 4°C. The supernatant was removed and discarded. 
This step was repeated. A Protease Inhibitor Solution (PIS) (100x) was added to the Extraction 
Buffer CE1. The cell pellet was resuspended in 1 mL ice-cold Extraction Buffer CE1 by 
pipetting up and down using a 1 mL pipette tip, incubated for 10 minutes at 4°C on an end-
over-end shaker. The lysate was centrifuged at 1000 x g for 10 minutes at 4°C. The supernatant 
containing cytosolic proteins was transferred into a fresh microcentrifuge tube and stored on 
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ice. A PIS (100x) was added to Extraction Buffer CE2. The pellet was resuspended in 1 mL 
ice-cold Extraction Buffer CE2 by pipetting up and down using a 1mL pipette tip and incubated 
for 30 minutes at 4°C on an end-over-end shaker. The subsequent suspension was centrifuged 
at 6000 x g for 10 minutes at 4°C. The supernatant containing the membrane proteins was 
transferred into a fresh microcentrifuge tube and stored on ice. 
 
4.2.4. Transformation of E. coli cells with GFP vector. 
Plasmid Green Fluorescent Protein (GFP) DNA (EX-Mm19596-M03, GeneCopoeia, United 
BioResearch Products, New South Wales, Australia) (Figure 4.1) was transformed into high-
efficiency E. coli bacterial cells (Alpha-select chemically competent cells, Bioline, New South 
Wales, Australia). Briefly, 5 µL of DNA solution was added to 100 µL cells suspension 
(≥109cfu/µg) and incubated on ice for 30 minutes. Then, the tube was placed in a 42◦C water 
bath for 45 seconds. The tube was then placed on ice for 2 minutes. The transformation reaction 
was diluted to 1 mL by the addition of 900 µL SOC medium (2% Tryptone, 0.5% Yeast Extract, 
0.4% Glucose, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2 and 10 mM MgSO4) and aerated at 
200 rpm for 60 minutes at 37◦C. The transformation mixture was plated on LB agar plates 
containing appropriate antibiotic (Ampicillin) and incubated overnight at 37◦C. 
 
 
Bacterial colonies were harvested, and plasmids were isolated using an ISOLATE II plasmid 
Midi kit as per the manufacturer’s instructions (Bioline). Briefly, overnight bacterial culture 
was harvested by centrifuging at 6000 x g for 15 minutes at 4°C. The bacterial pellet was 
resuspended in 4 mL Buffer P1 followed by the addition of 4 mL of Buffer P2, was mixed 
thoroughly by vigorously inverting 4-6 times and incubated at room temperature for 5 minutes. 
Four mL of prechilled Buffer P3 was added and mixed by vigorously inverting 4-6 times and 
incubated on ice for 15 minutes and centrifuged at 20000 x g for 30 minutes at 4°C. The 
supernatant was applied to the QIAGEN-tip and allowed to enter the resin by gravity flow. 
DNA was eluted with 5 mL Buffer QF and precipitated by adding 3.5 mL room-temperature 
isopropanol and centrifuged at 15000 x g for 30 minutes. The DNA pellet was washed with 2 
mL room-temperature 70% ethanol and centrifuged at 15000 x g for 10 minutes. The DNA 
pellet was then air-dried for 10 minutes and redissolved in 10 mM Tris-Cl, pH 8.5. Restriction 
digest analysis using the enzymes EcoRІ and XhoІ were used to determine the correct insertion 
of the Glut4-GFP plasmid (Figure 4.1). Plasmids were transfected into skeletal muscle cells 
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using Lipofectamine 3000 reagent (Thermo Fisher) as per manufacturer’s instructions. Briefly, 
skeletal muscle cells were cultured in 8-well chambers. Once the cells have reached 70% 
confluence, approximately 1 μg of plasmid was mixed with the Lipofectamine 3000 in DMEM 
and placed on the cells for 24 hours. 
 
 
 
Figure 4.1. GFP EX-Mm19596-M03 Expression Clone (CMV Promoter) and Restriction 
Enzyme Information. GFP is driven by a CMV promoter and clones were isolated based on 
screening for ampicillin resistance. Restriction sites for EcoR1, Kpn1, Xho1 and Not1 are given 
for orientation of the open reading frame (ORF).   
 
4.2.5. Confocal Microscopy 
Confocal microscopy was performed following the methods described previously (12) with 
minor modifications. C2C12 skeletal muscle cells were grown in 8-well chamber slides at low 
density (1 x105 cells/well) and serum starved for 3 hours before incubation in the presence and 
absence of 100 nM insulin for 15 minutes, or in the presence and absence of 20 μM zinc + 
ionophore 10 μM for 15 minutes. Cells were then fixed using 4% (vol/vol) formaldehyde in 
PBS at room temperature for 10 minutes, quenched with 50 mM NH4Cl for 15 minutes and 
blocked for 1 hour with 10% FCS serum. Cells were incubated with anti-Glut4 primary 
antibody (Abcam, Victoria, Australia), diluted in blocking solution at 1:200 overnight at 4˚C, 
followed by three washes of 5 minutes with PBS. Cells were then incubated with Goat Anti-
Rabbit IgG H&L (FITC) secondary antibody (1:1000) (Abcam) for 30 minutes in a dark room. 
After three washes with PBS, slides were mounted with Prolong Diamond with DAPI (Thermo 
Promoter CMV 
Host cell Mammalian 
Bacterial selection antibiotics Ampicillin/Neomycin 
Mammalian selection marker Yes 
Tag C-GFP 
 
Vector Features 
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Fisher), left to cure overnight and imaged using an Olympus IX83 confocal microscope 
(Olympus, Victoria, Australia).  
 
To investigate Glut4 translocation using the plasmid encoding Glut4-GFP following treatments 
with zinc or insulin, cells were placed on ice immediately and washed three times with ice-cold 
Krebs-Ringer HEPES buffer [KRBH; 120 mM NaCl, 25 mM HEPES, 4.6 mM KCl, 1 mM 
MgSO4, 1.2 mM KH2PO4 and 1.9 mM CaCl2 (pH 7.4)]. Slides were mounted with Prolong 
Gold with DAPI from Thermo fisher, cured overnight and imaged as described above. 
 
4.2.6. Statistical analysis 
Protein expression data from western blots were quantified by ImageJ quantification 
normalised to Gapdh (Genesearch, Queensland, Australia). Microscopy images were analysed 
by Prism 7 software and an ANOVA with Dunnett’s pair-wise comparisons. All data is 
normalised to the control mean represented as control=100 ± standard deviation (SD) with *, 
** and *** indicating p<0.05, p<0.01 and p<0.001 statistical differences compared to control, 
respectively. 
 
4.3. Results. 
4.3.1. Zinc treatment increases Glut4 protein levels in normal C2C12 cells. 
To measure the protein expression of Glut4 in the presence of zinc, C2C12 skeletal muscle 
cells were treated with 20 μM ZnSO4 in the presence of 10 µM NaPy over 16 hours and 
subsequent western blots were performed on immunoreactive Glut4 (Figure 4.2). It was 
observed that zinc treatment resulted in a significant increase in the protein expression of Glut4 
(total cellular Glut4 content) after 2 (p<0.01), 4 (p<0.01) and 16 (p<0.001) hours compared to 
the zero control cells (Figure 4.2). 
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 Figure 4.2. Western blot results of Glut4 protein expression (a) and densitometry results 
(b) in mouse C2C12 skeletal muscle cells treated with 20 µM zinc and 10 µM NaPy over 
16 hours. a. Time is shown in hours from 0, 2, 4 and 16 and Gapdh was used as an internal 
loading control. b. Data are presented as means ±SD (n=3 independent experiments) and were 
analysed using one-way ANOVA followed by post-test Turkey. (Glut4: glucose transporter 4, 
GAPDH: Glyceraldehyde 3-phosphate dehydrogenase). 
 
4.3.2. Expression of cytosolic versus membrane Glut4 in mouse skeletal muscle cells 
treated with insulin or zinc. 
Insulin acts within minutes to mobilise Glut4 storage vesicles to translocate Glut4 to the plasma 
membrane to enhance glucose uptake (13). To determine whether zinc can also mobilise Glut4 
to the cell surface, western blots were performed on cytosolic and membrane proteins extracted 
from C2C12 skeletal muscle cells treated with zinc or insulin (Figure 4.3). There was a clear 
difference in the expression of Glut4 in the membrane fraction, compared to the cytosolic 
fraction in C2C12 zinc treated cells (Figure 4.3a). It appeared that the control C2C12 cells (not 
treated with insulin or zinc) also showed a clear difference in the membrane fraction versus the 
cytosolic fraction (Figure 4.3b). Following treatment of C2C12 skeletal muscle cells with 100 
nM insulin, Glut4 expression was abundant in the membrane fraction but not the cytosolic 
fraction (Figure 4.3c).  Gapdh was used as a control as this enzyme is localised to the cytosolic 
fraction. There is a clear differentiation between the expression levels of Gapdh in the cytosol 
versus the membrane fraction (Figure 4.4a-c).         
 
a.                                                                                     b.  
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Figure 4.3. Western blot result of Glut4 expression in subcellular fractionated C2C12 
cells. a. Cells were treated with 20 μM ZnSO4 in the presence of 10 µM NaPy for 15 minutes. 
b. Untreated control cells. c. Cells treated with 10 mM insulin for 15 minutes. Gapdh was used 
as a control protein specific to cytoplasm fraction. This is a representative blot from three 
independent experiments. (Glut4: glucose transporter 4, GAPDH: Glyceraldehyde 3-phosphate 
dehydrogenase). 
 
4.3.3. The localisation of Glut4 in the presence of insulin or zinc in the cytoplasm or 
membrane of C2C12 cells by confocal microscopy.  
Glut4 translocation to the cell surface is the final step of the insulin-stimulated glucose uptake 
process, and the quantity of Glut4 at the cell surface is the rate-limiting step of glucose disposal 
(9). To determine if Glut4 could be mobilised by zinc to the cell surface in C2C12 skeletal 
muscle cells, confocal microscopy was performed. C2C12 cells were treated for 15 minutes 
with 20 μM ZnSO4 in the presence of 10 µM NaPy, 10 nM insulin as a positive control and 
neither zinc nor insulin as a negative control. It was anticipated that C2C12 cells treated with 
insulin would show an increase in the mobilisation of cytosolic Glut4 to the plasma membrane. 
It was identified that in the presence of insulin, Glut4 was localised to the cell membrane 
however, the control cells not treated with insulin also showed Glut4 membrane-bound protein 
(Figure 4.4b and 4.4c). Similarly, treatment of C2C12 cells with zinc resulted in Glut4 being 
localised to the cell membrane, however, this was not different from the control group of cells 
not treated with zinc (Figure 4.4b and 4.4d).  
 
 
a.                                  b.                                 c.  
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a.                                                                      b. 
 
                                      c.                                                                       d. 
Figure 4.4. Glut4 expression of C2C12 cells quantified by confocal microscopy. a. Control 
cells (without secondary antibody); b. Control cells not treated with insulin or zinc; c. Cells 
treated with 10 mM insulin for 15 minutes; and d. Cells treated with 20 μM ZnSO4 in the 
presence of 10 µM NaPy for 15 minutes. Immunofluorescence staining was used to determine 
the subcellular localization of Glut4. The scale bars (yellow line) represent 10 µm. 
 
As shown in Figure 4.5, insulin (c) or zinc treatment (d) did not significantly induced Glut4 
membrane translocation over that of control (b) in C2C12 cells. 
    Treatments 
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Figure 4.5. Confocal microscopy of Glut4 expression in C2C12 cells. b. Control cells not 
treated with insulin or zinc; c. Cells treated with 10 mM insulin for 15 minutes; and d. Cells 
treated with 20 μM ZnSO4 in the presence of 10 µM NaPy for 15 minutes. N=7 cells from three 
randomly selected images and three independent assays were taken under 63X oil-emersion. 
 
To further investigate Glut4 mobilisation to the cell surface in C2C12 cells by confocal 
microscopy, a plasmid-based system encoding Glut4-GFP was used. Following treatments with 
insulin (Figure 4.6c) or zinc (Figure 4.6d), C2C12 skeletal muscle cells did not show any 
changes in the mobilisation of cytosolic Glut4 to the plasma membrane compare to the control 
(Figure 4.6b).  
 
a.                                                                      b. 
 
                                     c.                                                                        d. 
 
Figure 4.6. Glut4-GFP expression of C2C12 cells quantified by confocal microscopy. a. 
Control (without secondary antibody); b. Control cells not treated with insulin or zinc; c. Cells 
treated with 10 mM insulin for 15 minutes; and d. Cells treated with 20 μM ZnSO4 in the 
presence of 10 µM NaPy for 15 minutes. The scale bars represent 10 µm. 
 
As shown in Figure 4.7, there was no significant difference in Glut4 localisation in C2C12 
cells treated with insulin or zinc when compared to the control. 
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Figure 4.7. Confocal microscopy results of Glut4-GFP expression in C2C12 cells. b. 
Control cells not treated with insulin or zinc; c. Cells treated with 10 mM insulin for 15 minutes; 
and d. Cells treated with 20 μM ZnSO4 in the presence of 10 µM NaPy for 15 minutes. N=7 
cells from three randomly selected images and three independent assays taken under 63X oil-
emersion. 
 
4.4. Conclusion 
The glucose transporter, Glut4, facilitates the transport of glucose in skeletal muscle and 
adipose tissue (14). The mobilisation of Glut4 in the presence of insulin is a well-established 
mechanism that allows glucose to enter skeletal muscle cells and be utilised for metabolic 
processes including energy expenditure and glycogen storage (15). Upon digestion of food, 
glucose enters the blood stream and increases blood glucose levels. In response to this increase 
in blood glucose, insulin is secreted from the pancreatic beta-cells. Secreted insulin increases 
peripheral glucose utilisation and decreases hepatic gluconeogenesis. These set of events 
restore the blood glucose level to a physiological range within two to three hours following a 
meal. In IR and T2DM, this process is compromised and therefore fails to maintain glucose 
homeostasis (14). 
 
It has previously been reported that zinc exerts insulin-like effects by upregulating Akt 
phosphorylation and Glut4 translocation to the plasma membrane in normal rat L6 skeletal 
muscle myotubes (9). Previous investigations showed that zinc has the capacity to increase Akt 
phosphorylation leading to GSK-3β activation in addition to increasing total glucose 
consumption in skeletal muscle cells (7). This calls into question what effects zinc could elicit 
on the translocation of the glucose transporter, Glut4, in skeletal muscle? Understanding the 
Treatments 
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molecular mechanisms of zinc action has been of major interest since the discovery that zinc 
stimulates glucose oxidation in C2C12 skeletal muscle cells (7). Although the molecular 
mechanisms have yet to be elucidated, it is not clear how glucose oxidation is increased by zinc 
in this cell-based system. Therefore, the aim of this study was to investigate whether zinc 
increase the expression and translocation of Glut4 to the cell membrane in mouse C2C12 
skeletal muscle cells.  
 
This work demonstrated that zinc could increase the expression of Glut4 in a time-dependent 
manner but could not translocate Glut4 to the cell membrane in C2C12 skeletal muscle cells. 
Although it is well established that insulin stimulation of glucose uptake in skeletal muscle 
cells is mediated through translocation of Glut4 from intracellular storage sites to the cell 
surface (5), according to the results of confocal microscopy, the localisation of Glut4 in skeletal 
muscle cells was unchanged in cells treated with insulin or zinc when compared to the control 
cells not treated with these molecules. It is unclear why insulin could not modulate the 
translocation of Glut4 to the plasma membrane, given that this process is well-established (15). 
Moreover, the effect of zinc on Glut4 translocation was also negative. Accordingly, some 
clarification of the experimental design needs to be addressed. This is given in the following 
paragraphs below. 
 
Previous study identified that zinc enhanced glucose transport independent of insulin in 3T3-
L1 fibroblasts (10). Although this study identified that zinc significantly increased tyrosine 
phosphorylation of the insulin receptor and Akt, it was not identified whether this metal ion 
could potentiate the mobilisation and translocation of Glut4 in this system. Another study 
clearly identified that a reduction of the zinc transporter Zip7 in C2C12 skeletal muscle cells, 
significantly decreased glucose oxidation and this was concomitant with a reduction in Glut4 
mRNA and protein levels (16). Again, this study did not test the ability of zinc to translocate 
Glut4 in the C2C12 skeletal muscle cells. Recent studies identified that zinc treatment in both 
mouse C2C12 and human skeletal muscle cells significantly contributed to an increase in 
glucose oxidation and suggested that Glut4 was involved in these processes (7), however, this 
was not tested. To our knowledge, this is the first result showing zinc can increase Glut4 
expression in C2C12 skeletal muscle cells.  
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Western blot analysis on sub-fractionated cells (membrane versus cytosol) was utilised to 
determine if Glut4 was mobilised to the cell membrane in skeletal muscle cells.  Accordingly, 
C2C12 cells were treated with insulin or zinc and the cytosolic and membrane fractions were 
isolated followed by subsequent Western blot with Glut4 antibodies. It was observed that 
treatment of insulin or zinc localised Glut4 to the membrane fraction of the cells and not the 
cytosol. However, in the untreated control cells, Glut4 was localised to the membrane and not 
the cytosol. Glut4 localised in the cytosol is contained within intracellular vesicles that have a 
plasma membrane (17). Translocation of the Glut4 cytosolic vesicle to the outer plasma 
membrane occurs through a fusion event that results in the cytosolic vesicle fusing with the 
plasma membrane to expose Glut4 (18). Thus, the extraction utilised in this experiment sub-
fractionates separately the cytosol and membrane components. Given that Glut4 is contained 
within a membrane-bound vesicle localised in the cytosol, it is highly feasible that this 
component was extracted in the membrane fraction. This would therefore explain the lack of 
cytosolic Glut4. Moreover, the control Gapdh used in these experiments suggest this to be the 
case. Gapdh is a glycolytic enzyme that is solely localised in the cytosol (19). These studies 
identified abundant expression of Gapdh in the cytosolic fraction as expected and a small 
amount of expression in the membrane fraction. The expression of Gapdh in the membrane 
fraction is possibly due to cross-contamination. It has been noted that the kit used in these 
experiments, Qproteome Cell Extraction Kit (Qiagen), can result in substantial contamination 
of membrane fractions with cytosolic proteins (20).   
 
The studies also aimed to address the mobilisation and translocation of Glut4 to the plasma 
membrane in C2C12 skeletal muscle cells following zinc treatment. Initially an antibody 
directed at the endogenous Glut4 was utilised in the presence of insulin (control) and zinc. The 
data presented here shows Glut4 expression is confined to the cytosol and no translocation of 
Glut4 was observed on the outer plasma membrane in both insulin and zinc treated C2C12 cells 
when compared to the non-treated control cells. It was not clear why insulin-stimulated skeletal 
muscle cells did not cause a translocation of Glut4 to the outer plasma membrane surface. A 
previous study suggested that Glut4 is localised intracellularly in C2C12 cells despite insulin 
stimulation (21). The authors suggest that C2C12 cells exhibit little, if any, insulin-stimulated 
glucose uptake. However, this is in contrast with data showing a significant increase in glucose 
uptake in C2C12 cells stimulated with 200 nM insulin (22) and with our previous data showing 
10 nM of insulin was sufficient to activate glucose uptake in C2C12 and human skeletal muscle 
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cells (7). In fact, several studies have reported that C2C12 cells have the basic Glut4 
translocation machinery that can be activated by insulin (23-25).  
 
The concentration of insulin and treatment time in this study was 100 nM and 15 minutes, 
respectively. Other studies have used similar concentrations of insulin but varied the time of 
the treatment. For example, sixty minutes of insulin treatment at 100 nM was sufficient to 
activate Glut4 machinery and translocation to the outer plasma membrane (23). Thus, it could 
be that a greater time of treatment with insulin is required to activate the Glut4 machinery. 
Unfortunately, there is a lack of data showing zinc-mediated mobilisation and translocation of 
Glut4 to the outer membrane in skeletal muscle, or any other cell type.  
 
One of the main issues with muscle cultures in vitro is the lack of a fully differentiated 
phenotype, lower expression of Glut4, reduced response to insulin, and an underdeveloped 
tubular network (26). To overcome this problem often an exogenous system is utilised in the 
form of a Glut4-GFP labelled plasmid. To this end, similar results were obtained for the 
transfection of exogenous Glut4 in C2C12 cells where a district intracellular localisation was 
observed following both insulin and zinc stimulation. Others have previously reported that 
stably expressing heterologous Glut4 in Chinese hamster ovary (CHO) cells, that insulin-
stimulated translocation of the transfected Glut4 was not detectable by immunoblot analysis of 
subcellular fractions, nor by immunofluorescence microscopy (13, 27). It could be argued that 
the overexpression of exogenous Glut4 might fail to fold correctly and therefore this would 
compromise its ability to translocate to the outer plasma membrane. Although this is possible, 
it is unlikely due to the clear observations of a GFP signal. The GFP signal is important in these 
studies and will not fluoresce unless the protein of interest (Glut4 in this case) is correctly 
folded (26).  
 
Similarly, the studies using zinc as a treatment and measuring both the endogenous and 
exogenous Glut4, resulted in no translocation of Glut4 to the outer plasma membrane (7). 
While zinc can certainly mediate glucose oxidation in C2C12 cells (7, 16), it is not clear how. 
Potentially, similar problems exist as outlined above for insulin treatment of C2C12 cells and 
Glut4 translocation. Alternatively, zinc might require other mechanisms either overlapping, or 
distinct from the insulin signalling axis to mediate glucose uptake in C2C12 cells. Evidence 
for this is lacking, although recently we showed that inhibition of the insulin receptor with 
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HNMPA-(AM)3 resulted in a significant reduction in zinc-mediated pAkt (7). These data 
suggest that zinc potentially acts through the insulin receptor signalling axis and therefore 
might explain the lack of response knowing that insulin also was not capable of translocating 
Glut4 to the plasma membrane. Accordingly, more research is required to delineate the 
mechanisms of insulin-zinc mediated glucose metabolism in skeletal muscle.  
 
In summary, zinc treatment increases Glut4 protein expression in mouse C2C12 skeletal 
muscle cells. However, there was no observable changes in insulin or zinc-mediated Glut4 
translocation to the plasma membrane in these cells. Additional studies, alongside skeletal 
muscle cells, using adipocytes which express Glut4 may help delineate the mechanism of zinc-
mediated glucose transport.  
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Abstract: Background: The zinc transporter Zip7 modulates zinc flux and controls cell signaling
molecules associated with glucose metabolism in skeletal muscle. The present study evaluated the
role of Zip7 in cell signaling pathways involved in insulin-resistant skeletal muscle and mice fed
a high-fat diet. Methods: Insulin-resistant skeletal muscle cells were prepared by treatment with an
inhibitor of the insulin receptor, HNMPA-(AM)3 or palmitate, and Zip7 was analyzed along with
pAkt, pTyrosine and Glut4. Similarly, mice fed normal chow (NC) or a high-fat diet (HFD) were also
analyzed for protein expression of Glut4 and Zip7. An overexpression system for Zip7 was utilized
to determine the action of this zinc transporter on several genes implicated in insulin signaling
and glucose control. Results: We identified that Zip7 is upregulated by glucose in normal skeletal
muscle cells and downregulated in insulin-resistant skeletal muscle. We also observed (as expected)
a decrease in pAkt and Glut4 in the insulin-resistant skeletal muscle cells. The overexpression of Zip7
in skeletal muscle cells led to the modulation of key genes involved in the insulin signaling axis and
glucose metabolism including Akt3, Dok2, Fos, Hras, Kras, Nos2, Pck2, and Pparg. In an in vivo mouse
model, we identified a reduction in Glut4 and Zip7 in the skeletal muscle of mice fed a HFD compared
to NC controls. Conclusions: These data suggest that Zip7 plays a role in skeletal muscle insulin
signaling and is downregulated in an insulin-resistant, and HFD state. Understanding the molecular
mechanisms of Zip7 action will provide novel opportunities to target this transporter therapeutically
for the treatment of insulin resistance and type 2 diabetes.
Keywords: zinc; zinc transporter; Zip7; insulin signaling pathway; high-fat diet; skeletal muscle
1. Introduction
It was estimated in 2013 that 382 million people were affected by diabetes and this number is
expected to increase to 592 million by 2035 [1]. This rapid escalation in diabetes can be attributed to
rapid economic developments and lifestyle changes associated with reduced physical activity and
an increase in the consumption of high calorie diets, resulting in a higher obesity prevalence [2].
Adipose tissue dysfunction is one mechanism responsible for systemic metabolic complications, such
as type-2 diabetes (T2D) [3,4]. T2D is characterized by insulin resistance in major peripheral metabolic
tissues including adipose tissue, liver and skeletal muscle. While most obese individuals do not
become diabetic even in the face of a high degree of insulin resistance, most patients with T2D are
obese [5]. Thus, in addition to insulin resistance, compromised pancreatic β-cell function leads to
increased blood glucose and contributes to hyperglycemia and overt T2D [6].
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Research on T2D has revealed a role for the physiological importance of zinc and the proteins
that transport this metal ion in cells (zinc transporters) in diseases associated with abnormal cell
signaling pathways and metabolism such as insulin resistance (IR) and T2D [7]. Zinc is a vital trace
element that is present in organs, tissues, fluids and secretions and functions as a critical cofactor
in an extensive number of biological signaling pathways as a catalytic, structural or regulatory
component [8]. The storage, release and distribution of cellular zinc are regulated by a family of
zinc transporter proteins and metallothioneins. In mammals, there are 24 zinc transporter proteins
divided into two families. These are the zinc efflux (Slc30/ZnT, members 1–10) and the zinc influx
(Slc39/ZIP, members 1–14) proteins [9]. The ZnT members function to transport zinc from the cell or
into subcellular organelles when cytoplasmic zinc is high. In contrast, the ZIP members function to
transport zinc into the cell when zinc in the cytosol is low or depleted [10].
Emerging research has highlighted key roles for zinc transporter ZIP7 in signaling pathways.
ZIP7 is located in the endoplasmic reticulum (ER) membrane and it is regulated in response to
phosphorylation by casein kinase II (CK2), an enzyme that promotes cell division [11]. ZIP7 is
a gatekeeper of cytosolic zinc release from subcellular organelles including the ER and Golgi
apparatus [12]. It has been demonstrated that genetic ablation of ZIP7 resulted in reduced cytosolic zinc
levels, and abnormalities in cell proliferation and ER function in human osteosarcoma cell lines [13].
Similarly, dysfunctional ZIP7 caused proliferation of the tamoxifen-resistant MCF-7 breast cancer
phenotype [14]. Recent data on zinc transporters also suggests that Zip7 is implicated in glucose
metabolism and glycemic control in skeletal muscle cells [15]. The ablation of Zip7 in skeletal muscle
cells resulted in a substantial reduction in several genes and proteins involved in glucose homeostasis.
These included the phosphorylation of Akt, the insulin receptor (Ir), insulin receptor substrates 1 and 2
(Irs1 and Irs2), the glucose transporter Glut4, and glycogen branching enzyme (Gbe). Similarly, studies
identified a redistribution of cellular ER zinc in hyperglycemic rat heart cells that involved changes in
Zip7 protein and Zip7 phosphorylation [16]. Given the role of Zip7 in regulating zinc flux and the
activation of key cell signaling molecules associated with glucose metabolism, we propose that this
transporter controls cell signaling pathways involved in glucose metabolism in skeletal muscle.
2. Materials and Methods
2.1. Cell Culture
Mouse C2C12 cells were obtained from Professor Steve Rattigan, Menzies Institute for Medical
Research, Hobart, Australia. C2C12 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM)
(Thermo Fisher, Victoria, Australia) medium that contained 10% fetal calf serum (FCS) and 100 U/mL
penicillin/streptomycin (Thermo Fisher) and were maintained at 37 ◦C and 5% CO2 in a humidified
atmosphere. C2C12 cells were differentiated into myotubes by the addition of media containing
2% horse serum (Thermo Fisher) for seventy-two hours. The cells were then exposed to serum-free
conditions for three hours prior to the different treatments as outlined below.
2.2. Protein Extraction
Whole cell protein lysates were prepared in RIPA Lysis buffer in the presence of protease and
protein phosphatase inhibitors (Thermo Fisher) as previously described [17]. Briefly, whole cell lysates
were vortexed every 10 min for 1 h on ice and centrifuged at 15,000 rpm for 5 min. The protein
concentrations of the supernatants were determined by a BCA assay kit as per manufacturer’s
instructions (Thermo Fisher).
2.3. RNA Extraction
Total RNA was extracted using the Qiagen RNeasy Mini Kit as per manufacturer’s instructions
(Qiagen, Victoria, Australia). Briefly, cells were lysed in RLT Buffer, placed directly into a QIAshedder
spin column and centrifuged for 2 min. Lysates were then passed through a RNeasy spin column and
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purified by adding RW1 and RPE buffer. The purified RNA was eluted in RNAse-free water and total
RNA concentration was determined by UV spectrometry.
2.4. cDNA Synthesis
Complementary DNA (cDNA) was synthesized from extracted total RNA using a High-Capacity
cDNA Reverse Transcription Kit (Thermo Fisher, Victoria, Australia) and using random hexamers
according to the manufacturer’s instructions. Briefly, 10 µL cDNA reverse-transcription mix was added
to 10 µL genomic DNA elimination mix and incubated at 42 ◦C for 15 min. The reaction was stopped
by incubating the samples at 95 ◦C for 5 min. The resulting reverse transcription products were stored
at −20 ◦C until use.
2.5. Mice and Diets
The experimental procedures for all animal work has been previously described and the mice
used in these experiments represent a sub group of a previously published cohort of animals [18].
All experiments involving the use of animals for research were approved by the Alfred Medical
Research Education Precinct Animal Ethics Committee and were conducted in accordance with the
National Health and Medical Research Council of Australia guidelines. Ethics number E/1255/2012/B.
Mice (six mice per group) were fed either a normal chow (NC) diet (14.3 MJ/kg, 76% of kJ from
carbohydrate, 5% fat, 19% protein) or a high-fat diet (HFD), (19 MJ/kg, 36% of kJ from carbohydrate,
43% fat [42.7% saturated, 35.1% monounsaturated and 21.7% polyunsaturated fatty acids] and,
21% protein), Specialty Feeds, Glen Forrest, Western Australia, Australia). During the experiment,
the animals were given their prescribed diet and water ad libitum, except for fasting periods before
a glucose tolerance test and were housed at 22 ◦C on a 12-h light/dark cycle.
2.6. Body Composition Analysis
Body mass was measured using standard laboratory scales (Mettler Toledo, Greifensee, Switzerland).
Lean and fat mass was measured using a 4-in-1 EchoMRI (Houston, TX, USA).
2.7. Oral Glucose Tolerance Test
Mice were fasted for 6 h and subsequently received an oral gavage of 2 g glucose/kg lean body
mass (25% w/v glucose solution). An oral glucose tolerance test (OGTT) was performed and glucose
levels were measured from tail tip blood at 0, 15, 30, 45, 60, 90 and 120 mins.
2.8. Mouse Tissue Collection and Protein Extraction
Mice were sacrificed by sodium pentobarbital overdose. Skeletal muscle quadriceps were used
for analysis. Skeletal muscles used for protein analysis were frozen on dry ice and stored at −80 ◦C
until analysis. A protease inhibitor cocktail was added to the CelLytic MT (Mammalian Tissue
Lysis/Extraction Reagent, Sigma) reagent and a ratio of tissue to CelLytic MT reagent of 1:20 was used
for tissue protein extraction. Samples were then transferred to a pre-chilled microhomogenizer and
tissues were homogenized. The lysed samples were centrifuged for 10 min at 12,000–20,000× g to
pellet the tissue debris. The protein- containing supernatants were transferred to a chilled test tube
and stored at −80 ◦C. Protein concentrations of the supernatants were determined using the BCA assay
kit as per manufacturer’s instructions (Thermo Fisher).
2.9. Fatty Acid Preparation and Cell Culture Treatment
Palmitate was prepared as previously described [19]. Briefly, fatty acid was mixed with ethanol to
a final concentration of 100 mM. Then the mixture was sonicated on ice at 200W with 10-sec bursts,
3-sec off pulses until the mixture became a milky homogenous solution. Prepared fatty acid stock
was kept at 4 ◦C and protected from light. For fatty acid treatment, the fatty acid stock solution was
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added to the cell culture medium containing 2% horse serum at 60 ◦C to a final concentration as stated.
For the control, the same amount of ethanol was added to the cell culture medium containing 2%
horse serum. Cells were cultured with increasing concentrations of palmitate-containing media for
24 h followed by 10 nM insulin treatment for 30 min prior to cell lysate harvest. Following treatment,
whole cell lysates were prepared and immunoblot analysis was performed on pAkt, Zip7, glucose
transporter 4 (Glut4), phospho-tyrosine and Gapdh.
2.10. Cell Viability Assay [1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan] Assay
Cell viability was measured using the MTT (3-(4,5)-dimethylthiahiazo(−z-y1)-3,5-
diphenytetrazoliumromid) assay as per manufacturer’s instructions (Thermo Fisher). Briefly, C2C12
skeletal muscle cells were seeded at a density of 2 × 104 cells/well in a 96-well plate. Following
C2C12 differentiation the cells were treated with varying concentrations of palmitate (as described
in the results) for 24 h. Then 15 µL of 5 mg/mL MTT was added to each well. Following a 4 h
incubation at 37 ◦C, the produced formazan was solubilized in 150 µL dimethyl sulfoxide (DMSO).
The absorbance was measured at 490 nm using a microplate reader (TECAN infinite M200 PRO,
Männedorf, Switzerland).
2.11. Insulin Receptor Inhibition
Insulin receptor tyrosine kinase activity is inhibited by 50 µM insulin receptor tyrosine kinase
inhibitor hydroxy-2-naphthalenylmethylphosphonic acid trisacetoxymethyl ester (HNMPA-(AM)3)
after 1 h. It suppresses the activation of pAkt after 30 min of insulin treatment [17]. C2C12 skeletal
muscle cells were treated with the insulin receptor inhibitor [HNMPA-(AM)3] (Abcam, Victoria,
Australia) for 1 h at 0, 25 and 50 µM. This was followed by treating the C2C12 cells with 10 nM insulin
for 30 min. Following treatment, whole cell protein lysates were extracted and immunoblot analysis
was performed on pAkt, Zip7, glucose transporter 4 (Glut4) and Gapdh.
2.12. Western Blotting
Tissue or cell-extracted proteins (20 µg) were electrophoresed using 4–15% SDS-polyacrylamide
gels (Bio-Rad, New South Wales, Australia) and immunoblotted using semi-dry electrophoresis blotting
system. Phosphorylated Akt (1:5000), Zip7 (1:1000) or Glut4 (1:1000) (Cell Signaling Technology,
Beverly, MA, USA) primary antibodies were used for immunoblotting. Antibodies were detected with
HRP-linked secondary antibodies (1:5000) (Cell Signaling Technology, USA). Then, membranes were
stripped with Restore Plus Western Blot Stripping Buffer (Thermo Fisher) and reprobed for the related
housekeeping gene (Gapdh 1:2000 or total Akt 1:5000, Cell Signaling Technology, USA). Proteins were
visualized with SuperSignal West Femto Kit (Thermo Fisher) and imaged using an Odyssey infrared
imaging system (LiCor, Millennium Science, Victoria, Australia). Relative band density was quantified
using Image J software. Representative immunoblots are provided. Experiments were repeated three
times and statistical analysis was performed on the signal intensity of the protein of interest relative to
the house keeping gene on all protein bands from each of the experiments.
2.13. Zip7 Overexpression
To determine the role of Zip7 in modulating cellular pathways, a plasmid-based system was
constructed that overexpressed the Zip7 protein (Origene, Rockville, MD, USA, Clone ID MR216531;
plasmid cytomegalovirus, pCMV-Zip7). The vector was transformed into high-efficiency bacterial cells
and plasmid DNA was isolated using an ISOLATE Plasmid Kit. The bacterial transformation was
performed by heat-shock at 42 ◦C for 30 s as described by the manufacturer’s instructions (Thermo
Fisher). The transformed bacteria were plated onto LB agar plates containing appropriate antibiotics
and incubated overnight at 37 ◦C. Bacterial colonies were harvested and plasmids isolated using
an ISOLATE II plasmid midi kit as per the manufacturer’s instructions (Bioline, New South Wales,
Australia). Restriction digest analysis using the enzymes Sgf1 and and Mlu1 was used to determine
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the correct insertion of the Zip7 gene from the plasmid. Zip7 containing plasmids were transfected
into skeletal muscle cells using Lipofectamine 3000 reagent (Thermo Fisher) as per manufacturer’s
instructions. Briefly, skeletal muscle cells were cultured as previously described in 6-well dishes.
Once the cells had reached 70% confluence, approximately 1 µg of pCMV-Zip7 (and pCMV empty
vector) was mixed with the Lipofectamine 3000 in DMEM and placed on the cells. After 24 h the cells
were harvested for RNA and protein. The quality and quantity of RNA were assessed by nucleic acid
spectrometry (Bio-Rad) and the measurement of optical density at 260 and 280 nm.
2.14. Quantitative Real-Time PCR (qPCR)
To determine whether Zip7 is overexpressed in skeletal muscle cells, qPCR was performed as
previously described [15]. qPCR was performed using 20 ng of cDNA template with 2 x Sensi Fast
Sybr (Bioline) as per manufacturer’s instructions. The relative level of target gene expression was
normalized to eukaryotic elongation factor 2 (Eef2). Primers to amplify the Zip7 sequence were
designed using PrimerFind (NCBI: https://www.ncbi.nlm.nih.gov). Sequences of the primers were as
follows: Zip7 (forward: 5′- CGC ATG CCT TGG AAC CTC AT- 3′; Reverse: 5′- GGC GAC AAT CCC
ACT GAG AA-3′), Eef2 (Forward: 5′- CAC AAT CAA ATC CAC CGC CAT-3′; Reverse: 5′- TGG CCT
GGA GAG TCG ATG A- 3′) (Integrated DNA Technologies, Singapore Science Park II, Singapore).
RT2 qPCR Primer Assay for Mouse Slc2a4, (Qiagen), was used to amplify the Glut4 sequence.
2.15. Insulin Signaling Pathway Array
Insulin Signaling Pathway Array (SABiosciences, Qiagen) was utilized to detect the expression of
84 genes implicated in the insulin signaling pathway. cDNA from the control (empty vector; pCMV)
and pCMV-Zip7 transfected C2C12 cells was assayed across the array. Real-time PCR was performed
to analyze the expression of a focused panel of genes related to insulin-responsiveness and results
were analyzed using GeneGlobe Data Analysis Center (Qiagen, Australia).
2.16. Data Analysis
Results are presented as means ± SDs. Statistical comparisons were performed using Student’s
t-test (Prism GraphPad, version 8, San Diego, CA, USA) for mRNA expression and protein analysis.
A significant effect was demonstrated at p < 0.05. For mouse studies, differences between normal chow
(NC) and high-fat diet (HFD) (diet effect) were analyzed by a paired t-test. For the OGGT, two-way
analysis of variance (ANOVA) with a post-hoc analysis (Bonferroni) was used to detect the effect of diet
on glucose clearance. Analysis was performed by Prism GraphPad (version 8). A P value less than
0.05 was considered statistically significant.
3. Results
3.1. Glucose Regulates Zip7 Expression in C2C12 Skeletal Muscle Cells
Previously we have shown that reduced Zip7 in C2C12 skeletal muscle cells led to a significant
decrease in the phosphorylation of Akt, reduced Glut4 expression and compromised insulin-mediated
glycogen synthesis [15]. Accordingly, we wanted to test whether glucose could regulate Zip7 in C2C12
skeletal muscle cells to establish a role for this transporter in glycemic control. Previous studies have
reported that Zip7 is upregulated by glucose in rat cardiomyocytes [16] and mouse pancreatic islets [20].
Accordingly, treatment of C2C12 cells with 0, 10 and 25 mM glucose for 2 h resulted in a robust increase
in the protein expression of Zip7 (Figure 1a,b).
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Figure 1. Analysis of Zip7 in mouse skeletal muscle cells treated with glucose. (a) Increasing
concentrations of glucose (0, 10 and 25 mM) were added to C2C12 cells over 24 h. G pdh w used as
a in er al loading control and levels of Zip7 w re normalized to Gapdh. Represent tive im ge of
three indepe dent western blot assays that were perform on three independe t reatments (n = 3).
(b) Densitometry graphs for Zip7 from thre independent data westerns blots. * = p < 0.05.
3.2. The Expression of Zip7 and Glut4 Is Suppressed in Insulin-Resistant C2C12 Cells Treated with Either
an Insulin Receptor Inhibitor Hnmpa-(Am)3 or Palmitate
Given that Zip7 could be regulated by glucose in C2C12 skeletal muscle cells, we decided to
perform several studies to recapitulate a compromised glucose state in skeletal muscle by creating
insulin-resistant C2C12 cells. To recapitulate an insulin-resistant state in skeletal muscle we utilized two
experimental procedures: (1) an inhibitor of the insulin receptor and, (2) palmitate treatment [19,21,22].
Initially we tested the ability of the insulin receptor inhibitor HNMPA-(AM)3 to inhibit the insulin
signaling pathway by measuring the downstream target of the insulin receptor, Akt. It has been
previously shown that 50 µM of HNMPA-(AM)3 is sufficient to inhibit insulin-induced pAkt in C2C12
cells [19]. Accordingly, 50 µM of HNMPA-(AM)3 was sufficient to inhibit the insulin-dependent
activation of pAkt in C2C12 skeletal muscle cells (Figure 2a,b). We also assayed the levels of Zip7 and
Glut4 in the HNMPA-(AM)3 treated C2C12 cells and identified a significant reduction in the levels of
these proteins (Figure 2a,c,d).
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Figure 2. Western blot results of pAkt, Zip7 and Glut4 expression in C2C12 cells treated with insulin
receptor tyrosine kinase inhibitor HNMPA-(AM)3. (a) The inhibitor concentration was 0, 25 and 50 µM.
From the top the proteins are, pAkt, Zip7, Glut4 and Gapdh. Gapdh was used as an internal loading
control. Th ee independent western blots on thre ind pende t treatments wer performed ( = 3).
(b–d). De sitometry graphs for pAkt, Zip7 and Glut4, respectively from three independent data
westerns bl ts. * = p < 0.05, ** = < 0.01, *** = p < 0.001.
It has been shown previously that saturated fatty acid palmitate reduces insulin sensitivity and
induces insulin resistance in skeletal muscle [18]. In this experiment, the inhibitory effect of palmitate
on the insulin signaling pathway in C2C12 myotubes was tested. Initially we aimed to test the viability
of the C2C12 cells following palmitate treatment. The result of the MTT assay showed that 0.3 mM
of palmitate did not significantly suppress C2C12 cell viability (Figure 3a), while at the same time,
Cells 2019, 8, 663 7 of 19
it suppressed insulin-stimulated phosphorylation of Akt (Figure 3b,c). Accordingly, we chose 0.3 mM
of palmate as the highest concentration of this fatty acid in the following experiments.
To determine the effect of palmitate treatment on Zip7 we assayed the level of Zip7 protein in
palmitate-treated C2C12 cells. The expression level of Zip7 protein were reduced when treated with
increasing concentrations of palmitate (Figure 3b,d). We also observed a reduction in pAkt in the
presence of palmitate as previously described [19]. Glut4 was also reduced in the presence of increasing
palmitate concentrations (Figure 3b,e). We also tested the ability of palmitate to reduce the levels of
phospho-tyrosine, a key amino acid involved in cellular signal transduction. Following palmitate
treatment, the levels of phospho-tyrosine were also reduced (Figure 3b,f). These results indicate that
palmitate treatment was sufficient to induce an insulin-resistant state in C2C12 skeletal muscle cells (as
evidence by the reduction in pAkt and phospho-tyrosine).
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Figure 3. Recapitulation of an insulin-resistant state with palmitate. (a) MTT assay for cell viability
assay in C2C12 cells treated with increasing concentrations of palmitate. Concentrations of palmitate
are 0, 0.2, 0.3 and 0.4 mM (white bars); 0.5, 0.6. 0.8 and 1 mM (black bars). Cell viability was performed
three times (n = 3). (b) Palmitate-induced insulin resistance in C2C12 cells. Cells were treated with 0,
0.1, 0.2 and 0.3 mM palmitate over 24 h, then stimulated with 10 nM insulin for 30 min before harvesting
total protein. Phosphorylated Akt (Ser473), Zip7, Glut4 and phosphor-tyrosine were immunoprobed
by western blotting. Gapdh was used as an internal control. Three independent western blots on three
independent treatments were performed (n = 3). (c–f). Densitometry graphs for pAkt, Zip7, Glut4,
and pTyrosine, respectively from three independent data westerns blots * = p < 0.05, ** = p < 0.01,
*** = p < 0.001.
3.3. Testing the Function of ZIP7 in Controlling Genes Involved in Insulin Signaling
The above studies suggest that Zip7 is involved in metabolic processes that could enhance cell
signaling pathways associated with glucose metabolism. Accordingly, we wanted to test whether Zip7
could cti ate gen s implica ed in insulin s gna ing and glucose homeostasis. Initially w overexpr ssed
Zip7 in C2C12 skeletal muscle cells utilizing an overexpression plasmid pCMV (Figure 4). We observed
a signific nt increase in pCMV-Zip7 mRNA compared to pCMV control (Figure 4a). Similarly,
we observed a sig ificant increase in pCMV-Zip7 protein c mpared to pCMV control (Figure 4b,c).
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Figure 4. Overexpression of Zip7 in C2C12 skeletal muscle cells. (a) Quantitative real-time polymerase
chain reaction (PCR) for the overexpression of Zip7 RNA in pCMV versus pCMV-Zip7. (b) Western
blot for pCMV-Zip7 protein. Gapdh was used as a loading control. (c) Densitometry results from
the western blot data pCMV versus pCMV-Zip7. The experiments were perfor ed three times and
statistical significance compared ZIP-7 over-expressed group to the control. *** = p < 0.001.
To further identify the effect of pCMV-Zip7 overexpression on insulin signaling, we used an insulin
signaling pathway array, which has the targeted expression of eighty-four genes involved in insulin
signaling and glucose metabolism. The genes were selected based on a commercially available insulin
signaling array (SABiosciences, Qiagen) and focused cellular pathways. We tested the pCMV-Zip7
overexpression plasmid to target the expression of genes on this array. Following transfection of the
pCMV-Zip7 overexpression plasmid and control empty vector (pCMV) in C2C12 cells, total RNA
was extracted, and cDNA synthesis performed. Changes in the expression of all genes on the array
following pCMV-Zip7 overexpression transfection are presented as (1) the gene name, (2) fold up or
down regulation, and (3) the p-value (Table 1). Although we identified several genes with fold-change
expression greater than the statistically significant highlighted genes in Table 1 below (in bold), these
did not reach significance and did not meet the stringent data normalization processes (GeneGlobe
Data Analysis Center Qiagen).
Table 1. Insulin signaling gene array.
Gene Name Fold–Up orDownregulation p–value
Insulin Receptor–Associated Proteins
Eukaryotic translation initiation factor 4E binding protein 1 (Eif4ebp1) −5.42 0.109812
Insulin−like growth factor 2 (Igf2) −2.51 0.119985
Growth factor receptor bound protein 2 (Grb2) −1.81 0.044301
Fibroblast growth factor receptor substrate 3 (Frs3) −1.78 0.342511
Sorbin and SH3 domain containing 1 (Sorbs1) −1.57 0.261979
Protein tyrosine phosphatase, receptor type, F (Ptprf) −1.49 0.376424
Grow h factor receptor bound protein 2−associated protein 1 (Gab1) −1.48 0.237770
Non−catalytic region of tyrosine kinase adaptor protein 1 (Nck1) −1.24 0.479138
Fibroblast growth factor receptor substrate 2 (Frs2) −1.21 0.514579
Protein tyrosine phosphatase, non−receptor type 1 (Ptpn1) −1.19 0.481621
Heat shock protein 90 alpha (cytosolic), class B member 1 (Hsp90ab1) 1.04 0.965684
src homology 2 domain−containing transforming protein C1 (Shc1) .13 0.659820
Protein phosphatase 1 catalytic subunit alpha (Ppp1ca) 1.15 0.595936
Casitas B−lineage lymphoma (Cb1) 1.15 0.759472
Insulin receptor substrate 1 (Irs1) 1.47 0.435010
Insulin−like growth factor I receptor (Igfr) 1.54 0.241275
Insulin receptor substrate 2 (Irs2) 1.67 0.240410
Prolactin (Prl) 1.82 0.518438
Insulin 1 (Ins1) 2.04 0.401028
Insulin−like growth factor binding protein 1 (Igfbp1) 2.14 0.391212
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Table 1. Cont.
Gene Name Fold–Up orDownregulation p–value
Neuropeptide Y (Npy) 2.60 0.057738
Docking protein 1 (Dok1) 2.91 0.103312
Docking protein 3 (Dok3) 3.30 0.315765
Growth factor receptor bound protein 10 (Grb10) 3.75 0.140065
Insulin−like 3 (InsI3) 4.33 0.287920
Thyroglobulin (Tg) 5.53 0.179122
Docking protein 2 (Dok2) 21.79 0.031048
PI3 Kinase Signaling
Thymoma viral proto−oncogene 3 (Akt3) −2.16 0.019032
Phosphoinositide−3−kinase regulatory subunit 1 (Pik3r1) −1.57 0.350159
Thymoma viral proto−oncogene 2 (Akt2) −1.46 0.384953
Protein kinase C, gamma (Prkcg) −1.42 0.281971
Eukaryotic translation initiation factor 2B, subunit 1 (alpha) (Eif2b1) −1.39 0.219592
Phosphatidylinositol−4,5−bisphosphate 3−kinase catalytic subunit alpha (Pik3ca) −1.38 0.333187
Phosphatidylinositol−4,5−bisphosphate 3−kinase catalytic subunit beta (Pik3cb) −1.30 0.444354
3−phosphoinositide dependent protein kinase 1 (Pdpk1) −1.15 0.751995
Protein kinase C, iota (Prkci) −1.14 0.707935
Mechanistic target of rapamycin kinase (Mtor) 1.08 0.874784
BCL2−like 1 (Bcl2l1) 1.21 0.631682
Phosphoinositide−3−kinase regulatory subunit 2 (Pik3r2) 1.22 0.653162
Adrenergic receptor, alpha 1d (Adra1d) 1.25 0.391856
Thymoma viral proto−oncogene 1 (Akt1) 1.36 0.241863
Dual specificity phosphatase 14 (Dusp14) 1.42 0.465154
Protein kinase C, zeta (Prkcz) 2.00 0.327070
Serine peptidase inhibitor, clade E, member 1 (Serpine 1) 2.09 0.131939
MAP Kinase Signaling
Related RAS viral (r−ras) oncogene 2 (Rras2) −1.86 0.075688
Braf transforming gene (Braf) −1.78 0.127855
Related RAS viral (r−ras) oncogene (Rras) −1.63 0.070002
Araf proto−oncogene, serine/threonine kinase (Araf) −1.40 0.331800
SOS Ras/Rac guanine nucleotide exchange factor 1 (Sos1) −1.21 0.477393
Excision repair cross−complementing rodent repair deficiency, complementation
group 1 (Ercc1) −1.02 0.884782
v−raf−leukemia viral oncogene 1 (raf1) 1.03 0.834133
Uncoupling protein 1 (mitochondrial, proton carrier) (Ucp1) 1.26 0.433977
Mitogen−activated protein kinase kinase 1 (Map2k1) 1.43 0.244012
Mitogen−activated protein kinase 1 (Mapk1) 1.82 0.134200
Kruppel−like factor 10 (Klf10) 2.12 0.143675
Nitric oxide synthase 2, inducible (Nos2) 2.21 0.030364
Harvey rat sarcoma virus oncogene (Hras) 2.30 0.027193
Ribosomal protein S6 kinase polypeptide 1 (Rps6ka1) 2.93 0.286011
FBJ osteosarcoma oncogene (Fos) 4.42 0.014490
Carbohydrate Metabolism
Phosphoenolpyruvate carboxykinase 2 (mitochondrial) (Pck2) −2.73 0.046319
Glucuronidase, beta (Gusb) −2.44 0.057494
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Table 1. Cont.
Gene Name Fold–Up orDownregulation p–value
Pyruvate kinase liver (Pkl) −2.00 0.361565
AE binding protein 1 (Aebp1) −1.36 0.346200
acyl−Coenzyme A oxidase 1, palmitoyl (Acox1) −1.23 0.517860
Hexokinase 2 (Hk2) 1.06 0.892955
Glycogen synthase kinase 3 beta (Gsk3b) 1.04 0.908617
Glyceraldehyde−3−phosphate dehydrogenase (Gapdh) 1.15 0.642638
Glucose−6−phosphatase, catalytic (G6pc) 1.22 0.432012
Glycerol−3−phosphate dehydrogenase 1 (Gpd1) 1.43 0.434684
Solute carrier family 2 (facilitated glucose transporter), member 1 (Slc2a1) 1.50 0.246541
Glucokinase (Gck) 1.96 0.316235
Fructose bisphosphatase 1 (Fbp1) 3.40 0.315244
Glucose−6−phosphatase, catalytic, 2 (G6pc2) 4.71 0.189288
Lipid Metabolism
Complement factor D (adipsin) (Cfd) −3.66 0.370569
Peroxisome proliferator activated receptor gamma (Pparg) −3.31 0.007128
Sterol regulatory element binding transcription factor 1 (Srebf1) −1.59 0.041612
Resistin (Retn) −1.71 0.786857
Low density lipoprotein receptor (Ldlr) −1.11 0.938288
Leptin (Lep) 1.31 0.490170
Solute carrier family 27 (fatty acid transporter), member 4 (Slc27a4) 1.33 0.350357
Cell Growth and Differentiation
Kirsten rat sarcoma viral oncogene homolog (Kras) 2.12 0.025606
CCAAT/enhancer binding protein (C/EBP), alpha (Cebpa) −1.41 0.700291
Vascular endothelial growth factor A (Vegfa) −1.14 0.660055
CAP, adenylate cyclase−associated protein 1 (Cap1) −1.13 0.673316
Jun proto−oncogene (Jun) 1.02 0.996474
Beta−2 microglobulin (B2m) 1.13 0.700177
Actin, beta (Actb) 1.28 0.577259
CCAAT/enhancer binding protein (C/EBP), beta (Cebpb) 2.33 0.145381
Note: Genes are listed by specific pathways: insulin receptor and associated proteins, PI3 kinase signaling, MAP
kinase signaling, carbohydrate metabolism, lipid metabolism, and cell growth and differentiation. Please also note
that several genes can belong to multiple pathways. The fold change for each gene within the pathway is shown
initially as the highest value for the downregulation (a negative symbol) followed by a sequential increase in values
into the positive range.
Representative graphs are given for the genes that were significantly changed due to the over
expression of pCMV-Zip7. These include Akt3, Dok2, Fos, Hras, Kras, Nos2, Pck2, and Pparg,
(Figure 5a–h).
3.4. The Expression of Zip7 and Glut4 Is Reduced in the Skeletal Muscle of Mice Fed a High-Fat Diet
The results above suggest that Zip7 has a role in modulating genes involved in glucose metabolism
and is reduced in an insulin-resistant state when treated pharmacologically or with fatty acids.
This suggests that Zip7 could be regulated by changes in fatty acids or a high-fat diet, for example.
To determine if Zip7 is modulated by a high-fat diet we performed experiments on C57BL/6J mice
consuming a normal chow (NC) or high-fat diet (HFD) for 10 weeks. As expected on the HFD, body
weight, fat mass and body fat percentages were increased compared to the NC-fed mice while lean
mass remained unchanged (Figure 6a–d). Next, we performed an oral glucose tolerance test (OGTT)
to assess insulin-stimulated glucose clearance. While blood glucose decreased over a 120-min time
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course in both NC and HFD cohorts, there was an overall dietary effect on glucose clearance in the
HFD mice versus the NC control (Figure 6e).
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Figure 5. Quantitative real time PCR on an insulin signaling RT-Profiler Array for pCMV-Zip7
overexpression. Genes are (a) Akt3, (b) Dok2, (c) Fos, (d) Hras, (e) Kras, (f) Nos2, (g) Pck2, (h) Pparg.
Control = pCMV empty vector. Zip7 = overexpression pCMV-Zip7. * p < 0.05, ** p < 0.01.
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Figure 6. Characteristics of mice fed a normal chow (NC) diet or a high-fat diet (HFD) for 10 weeks.
(a) body weight (g), (b) fat mass (g), (c) lean mass (g), (e) fat mass (%), (f) plasma glucose levels over
120 min following an oral gavage of 2 g glucose/kg lean body mass (25% w/v glucose solution). Unpaired
t-test was used for the NC versus the HFD comparisons (a–d) and a two-way repeated measure ANOVA
was used for the OGTT (e). Graphs indicate mean ± SD. * = p < 0.05. *** p < 000.1.
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To determine the protein expression of Zip7 in NC versus HFD-fed mice, we performed western
blots on proteins extracted from quadricep skeletal muscle tissue from both cohorts. We observed
a significant decrease in the expression of Zip7 and Glut4 in the HFD mice groups relative to control
mice (Figure 7a,b).
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Figure 7. Analysis of Zip7 in mouse skeletal muscle tissues in NC versus HFD mice. Gapdh was used
as an internal loading control and levels of Zip7 were normalized to Gapdh. (a) Western blot for Zip7
in NC versus HFD. (b) Densitometry of the western blot results. The experiments were performed on
six animals per group (n = 6) and statistical significance was compared between the HFD to the NC
mice group. * = p < 0.05.
We also measured the protein levels of Glut4 in the NC versus the HFD mice. We observed
a significant reduction in the protein levels of Glut4 in the HFD mice when compared to the NC mice
(Figure 8a,b).
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Figure 8. Analysis of Glut4 in NC versus HFD mouse skeletal muscle tissues. Gapdh was used as an
internal loading control and levels of Glut4 were normalized to Gapdh. (a) Western blot for Glut4 in
NC mice versus HFD. (b) Densitometry of the western blot results. The experiments were performed
on six animals per group (n = 6) and statistical significance was compared between the HFD to the NC
mice group. ** = p < 0.01.
4. Discussion
We have previously demonstrated the effect of zinc as an essential trace element implicated
in the insulin signaling pathway [17]. However, its mechanism of action in the insulin signaling
pathway and glucose uptake has not been determined. Insulin resistance, a hallmark of T2D [23],
is characterized by compromised insulin-mediated activation of the PI3K/Akt pathway regulating
glucose uptake via Glut4 transporters [24]. Skeletal muscle is the major site of peripheral insulin
resistance of which much of the complexity of this disorder remains undefined, including the role of
zinc and zinc transporter Zip7 in insulin signaling and glucose metabolism. Previous investigations
showed that zinc has insulin mimetic activity leading to increased total glucose consumption [17].
Glucose transporters are important proteins that regulate glucose uptake through cellular membranes.
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In this regard, Glut4 facilitates the transport of glucose in skeletal muscle [25]. Glut4 translocation to
the cell membrane from specialized storage vesicles in the cytosol by insulin is a rate-limiting step of
glucose disposal [26]. Accordingly, treatment of L6 rat skeletal muscle cells with zinc induced Glut4
translocation in a dose-dependent manner [26]. These studies showed that zinc exerted insulin-like
effects by phosphorylation of Akt and subsequent mobilization of glut4.
Several studies have shown that disturbances in zinc transporter function and consequently zinc
signaling lead to cellular and physiological disturbances. For example, zinc transporter ZnT8-deficient
mice exposed to a high-fat diet develop severe insulin resistance and obesity [27]. Similarly,
Zip13-deficient mice have enhanced beige adipocyte production and energy expenditure and this was
concomitant with resistance to HFD-induced obesity, and improved glucose and insulin tolerance [28].
Other studies have shown that ZIP7 (and ZIP6) play an important role in regulating zinc homeostasis in
MIN6 pancreatic beta cells [29]. These studies identified a compensatory increase in the expression of
ZIP7 in the presence of a targeted ZIP6 knockdown. It was suggested that ZIP6 and ZIP7 transporters
orchestrate cytosolic zinc flux by increasing extracellular zinc uptake or by releasing ER-stored zinc
into the cytosol when required. This is supported by studies where ZIP7 knockdown in human
osteosarcoma (MG-63) cells exhibited an increase in ER zinc and a decrease in cytosolic zinc [13].
Moreover, other studies have identified a dual role for ZIP7 and ZnT7 in cardiomyocytes [16]. Here it
was identified that changes in the expression of ZIP7 and ZnT7 induces ER stress through the loss
of ER zinc during hyperglycemic conditions. These authors also suggest that perturbations in the
expression of ZIP7 and ZnT7 may lead to decompartmentalization of zinc across the ER and therefore
lead to persistent ER stress.
In the context of Zip7, ablation of this transporter in mouse skeletal muscle cells resulted in
reduced Glut4 protein and a reduction in insulin-stimulated glycogen synthesis [15]. To expand on this
study, we examined the protein levels of both Zip7 and Glut4 in an in vitro insulin-resistant skeletal
muscle cell model and an in vivo skeletal muscle of mice fed normal chow (NC) versus a high-fat
diet (HFD).
First, we treated C2C12 skeletal muscle mouse cells with glucose to recapitulate hyperglycemic
conditions and measured the protein levels of Zip7. We observed a significant increase in the protein
levels of Zip7 in cells treated with increasing concentrations of glucose. This result is supported by
studies showing high glucose induces the expression of Zip7 mRNA in mouse pancreatic islets [20]
and Zip7 mRNA and protein in rat cardiomyocytes [16].
Second, we aimed to recapitulate an in vitro insulin-resistance cell culture model and investigate
the protein levels of Glut4 and Zip7. C2C12 skeletal muscle cells were treated with HNMPA-(AM)3,
an inhibitor of insulin receptor tyrosine kinase activity, and palmitate. HNMPA-(AM)3 abolished the
expression of insulin-induced pAkt and is supported by previous studies [17,30,31]. We observed
a clear reduction in Zip7 and Glut4 protein upon treatment with HNMPA-(AM)3. To our knowledge no
data exists showing insulin receptor inhibition action on Zip7 expression. Similarly, palmitate-induced
insulin resistance in C2C12 skeletal muscle cells was comparable with the insulin receptor inhibition
study. Excessive plasma free fatty acids are associated with insulin resistance in both diabetic and
non-diabetic subjects [19]. Palmitate plays a critical role in the initiation and development of insulin
resistance as exposure of C2C12 cells to palmitate suppressed insulin-stimulated Akt1 phosphorylation
and glucose uptake [19]. It was observed that palmitate treatment reduced insulin-induced Akt
phosphorylation that is consistent with an insulin resistant state [21]. Moreover, the protein expression
of Zip7 and Glut4 were reduced by palmitate and by HNMPA(AM)3. We also detected a decrease in the
phospho-tyrosine expression in palmitate-treated C2C12 cells. These data suggest that Zip7 is involved
in the insulin signaling pathway and glucose metabolism. While it is unclear how Zip7 contributes
to the control of these pathways, there is some evidence on the potential mechanisms. For example,
studies in C2C12 mouse skeletal muscle cells identified that ablation of Zip7 resulted in the modulation
of key genes implicated in glucose metabolism including those of glycolysis, gluconeogenesis, the
citric acid cycle, and glycogen metabolism [15]. Moreover, a reduction in the mRNA of the insulin
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receptor and insulin receptor substrates 1 and 2, Glut4 protein, pAkt and insulin-induced glycogen
synthesis was observed.
While these studies suggest that ZIP7 is associated with the insulin-signaling axis, how this
association occurs in unclear. The role of ZIP7 in initiating zinc flux from the ER into the cytosol poses
several questions, and are therefore limitations of this manuscript. For example, what are the cellular
concentrations of zinc during treatment with palmitate or HNMPA-(AM)3 in an insulin-resistant
state? To our knowledge, there are limited studies addressing the effect of fatty acids on cellular zinc
status. One study identified the fatty acids oleate, elaidate, stearate and palmitate increased zinc
concentrations in human macrophages, with elaidate having the greatest effect [32]. The authors suggest
the importance of this based on zinc being a major regulator of macrophage activity. Accordingly,
it will be important to determine cellular zinc status in insulin resistant skeletal muscle cells and
determine whether zinc signaling processes are compromised. Moreover, the role of ZIP7 in these
processes needs to be addressed. For example, if ZIP7 is reduced (or defective) in an insulin-resistant
state, what effect does this have in zinc mimetic activity, and glucose metabolism?
To further investigate effects of Zip7 on glucose metabolism and insulin signaling, we established
a Zip7 overexpression cell culture model. Previous studies identified that a reduction in Zip7 in skeletal
muscle cells resulted in changes in several genes involved in glucose metabolism [15]. To extend on
these studies, a plasmid-based system that overexpressed Zip7 was utilized to determine the ability of
this transporter to regulate genes involved in the insulin signaling pathway. These studies identified
significant changes in several genes including Akt3, Dok2, Fos, Hras, Kras, Nos2, Pck2, and Pparg.
It was observed that Akt3, Pck2, and Pparg were significantly downregulated in the
Zip7-overexpressing cells. The roles of Akt1 and Akt2 are well established in metabolism, however
there is less known about Akt3 [33]. It is suggested that Akt3 may play a role in defects in insulin
signaling that occur in insulin resistant states [34].
There are two Pck isoenzymes, phosphoenolpyruvate carboxykinase (PEPCK-C, cytoplasmic)
encoded by Pck1 and PEPCK-M (mitochondrial), encoded by Pck2 (mitochondrial). Although the role
of Pck1 has been extensively studied for its role in gluconeogenesis in the liver, Pck2 remains somewhat
unknown [35]. However, these data for Pck2 are consistent with previous studies where a reduction in
Zip7 mRNA led to an increase in this gene in C2C12 skeletal muscle cells [15].
Pparg (peroxisome proliferator activated receptor gamma) is a member of the nuclear hormone
superfamily of transcription factors that modulates genes involved in insulin signaling and lipid
metabolism [36]. While Pparg expression is low in skeletal muscle, C2C12 skeletal muscle cells
stably overexpressing Pparg resulted in increased glucose uptake and inhibition of Pparg expression
induced insulin resistance as determined by reduced deoxyglucose uptake [36]. In contrast, mice
heterozygous for Pparg+/- displayed greater insulin sensitivity than the wild-type animals [37] and
improved insulin resistance and obesity [38]. While these studies counter the current dogma on Pparg
action in metabolism, it is not clear why Pparg expression is reduced in our overexpression Zip7 studies.
A recent study identified Zip7 was upregulated by ethanol exposure in the livers of mice and this was
concomitant with a downregulation of anotherPpar family member, Ppara [39]. In C2C12 skeletal muscle
cells with an ablation of Pparg, it was identified that myogenic differentiation was compromised [40].
These studies suggest that Pparg is critical for the differentiation of skeletal muscle myoblast to
myotubes and perhaps Zip7 overexpression overrides the mechanism of Pparg-inhibitory effect on the
myogenic phenotype. Support for a Zip7-mediated role in promoting myogenic differentiation was
recently identified [41]. It was identified that zinc promotes myoblast proliferation and differentiation
of mature myotubes via Zip7 activation and the modulation of the Pi3k/Akt pathway in C2C12 skeletal
muscle cells.
We also observed significant upregulation of several genes in the Zip7 overexpression cell model
including Dok2, Fos, Hras, Kras, and Nos2. Dok2 (docking protein 2), along with its closest homologue
Dok1 work as adapter proteins that recruit and assemble multiple SH2-containing molecules including
p120 rasGAP and Nck [42]. There is little information on the role of Dok2 in skeletal muscle or
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insulin resistance, however experiments in mice lacking Dok1 or Dok2 showed enhanced expression
of Erk and Akt in myeloid cells [43]. Similarly, Dok2 significantly inhibited insulin-stimulated Akt
phosphorylation in COS7 cells and these authors suggested that Dok2 acts as an inhibitor of insulin
action [44]. These data therefore suggest that a reduction in Dok2 would have an enhancing effect on
insulin signaling.
c-Fos (FBJ osteosarcoma oncogene) is a protooncogene that dimerizes with c-Jun to form the
activator protein AP1 transcription complex [45]. C-Fos is implicated in several molecular mechanisms
that contribute to cellular processes including proliferation, differentiation, and apoptosis [46]. Recently,
parathyroid hormone-related peptide (PTHrP) induced c-Fos expression was significantly reduced in
Zip14-KO chondrocytes [47]. In chondrocyte differentiation, PTHrP induces phosphorylation of cAMP
and the subsequent regulation of c-Fos via phosphorylation of the cAMP response element-binding
protein (CREB) [47]. These studies suggest that Zip14 controls basal cAMP levels and its role may
provide a mechanism for the zinc-mediated regulation of endocrine signaling. Whether Zip7 controls
similar cAMP-mediated events (or whether Zip7 is regulated by cAMP) in skeletal muscle is yet to be
determined. Zinc itself affects a wide range of second messenger and signaling molecules including
Ca2+/calmodulin-dependent protein kinase II [48], Erk1/2, protein tyrosine phosphatase [17] and
cAMP-dependent protein kinase [49]. Future studies eliminating Zip7 in skeletal muscle for example
could provide valuable insight into the specific pathways controlled by Zip7-mediated zinc flux.
We also identified an increase in the expression of Hras (Harvey rat sarcoma virus oncogene) and
Kras (Kirsten rat sarcoma viral oncogene homolog) in the Zip7 overexpressing skeletal muscle cell
lines. Hras and Kras are canonical ras genes and are critical components of cell signaling pathways
that control proliferation, survival, and differentiation [50]. Ras activity induces Raf and subsequent
regulation of protein kinases Mek1/2 which phosphorylate ERK1/2. Mostly, the Ras/Raf/Mek/ERK
pathway is critical for cell proliferation and differentiation [51].
Finally, we assayed the expression levels of Zip7 in an in vivo HFD mouse model. Our results
revealed a decrease in the protein expression of both Zip7 and Glut4 in the skeletal muscle of HFD-fed
mice compared to the NC controls. While there are no other studies reporting this observation for
reduced Zip7 in skeletal muscle of HFD-fed mice, studies on obesity-associated inflammation in
mammary gland tissue found HFD mice had decreased levels of Zip7. These authors suggest that
inflammation in mammary tissue compromises lactation by mediating zinc retention in the endoplasmic
reticulum [52]. However, several studies have assessed zinc in the context of HFD. For example,
male rats fed a HFD had reduced weight gain, abdominal fat pads, plasma insulin levels, leptin and
triglycerides when supplemented with zinc [53]. Similarly, it was identified that zinc supplementation
improved glucose tolerance, HOMA-β, and glucose-stimulated insulin secretion in HFD mice by
enhancing pancreatic β-cell function [54]. In the context of plasma zinc levels, it has been identified
in obese humans and mice that leptin levels are increased with concomitant reduced plasma zinc
concentrations [55]. It was suggested by these authors that reduced zinc compromises several cell
signaling pathways that regulate inflammation and leptin. This is significant given that zinc-deficiency
is common in obese individuals [56].
While, the connection between Zip7 and Glut4 regulation is not known, our previous data
showing a reduction in Zip7 in C2C12 skeletal muscle cells led to a significant decrease in Glut4 protein
and compromised insulin-mediated glycogen synthesis [15] suggests that Zip7 might be involved
in skeletal muscle glycemic control. However, the mechanisms involved in these processes requires
further investigation.
The studies presented suggest that Zip7 has a role in modulating insulin-signaling molecules and
is reduced in an insulin-resistant state and in mice fed a HFD. While there were several changes in
genes associated with Zip7 overexpression, it is unknown how these changes contribute to insulin
signaling and cell signaling processes and affect glycemic control in skeletal muscle. Further studies are
required to delineate the molecular mechanisms of Zip7 action on cell signaling in both insulin-resistant
and diabetic in vitro and in vivo models.
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6.1. Final Discussion 
The overall aim of this thesis was to identify the role of zinc and the zinc transporter Zip7 in 
modulating the insulin signalling pathway and glucose metabolism in skeletal muscle cells. 
Zinc is an essential metal ion implicated in several biological processes and dysfunctional zinc 
signalling is associated with various disease states (1). The results from these studies suggest 
that zinc induces cell signalling molecules associated with glucose homeostasis in skeletal 
muscle. The subsequent zinc-mediated phosphorylation of cell signalling molecules associated 
with the insulin-signalling axis and increased glucose oxidation suggests that both insulin and 
zinc are critically important in maintaining glucose homeostasis in skeletal muscle (1).  
 
The insulin-like activity of zinc in processes involved in cellular function and homeostasis 
suggests that aberrant levels of zinc, and decompartmentalisation of zinc will have biological 
effects that could be amendable to clinical intervention. Zinc transporter proteins are implicated 
in several cell processes that facilitate insulin signalling and glucose control and therefore could 
offer exciting new molecular targets that have utility for clinical intervention in the treatment 
of IR and T2DM and other diseases associated with compromised metabolism. According to 
several studies on  Zip7 as the “gate-keeper” of zinc release from subcellular organelles and 
subsequent Zip7-mediated cell signalling events in skeletal muscle, no doubt place this 
transporter in an important position for further studies (2).  
 
In this thesis it was identified that zinc has insulin-mimetic-like activity in skeletal muscle 
through the activation of several cell signalling molecules and the concomitant mobilisation of 
glucose uptake. Moreover, it was observed that the Zip7 protein is diminished in 
pharmacologically and fatty acid-induced insulin-resistant mouse skeletal muscle cells and in 
mice fed a HFD. Moreover, the overexpression of Zip7 protein in mouse skeletal muscle cells 
regulated the modulation of several key insulin signalling molecules. Therefore, these studies 
now provide an important process to further delineate the molecular mechanisms of zinc and 
Zip7 in the context of IR and T2DM. These results also provide a significant advancement in 
knowledge contributing to the emerging concept and paradigm that zinc transporters are 
important factors involved in maintaining physiological zinc processes and cellular 
homeostasis and that dysfunctional zinc signalling contributes to insulin resistance and T2DM 
progression. These key findings are novel and will add to the current scientific knowledge of 
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zinc and the zinc transporter Zip7 in the context of mediating cell signalling activity in skeletal 
muscle and therefore may contribute to the discovery of novel treatments for IR and T2DM. 
 
6.2. Future research 
The broad nature of insulin resistance in skeletal muscle suggests a defect in the proximal 
component of the insulin signalling network. Given the unique role of zinc in cellular signalling 
and the activity of ZIP7 as the ‘gatekeeper’ of zinc release, it will be important to further 
characterise their mechanisms of action in insulin-sensitive tissues. Some examples of future 
research include: 
 
6.2.1. Inhibition studies to determine how zinc targets cell signalling molecules 
In this thesis it was shown that the insulin receptor tyrosine kinase inhibitor HNMPA-(AM)3 
inhibited zinc-induced Akt activation suggesting that zinc acts through the insulin signalling 
pathway. To extend this study, several inhibition studies can be performed to block various cell 
signalling molecules “upstream” of Akt, and “downstream” of the insulin receptor to determine 
how zinc is acting on the phosphorylation of Akt and thus glucose homeostasis. Several cell 
molecule inhibitors can be used in various combinations. These include LY294002 (a 
reversible inhibitor of PI3K) (3); Wortmannin (an irreversible inhibitor of PI3K) (3); UO126 
(a selective inhibitor of MAP kinase kinases, MEK1 and MEK2) (4) and OSU-03012 (a PDK1 
inhibitor) (5). These inhibitors will help “dissect” out the pathways of zinc-mediated cell 
signalling events. For example, inhibition of upstream molecular targets of Akt and treatment 
of skeletal muscle cells with zinc will elucidate whether zinc can independently activate Akt 
in the presence of a non-functional insulin signalling axis.     
 
Similarly, treatment of skeletal muscle cells with a zinc chelator (e.g. TPEN) will provide an 
insight into whether zinc treatment can independently activate cell signalling molecules and 
glucose uptake over that of insulin treatment. For example, skeletal muscle cells could be 
treated with insulin to activate pAkt in the presence of TPEN. If pAkt is not activated by insulin 
in this situation, then this will suggest that zinc is required and the insulin signalling axis 
depends on zinc. Moreover, utilising siRNA technology to reduce the levels of Zip7 in skeletal 
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muscle cells and subsequently treating cells with insulin to activate the insulin signalling axis 
will determine if Zip7 is required for this axis.  
6.2.2. Assess the 'gated' release of zinc from intracellular stores by Zip7 and subsequent 
activation of the insulin signalling pathway in non-insulin resistant versus insulin-
resistant skeletal muscle cells. 
The idea that Zip7 controls zinc flux from subcellular organelles and consequently zinc-
mediated activation of cell signalling molecules presents an opportunity to further delineate the 
mechanisms of action of this transporter. To understand these mechanisms in more detail, 
insulin-resistant skeletal muscle cells can be created by chronically treating skeletal muscle 
cells in the presence of palmitate or pharmacologically with an insulin receptor inhibitor. 
Initially, non-insulin resistant control and insulin resistant skeletal muscle cells could be 
monitored by live cell imaging confocal microscopy for changes in cytosolic zinc 
concentrations by application of exogenous zinc treatment and detection with FluorZin-3 (a 
high affinity zinc fluorimetric probe that binds zinc). Then, changes in zinc flux could be 
monitored in the presence of a Zip7 overexpression or Zip7 knockdown. Following the changes 
in zinc flux in the presence of an overexpressing Zip7 or knock-down Zip7, changes in insulin 
signalling molecules could be monitored by investigating downstream targets of insulin 
signalling utilising antibody protein arrays and changes in glucose oxidation in both the insulin-
resistant and non-insulin resistant skeletal muscle cells.  
6.2.3. Assess the Zip7-mediated zinc mobilisation of Glut4 protein and subsequent 
glucose oxidation in non-insulin resistant versus insulin resistant skeletal muscle. 
Building on from the above studies it will be important to identify the link between Zip7 and 
glucose oxidation through the mobilisation of Glut4 in insulin-resistant skeletal muscle. 
Accordingly, Glut4 mobilisation could be monitored by the construction of skeletal muscle 
cells stably expressing GFP epitope-tagged Glut4. Given the experimental problems of 
determining insulin and zinc-mediated mobilisation and translocation of Glut4 in Chapter 4, 
some redesign of the methods is required. Thus, the following experiments could be performed. 
1). Utilisation of different cell lines that are more insulin-sensitive, such as other skeletal 
muscle cells and adipocytes that express Glut4. For example, 3T3-L1 fibroblasts can be 
effectively differentiated into adipocyte cells which expresses Glut4 and responds well to 
insulin (6). In cultured muscle cells, it is suggested that the acquisition of the myoblast to the 
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mature myotubular phenotype is not an efficient process and therefore muscle cells lack 
important phenotypic characteristics including lateralised nuclei, a developed tubule network 
and insulin sensitivity (7). Therefore, another strategy would be to obtain muscle biopsies from 
non-diabetic and type 2 diabetic patients and use these to culture primary skeletal muscle cell 
lines that would have the developed phenotypic characteristics.   
 
Another strategy would be to use a Glut4 redistribution assay designed and manufactured by 
Thermo Fisher. The redistribution technology monitors the cellular translocation of GFP-
tagged Glut4 in response to compounds (e.g. insulin or zinc) or other stimuli. The assay is 
based on receiving cell lines that already stably express the human Glut4 fused to the N-
terminus of GFP. Insulin is used in this assay as a reference agonist. The assay can be used to 
screen for compounds that enhance the translocation of Glut4 in response to sensitisers (e.g. 
zinc).      
 
The above studies could be combined with a Zip7 overexpression system or a Zip7 knock down 
to assess the role of this transporter in regulating, not only zinc flux, but Glut4 mobilisation 
and translocation to the outer plasma membrane.   
 
6.2.4. Determine the consequence of overexpression of Zip7 or Zip7 knock down in 
mouse skeletal muscle tissue on modulating pathways implicated in glycaemic 
control and homeostasis.     
While studies in cell lines in vitro are essential for understanding mechanisms related to zinc-
mediated cell signalling processes and subsequent glucose metabolism, it will be essential to 
create an in vivo model to better understand these mechanisms in a biological and physiological 
context. Several experiments could be performed including in vivo electroporation (IVE) of 
Zip7 overexpression plasmid or knock-down siRNA plasmid in mouse skeletal muscle (tibialis 
anterior, TA). IVE is a powerful experimental approach that allows manipulation of the gene 
of interest in the test leg and comparison with the control leg in the same animal. Initially we 
could use wild-type C57Bl/6 mice for IVE of Zip7 into TA and the subsequent measurement 
of insulin signalling pathway proteins. Serum levels of glucose and insulin could also be 
measured to give an indication of whether there are any changes in response to these molecules 
in skeletal muscle.  
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6.2.5. Animal knock out studies 
It will be also essential to test the Zip7 function in animal knockout and/or overexpression 
models. Currently the majority of knockout and overexpression studies for Zip7 have been 
performed in cells and there is no Zip7 knockout animal model system. Gene knockout and 
overexpression models represent powerful tools for studying possible functions and targets of 
regulatory factors involved in physiological processes (8). Given that zinc is essential for cell 
survival, a global knockout of Zip7 would probably have deleterious effects on the animal. 
Therefore, skeletal muscle-specific knockdown and or overexpression of Zip7 could be created 
using an adeno-associated viral vector (AVV). For example, the Zip7 recombinant AAV vector 
could contain a skeletal-muscle-specific creatine kinase promoter to drive the expression of 
Zip7 in this tissue (9). Several studies could then be performed to determine the effect of Zip7 
changes on several parameters including: insulin and glucose tolerance tests, HFD induced 
weight gain or adiposity, metabolic parameters such as energy expenditure and physical 
activity. Animal models could include the db/db mice which have leptin deficiency and is 
currently the mostly widely used animal model of T2DM, or wild type mice fed HFD to induce 
adiposity and T2DM.   
 
6.2.6. Human insulin resistance and type 2 diabetes tissue 
While the above future studies to elucidate the molecular mechanisms of zinc- and Zip7-
mediated signalling will be highly important, it will be essential to perform these studies in 
insulin resistant and type 2 diabetic human skeletal muscle samples. Skeletal muscle tissue 
biopsies could be collected from both prediabetic and type 2 diabetic patients. Two strategies 
could be used to determine the clinical relevance of zinc and Zip7 in these disorders.  
 
1). Primary cell lines could be generated from prediabetic (insulin resistant) and type 2 diabetic 
skeletal muscle tissue. These cell lines could then undergo similar experiments as outlined in 
Chapters 3,4, and 5. Moreover, current drug therapies (e.g. metformin) could be tested in these 
cells to determine if zinc and/or Zip7 is required for their efficacy.      
 
2). Skeletal muscle tissue from prediabetic and type 2 diabetic patients could be screened for 
the changes in the expression of the family of zinc transporters. Thus far, this has not been 
done. This might provide insight into other potential zinc transporters that could perhaps be 
useful in further studies. For example, ZnT8, the key zinc transporter expressed in the pancreas 
and involved in importing zinc into the beta cells where it is involved in insulin crystallisation, 
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has several key SNPs that compromise its function (10). Perhaps SNPs could be screened for 
the zinc transporters in prediabetic and type 2 diabetic skeletal muscle. While this would 
require large cohorts of participants, it is certainly feasible.     
6.3. Limitations 
In terms of limitations, the work completed in this thesis would benefit from the inclusion of 
other cell models. Although skeletal muscle is responsible for 70% of glucose disposal (11), it 
would be of value to repeat these experiments in other insulin sensitive tissue cell lines such as 
liver and adipose cells/tissue (12, 13) to determine if these tissues can respond to the zinc. It 
will be important to address this as there is considerable “cross-talk” across these tissues that 
work together to improve overall metabolic health (14). Thus, it is a limitation in this thesis 
that only skeletal muscle was used as this does not inform the greater physiological challenges 
associated with a whole animal model. However, reducing cellular components into single cell 
types (such as skeletal muscle for example) is very useful to establish molecular mechanisms 
that are otherwise difficult to test in whole animal studies.  
Another limitation of these studies was that Zip7-mediated zinc flux was not assessed. Without 
these studies it is difficult to determine whether the effect observed from zinc-mediated cell 
signalling events was from the release of zinc from the endoplasmic reticulum by Zip7. While 
this is a limitation, it was not a major oversight as the thesis focus was on the molecular 
mechanisms of zinc-mediated activation of cell signalling molecules. However, future studies 
should most definitely address this.   
The work in this thesis was predominately in mouse cell lines. Accordingly, it will be important 
to consider a human cell model of diabetes for future work. Human diabetic cells can be 
purchased commercially and could be used to provide a more robust, physiological model to 
understand molecular mechanisms of zinc and Zip7 function. Similarly, human skeletal muscle 
tissue and serum could be collected from type 2 diabetic patients and analysed for Zip7 (and 
other zinc transporters) and zinc status.   
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To move toward a more physiologically relevant model, it will be important to repeat these 
studies in animal models where many factors interact to control physiological mechanisms. In 
the whole animal there are many stimulatory or inhibitory pathways that act to regulate each 
physiological mechanism. In cell culture it is possible to study one of these at a time, but it is 
difficult to study all the possible interactions that can occur in physiological circumstances. 
The ultimate information from these studies is not the effect on isolated cells, but how the 
mechanism is regulated under the myriad of interactions that occur in the whole living animal 
(15). 
 
6.4. Future challenges and opportunities for zinc biology and type 
2 diabetes 
Studies on the role of zinc and its transporters in skeletal muscle of insulin resistant and type 2 
diabetics are likely to manifest novel zinc functions, as well as promising approaches for the 
treatment of these diseases. This thesis has discussed several critical roles of zinc and the zinc 
transporter Zip7 in normal and insulin resistant/type 2 diabetic skeletal muscle. Although the 
role of zinc transporters in IR and T2DM is not fully understood, it is clear from studies on 
zinc transporters that they have utility for the development of novel diabetic therapies. The 
results from studies on skeletal muscle are beginning to reveal that zinc and Zip7 play an 
important role in the processes that facilitate insulin signalling and glycaemic control and 
therefore, could offer exciting new targets that are amendable to therapeutic intervention in the 
treatment of diseases associated with IR and T2DM. Some questions are not yet solved 
regarding Zip7 and the target molecules of zinc signalling. These include:  
• What are the mechanisms underlying the expression of Zip7? It is not clear how Zip7 
is regulated. For example, how is the Zip7-mediated gated release of zinc from the 
endoplasmic reticulum induced?  
• Are the mechanisms of Zip7-mediated zinc release dysfunctional in insulin resistance 
and type 2 diabetes?  
• Are there changes in the expression levels of Zip7 or changes in the concentration of 
zinc released in these models of insulin resistance and type 2 diabetes?  
• Is zinc decompartmentalised? That is, is zinc concentrations found in intracellular 
organelles that are not within a normal range?  
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• Are other zinc transporters implicated in zinc-mediated cell signalling events and 
glucose control in skeletal muscle (and other tissues)? 
• What are the molecular mechanisms of zinc-mediated activation of cell signalling 
molecules involved in glucose uptake?  
 
Elucidating novel biochemical functions of zinc and Zip7 within the cellular network of 
skeletal muscle will lead to improvements in the understanding of IR and potentially facilitate 
the development of diagnostic and effective therapeutic strategies. It should be highlighted that 
while current therapies to treat IR and T2DM are efficacious, some individuals do not respond 
to these treatments and there is associated side-effects. Thus, novel treatments targeting zinc 
transport in combination with current drug treatments could augment a better glycaemic 
response in patients. These studies could also open opportunities for the design of novel 
analogous of zinc that could be used as an adjunct therapy with existing drugs or used alone to 
improve glycaemic control in IR and T2DM.    
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Zinc is critical for the activation of cell signalling molecules in skeletal 
muscle: implications for insulin resistance and type 2 diabetes
Shaghayegh Norouzi and Stephen Myers
School of Health Sciences, University of Tasmania, Launceston, Australia
INTRODUCTION
Insulin resistance (IR) is a major risk factor for
the development of chronic disease including
type 2 diabetes mellitus (T2D) [1]. Skeletal
muscle is the major site of peripheral insulin
resistance and glucose intolerance [2] and is
the major storage tissue for zinc ion [3]. Zinc
plays an important role in glucose
homeostasis through the regulation of
various cell signaling pathways and evidence
suggests that it acts as an insulin-mimetic in
the control of cellular metabolism [4]. Zinc
has emerged as potential therapeutic targets
for disease states associated with
dysfunctional metabolism [5]. For example,
essential dietary zinc plays a major role in
metabolic homeostasis in peripheral tissues
that respond to insulin [6]. While zinc is an
important component of maintaining cellular
homeostasis; it will be important to further
define its mechanisms of zinc action in
regulating insulin sensitivity in peripheral
tissue such as skeletal muscle.
METHODS
skeletal muscle (C2C12) cells were cultured
and treated with 10 nM insulin and/or 20
μM zinc over 0-60 minutes and assayed for
the phosphorylation of AKT (protein kinase
B) by western blotting. The activation of
Extra cellular signal-regulated kinases
(ERK1/2), Proline-rich AKT substrate of 40
kDa (PRAS40) and Glycogen synthesis kinase
3 beta (GSK-3β) also detected using
intracellular signalling protein array kit.
RESULTS DISCUSSION
We found that zinc could activate pAKT in a
time-dependent manner which is
consistent with the literature. Akt is an
important molecule involved in activating
downstream pathways of glucose
mobilisation and uptake [7]. We identified
that zinc also activates ERK1/2, PRAS40
and GSK-3β which they are important in
cell proliferation and survival [8], insulin-
stimulated mTORC [9], and glycogen
synthesis [10], respectively. So, zinc
activates important molecules implicated
in glucose metabolism in skeletal muscle.
This study may result in fundamental
outcomes that will provide a platform to
help understand other organ systems and
disease states. For example, many
approved or being studied drugs that
target zinc signalling might prove useful for
the treatment of T2D or other diseases.
Figure 2. The results of 3 independent 
experiments are presented as mean ± standard 
error. **P < 0.01 and ***P <0.001 considered 
significant compared with Control.
Figure 4. The results of 3 independent 
experiments are presented as mean ± standard 
error. *P < 0.05 and ***P <0.001 considered 
significant compared with Control.
Figure 1. Western blot analysis of pAkt
expressions in C2C12 cells treated with 10 nM
insulin, nothing, 10 µM zinc, 10 µm zinc and 
ionophore, respectively.
Figure 3. The results of 3 independent 
experiments are presented as mean ± standard 
error. *P < 0.05 and ***P <0.001 considered 
significant compared with Control.
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Zinc Regulates Molecules Implicated in Insulin Signaling: 
g        Implications for Insulin Resistance 
 Shaghayegh Norouzi and Stephen Myers  
 School of Health Sciences, University of Tasmania, Launceston, Australia 
Skeletal muscle (C2C12) cells were treated with 10 nM insulin 
or 20 μM zinc over 0-60 minutes and assayed for the phos-
phorylation of signalling molecules using western blotting and 
signalling array kit. 
Insulin resistance is a common pathophysiological condition 
which is related to the development of chronic disorders in-
cluding type 2 diabetes. Evidence shows that zinc has insulin-
mimetic activity and plays an important role in glucose homeo-
stasis. In this study, we investigated the insulin mimetic activi-
ty of zinc on insulin signalling (Figure 1).  
Our results indicate that zinc activates important molecules 
implicated in glucose metabolism in skeletal muscle cells. 
Understanding how zinc is involved in insulin signalling path-
way, may present opportunities to develop novel therapies 
to prevent or treat insulin resistance and type 2 diabetes. 
This research was financially supported by University of Tas-
mania and a Clifford Craig Medical Research Trust Grant. 
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Cell culture 
 Western blot Signalling array 
? 
Figure 3. Protein array 
results of PRAS40, ERK 
and GSK-3 expression *P 
< 0.05 and ***P <0.001 
considered significant 
compared with Control. 
Figure 2. Western blot analysis results of Akt, SHP and 
ERK expression in C2C12 cells treated with zinc or insulin. 
DISCUSSION 
RESULTS 
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INTRODUCTION 
METHODS 
Figure 1. Schematic diagram of insulin signalling pathway pathway.
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Zinc activates signalling molecules important in insulin signal-
ling (Figure 2 and 3). 
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Zinc induces the insulin signaling cascade in human 
skeletal muscle cell line
Shaghayegh Norouzi, John Adulcikas, Sukhwinder Singh Sohal and Stephen Myers
School of Health Sciences, University of Tasmania, Launceston, Australia
E-mail: Shaghayeg.Norouzi@utas.edu.au
INTRODUCTION
Insulin resistance (IR) is a medical disorder that is associated with the development
of type-2 diabetes (T2D) (1). Previous studies have suggested that the essential trace
element, zinc, is a crucial component of insulin signaling and glucose metabolism
and it may delay the onset of T2D among patients with IR (2). However, the
potential mechanisms by which zinc can improve insulin signaling and thus
glycaemic control, are not claerly understood. Our study evaluated the insulin-like
effects of zinc on the insulin signalling cascade in human skeletal muscle cells to
further investigate the role of zinc in the management of IR and T2D (Fig, 1).
Figure 1. Schematic diagram of insulin signaling pathway.
METHODS
Human skeletal muscle cells were cultured and treated with 10 nM insulin or 20 μM
zinc over 60 minutes and protein lysates were collected. Immunoblotting analysis
was performed on several cell signaling proteins implicated in the insulin signaling
pathway. Glucose oxidation assays were performed on skeletal muscle cells treated
with insulin, zinc, or a combination of both. Data, represented as the means ± SEM,
were analysed by the one-way ANOVA for multiple comparisons using the Graph Pad
Prism 5 software to determine any significant differences.
RESULTS
This study demonstrates that zinc activated the insulin signalling pathways and it
was involved in glucose uptake in human skeletal muscle cells. Understanding how
zinc regulates processes involved in insulin signalling may present opportunities to
reduce or better manage insulin resistance and the progression of T2D.
1. S Myers and S Norouzi, The Relationship between Zinc and Insulin Signaling: Implications for Type 2 Diabetes. J Clin
Diabetes Pract, 2016. 1:3
2. S Norouzi, J Adulcikas, S Sohal and S Myers, Zinc transporters and insulin resistance: Therapeutic implications for
type 2 diabetes and metabolic disease. JBMS 2017. Accepted
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CONCLUSION
We identified that, zinc exhibited insulin-mimetic activity on the protein expression of
key markers implicated in insulin signaling including Akt, ERK1/2, SHP-2, PRAS40 and
GSK3β (Fig, 2 and 3). Zinc also increased the protein expression of glucose transporter
Glut-4 (Fig, 4) and increased glucose consumption in human cells (Fig, 5).
Figure 2. Analysis of Akt, ERK1/2, SHP-2 and Tyrosine in human skeletal muscle cells
treated with insulin, zinc and NaPy over 60 min.
Figure 3. Densitometry results of protein signaling array in human skeletal muscle cells. *P
< 0.05, **P <0.01 and ***P <0.001 considered significant compared with Control.
Figure 4. Analysis of Glut-4 in human skeletal muscle cells treated with zinc and NaPy over 
16 hours.
Figure 5. Glucose oxidation assay in the presence of insulin, zinc and NaPy. *P < 0.05 and
***P <0.001 considered significant compared with Control.
RESULTS
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